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General introduction and outline
1
Incidence
In the Netherlands, over 100.000 patients are diagnosed with cancer yearly, while more 
than 40.000 patients die each year because of the disease. (1) The total number of cancer 
patients is increasing due to, on the one hand, growth and ageing of the population with 
a longer life expectancy and, on the other hand, improved cancer treatments and 
therefore increased disease-specific survival. (2,3)
Bone metastases
In itself, every cancer has the potential to spread to other organs or tissues. Distant metastases 
arise through the lymphatic system and/or hematogeneous. Bone tissue for example, 
is highly vascularized and contains bone marrow, which is a fertile soil for tumor cells to 
seed. (4,5) Therefore, patients with cancer frequently develop bone metastases as a sign 
of disseminated disease. The chance of developing bone metastases depends, among 
many other factors, on the primary tumor type. Older studies show that breast cancer and 
prostate cancer metastasize to the bone frequently, with incidences up to 70%, while 
melanoma or bladder cancer have a lower tendency to metastasize to bone. (5-7) 
Bone metastases can become symptomatic in more than 50% of patients with bone 
metastases from breast cancer. (8,9) Patients may experience pain or compression of the 
spinal cord may occur, leading to neurological deficits. Other possible sequelae are bone 
marrow suppression leading to anemia and thrombocytopenia, fractures of the involved 
Figure 1  Incidence and mortality of cancer in the Netherlands.
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bone, leading to pain and functional problems, and hypercalcaemia, due to bone destruction, 
which can be life-threatening if untreated. (8-11) Patients with disease confined to the bone 
at the time of diagnosis of bone metastases have the highest chance of developing those 
events, probably due to the longer survival time compared to patients with synchronous 
visceral metastases. (8,12) 
Pain is a common symptom in palliative cancer patients. In a large systematic review 
involving more than 25.000 palliative cancer patients, the reported mean prevalence of 
pain was 71% (13) and numbers do not seem to decrease over the years. (14,15) Bone 
metastases are a major source of pain. 
In patients with bone metastases, the underlying mechanisms that cause pain are not 
completely understood. Pain is probably due to several factors, like the local destruction 
of the bone by the tumor, activation of the nociceptors by stretching of the periosteum 
and increased pressure within the bone. (5,16,17)  
Quality of life and painful bone metastases
Patients with a solitary or a maximum of five metastases (in bone or elsewhere, the 
so-called oligometastatic disease), in a good clinical condition and a favorable primary 
tumor such as breast cancer, may represent a subgroup of patients, where the goal of 
treatment may be long-term pain control and perhaps even long-term survival. (18,19)
In the majority of patients with painful bone metastases however, multiple bone meta- 
stases and frequently also visceral metastases are present. (12,20) In those patients, the focus 
of treatment shifts from cure to a phase where improvement or maintaining quality of life 
is the main aim. The traditional oncological treatment endpoints, like prolonging survival 
are often less or even not appropriate. It is important for both patients and their relatives 
as well as their caregivers to be aware of this shift in focus. 
The World Health Organization (WHO) defines palliative care as “an approach that improves 
the quality of life of patients and their families facing the problem associated with life-threatening 
illness, through the prevention and relief of suffering by means of early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychosocial and spiritual.” 
“Palliative care is applicable early in the course of illness, in conjunction with other therapies that 
are intended to prolong life, such as chemotherapy or radiation therapy.” (21)
In palliative care, symptom control and improving or at least maintaining quality of life 
(QoL) are key issues. Therefore, all decisions regarding palliative treatment of cancer should 
weigh the impact of side-effects on quality of life against the benefit in terms of disease 
control and QoL it provides for the individual patient. If patients and their treating physicians 
are aware of the expected course of QoL, this may help them in treatment decisions in 
the context of a limited survival. Based on a literature search, Murray et al. have developed 
a distinctive pattern of the course of QoL in patients with metastasized cancer, showing 
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Figure 2  Typical illness trajectories for people with progressive chronic illness.




a rather stable course for a long time, followed by a short and swiftly declining phase 
towards the end of life. This pattern is different from the course in other life-threatening 
diseases like chronic obstructive pulmonary disease and cardiac failure.(22)
Painful bone metastases have a negative impact on the overall QoL of patients (23,24), 
therefore adequate pain control is of utmost importance. 
Pain management 
Pain management can be achieved by a multimodality approach, depending on the 
needs and wishes of the individual patient, involving non-pharmacological and pharma-
cological treatment, psychosocial support, systemic anticancer treatment and/or local 
treatment like radiotherapy. (25) Initially, most patients start with pain medication only. 
The WHO initiated the so-called analgesic ladder, starting with non-opioids (step I). If this 
step provides insufficient pain relief, it was followed by weak opioids (step II) and in the last 
step by strong opioids (step III). (26) In oncology however, step II is frequently left out, and 
strong opioids are started when non-opioids provide insufficient pain relief. (27) When 
using strong opioids, side effects may occur, like constipation, drowsiness and nausea. 
(28,29) Despite pain management guidelines, treatment of pain may be inadequate, as 
shown in a Canadian study in which up to 48% of patients did not receive adequate pain 
medication for painful bone metastases. (30) 
Radiotherapy 
Radiotherapy is frequently used to treat painful bone metastases. In two retrospective 
studies including in total over 1100 patients with bone metastases from breast and 
non-small cell lung cancer, more than 74% of those patients received radiotherapy. (11,12) 
Multiple randomized controlled trials have compared different treatment schedules for 
this indication, varying from a single fraction to twenty fractions. (31,32) 
A recent systematic review including all 25 randomized controlled trials reports an equal 
response rate after a single fraction compared to multiple fractions. In intention-to-treat 
analyses, the overall response rate was 60 and 61% respectively, with a complete response 
rate of 23% and 24%. When drop-out patients were excluded, the overall response rate 
was 72% and 74%, with a complete response rate of 28% versus 30% for single and 
multiple fraction treatment respectively. No significant differences were noticed in 
complete or overall response rates between the treatment schedules. Furthermore, no 
differences in toxicity between treatment schedules were observed. (31,32) 
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Dutch Bone Metastasis Study 
The Dutch Bone Metastasis Study (DBMS) is unique compared to the other trials in terms 
of the amount of patients and the contents, frequency and duration of follow-up and 
gave already answers not only on pain response but also on several other questions 
concerning patients with painful bone metastases.
The DBMS is the largest randomized trial worldwide in patients with painful bone metastases. 
It was a nationwide, randomized trial, with 17 out of 21 radiotherapy institutions in the 
Netherlands participating. From March 1996 to September 1998, 1.157 patients with 
uncomplicated painful bone metastases from solid tumors were randomized between 
a single fraction of 8 Gray (Gy) or 24 Gy in six fractions. At randomization and during 
follow-up, patients filled out weekly questionnaires for thirteen weeks and monthly 
thereafter until two years of follow-up, death or closure of the study. Those questionnaires 
contained, among others, questions from the Rotterdam Symptom Checklist (33) on different 
domains of quality of life, questions about pain score, side-effects from treatment, general 
well-being and pain medication. (34,35) 
Pain response
The main endpoint was pain response, which was initially defined as a decrease of at least 
two points on a scale of 0 to 10 compared to the baseline pain score. Overall, 71% of 
patients experienced a pain response within 3-4 weeks after treatment, with no difference 
between treatment arms. Toxicity and overall QoL were comparable. However, 25% of 
patients initially treated with a single fraction of 8 Gy were retreated, compared to 7% of 
patients treated with 6 fractions of 4 Gy. (35)
After the initial publication, the international consensus agreement was published in 2002 
about endpoint definitions in clinical trials in bone metastases (36). Subsequently, a further 
analysis of the DBMS was published, using those international criteria in terms of pain 
response and taking into account the effect of retreatment (34). In those criteria, which 
were updated in 2012, a complete pain response is defined as a pain score of 0 at the 
treated site with no concomitant increase in analgesic intake. A partial pain response 
includes a pain reduction of 2 or more at the treated site on a scale of 0 to 10 without 
analgesic increase, or analgesic reduction of 25% or more from baseline without an 
increase in pain. (37) The re-analysis of the DBMS confirmed equal effectiveness between 
both treatment arms, with a pain response rate of 71% and 73% for the single fraction and 
the multiple fractions respectively, taking into account changes in pain medication and 
excluding the effect of re-irradiation. Including retreatment, the response rate for single 
fraction treatment increased to 75%, while the response rate of multiple fraction treatment 
remained unchanged. In conclusion, both single and multiple fraction treatment provided 





When treatment arms show comparable results, other factors like costs may play a role in 
the choice of treatment. In the multiple fraction arm, patients have to pay several visits 
to the hospital, with theoretically more costs than a single visit. However, the higher 
percentage of retreatment in the single fraction treatment arm may result in higher costs. 
In a cost-utility analysis, the total costs for both treatment arms were compared, including 
retreatment and non-medical costs, like travel costs or costs of domestic help. For the 
non-medical cost estimation, a subset of 166 patients answered additional questionnaires. 
It appeared that, in the Netherlands, a single fraction treatment had lower costs, both 
medical and societal, compared with the multiple fraction treatment. At that time, the 
medical costs differed almost 900 dollar, while the societal costs differed over 1700 dollars, 
both in favor of the single fraction regimen. This outcome, combined with the comparable 
pain response rates and quality of life, confirmed the conclusion that a single fraction 
treatment should be standard of care in patients with uncomplicated painful bone 
metastases.(38) 
Spinal metastases
However, other treatment modalities might be also relevant in specific patients and choices 
between treatments have to be made. In patients with painful vertebral metastases for 
example, although radiotherapy is in general treatment of choice, surgery may also be a 
treatment option, mainly in patients with neurological complaints or vertebral instability 
or in situations where the limit of radiation dose to the spinal cord has been reached. 
When considering a major treatment like surgery, prognosis becomes more relevant. 
Therefore, all 342 patients included in the DBMS with painful vertebral metastases were 
studied and prognostic factors for survival were identified. The final scoring system 
contained three factors, namely Karnofsky Performance Status (39), primary tumor and 
the absence of visceral metastases. With those three factors, a scoring system was 
developed, dividing patients into three subgroups, with a median survival of 3 months 
(group A), 9 months (group B) and 18.7 months (group C). (40) This scoring system enables 
physicians to determine which patients are suitable for an invasive treatment like surgery 
or which patients will not likely live long enough to benefit from those treatments.
Femoral metastases
In patients with femoral metastases, surgery may also be a relevant treatment option, 
if fracture risk is high. It is relevant to prevent fractures and identify those patients most 
at risk before a fracture might arise, in order to offer the appropriate treatment, like 
prophylactic surgery. In the DBMS 14 fractures arose in 102 patients with in total 110 
painful femoral metastases. Twenty-three percent of patients with femoral metastases 
experienced a fracture after a single fraction versus 7% after multiple fractions. In order to 
identify the factors predicting patients most at risk, the radiographs of all 102 patients 
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were studied. The analyses showed that fracturing of the femur mostly depended on the 
amount of axial cortical involvement of the metastasis and not on treatment schedule. 
Therefore, it was recommended that patients with metastases involving 30 mm or more 
of the axial cortex should be referred to discuss a prophylactic surgical procedure to 
prevent fracturing. When the patient is not eligible for surgical treatment, then a higher 
total radiation dose should be considered. (41) Furthermore, analysis showed that 
conventional risk factors, commonly used at the time of publication, like circumferential 
cortical destruction, increasing pain or radiographic osteolytic appearance, overestimated 
the risk of a fracture. (42) Up to date, research aiming at identifying patients most at risk for 
a fracture does still not show a better clinical risk factor to use, although progress is being 
made using computer models. (43,44) 
Patients with relatively long survival
In patients with a relatively long survival, the question remained which treatment schedule 
should be preferred, if chances were for example that complaints would recur earlier after 
one of the treatment arms. In total 320 patients with a survival of one year or longer after 
treatment were included in the DBMS. In those patients, pain response rates were similar 
after both treatments: 87% after 8 Gy and 85% after 24 Gy. Duration of response and 
progression rates were also similar, leading to the conclusion that a single fraction of 8 Gy 
is also justified in patients with a favourable prognosis. (45) 
On the other hand, patients with limited survival were also studied, to determine the 
efficacy of palliative radiotherapy for painful bone metastases in these patients. Since they 
might represent a different group than patients who survive longer, with a more aggressive 
disease and other primary tumors, their response to palliative radiotherapy might be 
different. (46) Furthermore, earlier analyses showed a mean time to response of three 
weeks (34), which might be too long for patients with a short survival to benefit. In total, 
in the DBMS, 274 patients died within twelve weeks after randomization, mainly patients 
with primary lung cancer. Using intention-to-treat analysis, 44% of patients treated with 
multiple fractions experienced a pain response, compared to 47% of patients treated with 
a single fraction. When comparing the pain response in assessable patients only, these 
numbers were 56% for multiple fractions and 53% for a single fraction. In both treatment 
groups, the median time to a pain response was two weeks. There were no differences between 
treatment groups in terms of progression of pain after initial response or retreatment rates. 
Thus, palliative radiotherapy of painful bone metastases is a valid treatment option in 
patients with a short survival, where a single fraction is preferred. (46)
Dose variation of single fraction radiotherapy
Some other trials studied a single fraction dose lower than 8 Gy. In 1992, a study was 
published comparing 8 Gy and 4 Gy in a single fraction. It showed a higher response rate, 
although only taking pain score into account, for the 8 Gy treatment (69% versus 44% at 
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4 weeks). (47) In 1998, results of a study comparing single fractions of 4 Gy, 6 Gy and 8 Gy 
were published. In total, 327 patients were randomized, showing overall response rates, 
again only taking pain scores into account, of 59%, 73% and 78% respectively. (48) Only one 
randomized trial studied a higher single fraction dose of conventional radiotherapy of 10 Gy, 
compared with 22,5Gy in 5 fractions. Overall response rates were 84% (single fraction) versus 
89% (multiple fractions), with no significant difference between treatment arms. (49)
A systematic review aiming to determine the optimal dose of single fraction, shows 8 Gy 
to be statistically superior to a single fraction of 4 Gy. (50) This was recently confirmed by 
a IAEA randomized multicentre trial comparing a single fraction of 4 Gy with a single 
fraction of 8 Gy. In this trial, 651 patients were randomized, showing overall response rates 
of 88-90% versus 80-86%, depending on the instrument of pain measurement, both 
significantly in favor of the 8 Gy treatment.(51)
Retreatment 
The duration of a pain response is also an important outcome. In the DBMS, median time 
to progression of pain was 24 weeks for the multiple fraction treatment and 20 weeks for 
the single fraction, while the median survival was 30 weeks. Mean times to progression 
were 19 and 18 weeks respectively. In  patients surviving one year, 49% showed progression 
during that first year. (34,35) Therefore, in long-term survivors, retreatment is an important 
issue.
In several studies, despite the documented equal response rates, an increase in retreatment 
was noticed after a single fraction compared to multiple fractions: 20 to 21.5 percent 
versus 7,4 to 8 percent of patients initially treated with a multiple fraction schedule. 
(31,32,52) This is in line with the DBMS, where the treatment schedule seemed to be 
predictive of retreatment. Retreatment was given earlier after a single fraction compared 
to multiple fractions and at lower pain scores. This difference was contributed to the 
expectations of treating physicians at that time, believing that multiple fractions would be 
better in relieving pain. (34)
Although re-irradiation is frequently performed, data on effectiveness and recommended 
treatment schedule are scarce. A systematic review including 10 articles showed a 
re-irradiation rate of 20%, ranging from 11 to 42% between studies. In a meta-analysis, 
including 7 articles using different dose schedules and different definitions of a pain 
response, an overall pain response was achieved in 58% of patients. Complete response 
rates ranged from 16 to 28% and partial response rates from 28 to 45%. Because overall 
study quality was found to be mediocre and many clinical and methodological differences 
existed between studies, no recommendation could be made for re-irradiation dose and 
fractionation. (53) Another systematic review included 15 articles and found an overall 
response rate of 68%, with a 20% complete response rate and a 50% partial response rate. 
This review concluded that further research was needed to answer further questions, for 
example which fractionation schedule should be recommended. (54) 
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To answer this question, a large international randomized trial was undertaken, in which 
sixteen Dutch radiotherapy institutions participated. The goal was to study the effectiveness 
of re-irradiation for recurrent or non-responding pain after initial radiotherapy, studying 
different dose schedules for re-irradiation. In this trial, 850 patients who were previously 
treated with radiotherapy for painful bone metastases and were referred for retreatment, 
were randomized between 8 Gy in a single fraction and 20 Gy in multiple fractions. The 
trial showed that a single fraction was not inferior to multiple fractions and less toxic. The 
overall response rate in the intent-to-treat analyses was 28% for patients treated with a 
single fraction of 8 Gy versus 32% in patients treated with 20 Gy in multiple fractions. In the 
per protocol analyses these numbers were 45% versus 51% respectively. No significant 
differences in global QoL were noted between both treatment arms. Toxicity consisted 
mainly of lack of appetite and diarrhea, which were both significantly less frequent after 
the single fraction treatment compared to the multiple fractions: 56% versus 66% and 
23% versus 31%, respectively. (55) A systematic review including these results showed 
overall response rates for both initial and retreatment of 71-73% in the intent-to-treat 
analyses and 85-87% in the assessable population, excluding the patients who dropped 
out. (56)
Radiotherapy – conclusions 
In conclusion, for the majority of patients with uncomplicated painful  bone metastases, 
radiotherapy provides good palliation and is the treatment of first choice. (25) Given the 
equal outcomes for single and multiple fractions, comparable toxicity and convenience 
for patients due to the reduction of hospital visits and reduced costs, a single fraction of 8 
Gy is the golden standard in the treatment of uncomplicated painful bone metastases.
Remaining questions  
Although the evidence for a single fraction of 8 Gy is overwhelming (31,32,55) and patients 
also prefer to be treated with a single fraction (57), globally, patients are still treated with a 
variety of treatment schedules (58,59). This choice of treatment schedule may be 
influenced by several factors, such as geographical location (58), prognosis, patient age, 
site of irradiation and experience of the treating physician (59). Patients with a poor 
prognosis or higher age are more often treated with a single fraction than younger 
patients and those with a better prognosis. (59) In this thesis, our goal is to further increase 
the insights in palliative radiotherapy for painful bone metastases and to help physicians 
determine the treatment strategy which is most appropriate for their individual patient. 
Therefore, we formulated the following remaining questions. 
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Estimation of survival 
For both patients and physicians, it is important to be able to predict remaining survival 
of the individual patient, because it is a vital element in decision making. (60-62) 
An estimation of survival is important for patients and their relatives (63), to be able to 
handle end-of-life issues and because it impacts their choice in treatments (61,62).  For the 
individual patient, the physician has to weigh the costs for the patient, in terms of time 
investment and toxicity, versus the benefit, namely the expected effectiveness, time to 
response and response duration. Inaccurate survival estimations may lead to inadequate 
treatment.
After developing bone metastases, survival is in general limited (8,20,64), but very hetero-
geneous. Among other factors, this heterogeneity is related to the presence of other 
metastases, mainly visceral, the primary tumor type, physical condition of the patient, 
systemic treatment options and response. (12,40,64-69) 
Several studies report that health care professionals tend to overestimate remaining survival 
time of their patients, based on the available clinical factors and their own experience. 
(60,70-75) The most helpful tool to estimate survival is the Karnofsky performance status 
(KPS) (39), a measure of a patients’ functional capacity, which has been shown to be 
correlated with survival. (40,45,70,73,75-80) Global quality of life scores or patient-reported 
pain scores may also be correlated with survival. (81,82) 
Since a single score of performance status or QoL is not likely to be accurate, several 
prognostic models exist, trying to estimate remaining survival times using multiple 
variables. Those models (40,65,80,83-85) are in general time-consuming, or use variables 
not widely available for every patient, for example laboratory variables (83,85) or specific 
clinical variables like dyspnea, edema or oral intake (65,83,84). 
These models are infrequently used in practice (60). Therefore, there remains a need for a 
simple, but valid tool to estimate remaining survival time in order to make adequate 
treatment decisions. 
Toxicity 
The physician has to weigh the impact of a palliative treatment in terms of the expected 
benefit and toxicity in order to make adequate treatment decisions. Side-effects from 
radiotherapy depend mainly on the treated location and the surrounding organs, like bowel, 
stomach or bladder. For treatment of the long bones for example, in general, those organs 
are not in proximity of the target volume, making it a treatment with little toxicity. For spinal 
metastases, those organs are more likely to be in the radiation field. In general, side-effects 
from radiotherapy of spinal metastases are mild and depend on factors like field size, 
dose and the anatomic area being irradiated. (34,86-88) Possible side-effects of radiotherapy 
of spinal metastases, experienced by 35-50% of patients, are nausea, vomiting, abdominal pain, 
diarrhea and skin complaints. (49,89-91) When treating painful spinal metastases, two 
conventional treatment techniques are frequently used, namely a single field from 
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posterior and two opposing fields from anterior and posterior.  Both techniques have their 
advantages, the posterior field results in a lower dose to the anterior organs, although at 
the cost of suboptimal coverage of the vertebra. The advantage of the opposing fields is 
a better dose distribution, while sparing the posterior skin, which can be relevant when a 
patient will undergo spine surgery in the future. (92-95) In the literature, no prospective 
data on the toxicity of those treatment techniques can be found. The question remains 
which technique should be preferred in terms of toxicity, also taking into account the 
response rates of both treatment techniques. To be aware of the expected toxicity is 
useful for both patients and their physicians, in terms of expectations, treatment choices 
and possibly prophylactic measures to reduce toxicity. 
Psychological distress
An important aspect of QoL is psychological distress, which is defined as a negative 
emotional experience that may interfere with the ability to cope effectively with the 
disease, its physical symptoms and treatment. (96) Symptoms like anxiety, worrying, 
nervousness and depression contribute to psychological distress (33) and are quite 
common in patients with metastasized cancer, with a prevalence of up to 50% in incurable 
cancer patients (13). Although nearly 50% of patients experiences psychological distress, 
only a small percentage is referred for intervention, mainly because distress is not 
recognized and because of unawareness of the treatment possibilities and the perception 
of not needing any help. (97,98) It would therefore be helpful to be able to identify those 
patients who are more prone to developing psychological distress, in order to recognize 
distress early and offer those patients treatment.
Quality of life in patients treated with radiotherapy for painful  
bone metastases
In the international consensus on bone metastases, 91% of international experts agree 
that quality of life instruments, preferably specifically validated for bone metastases, 
should be incorporated in all clinical trials. (37) Despite this recommendation, few of the 
aforementioned randomized trials (31,32) focus on the impact of radiotherapy on QoL or 
document this impact only briefly (49,99). In a systematic review (99), three randomized 
trials were identified reporting changes in QoL after palliative radiotherapy on bone 
metastases, with a maximum amount of 209 patients. Those three trials used four different 
QoL instruments, namely the Spitzer’s index, the Hospital Anxiety and Depression 
Questionnaire (49), a five point global QoL-scale (89) and a measurement of net pain relief 
(100). In general, those trials concluded that QoL improved after palliative radiotherapy. 
(99) Both Gaze and Nielsen found that improvements of QoL were of similar magnitude 
irrespective of treatment schedule (single or multiple fractions). (49,89) The more recent 
retreatment study found a better QoL two months after retreatment in responders 
compared to non-responders. (101)
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Several non-randomized trials studying radiotherapy on bone metastases report on QoL, 
but in most studies this is restricted to a very brief description of the impact of treatment on 
QoL, mostly measured at a limited amount of time points and with a variety of questionnaires, 
making it difficult to compare these outcomes. (99) In those articles, between 59 and 
528 patients were studied. (101-105) The amount of measurements in follow-up ranges 
between one (101,104,105), to a maximum of five, the latest twelve weeks after treatment 
(102). One article documenting the compliance of patients showed only 40% of patients 
filled-out their questionnaire after two months. (103)
In general, those studies concluded that radiotherapy improved QoL, mainly in patients 
experiencing a pain response. (99,102-105) The question remains how QoL develops after 
palliative radiotherapy for painful bone metastases and whether patients experiencing a 
pain response show a better QoL than patients without a pain response. Knowing this 
would help both patients and their physicians in adjusting their expectations.  
Influence of age on effectiveness of radiotherapy and QoL 
As mentioned earlier, the number of elderly cancer patients increases due to the longer 
life expectancy and improvements in cancer treatments (2,3). However, the elderly 
population is more fragile than the younger population. With their specific age-related 
problems and needs, older patients are possibly more vulnerable to side-effects of 
treatment. Furthermore, this group of patients is frequently excluded from or under-
represented in clinical trials, making it difficult to translate the results of the trials to the 
elderly population. (106)  Several studies show that elderly cancer patients receive different 
treatments than younger patients (107-110), and less often palliative treatments like 
radiotherapy. (111-113) 
The questions remains whether this difference in treatment choices is justified and 
whether QoL and response rates are different for elderly patients compared to younger 
patients. With the ongoing changes in the patient population, those questions become 
more relevant. 
Pain flare
Shortly after treatment for painful bone metastases, a pain flare may arise, which has a 
negative effect on QoL. (114) A pain flare is defined as a two-point increase of the worst 
pain score on an 11-point rating scale, compared to baseline, without a decrease in 
analgesic intake, or a 25% increase in analgesic intake without a decrease in worst pain 
score. A pain flare is distinguished from progression because the worst pain score and 
analgesic intake return to baseline levels after the flare. (115) 
In a review of the literature the reported incidence of a pain flare is up to 44% (116), with a 
median duration of 1.5 days. (117) The majority of patients who experienced a pain flare 
indicated to prefer the prevention of this pain flare instead of managing it with break - 
through medication. (114) However, prediction seems difficult. Although several factors 
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have been mentioned, there is no consistency in how to predict a pain flare. Its occurrence 
may depend on factors like primary tumor type or fractionation schedule. (117,118)
Since a pain flare is thought to be caused by edema and stretching of the periosteum, 
dexamethasone has been prescribed in two small studies to determine whether this 
would influence the incidence of a pain flare. In those two studies, the incidence of a pain 
flare with prophylactic dexamethasone in two different dose schedules, was 22 and 
24% respectively. (119,120) Recently, a large randomized trial in almost 300 patients was 
published, showing a reduction in pain flare when using dexamethasone. The study 
randomized between a daily placebo and 8 milligrams of dexamethasone for five consecutive 
days, starting on the day of treatment. In total, 26% of patients in the dexamethasone 
group developed a pain flare, compared to 35% of patients in the placebo group (p:0.05). 
The authors concluded that dexamethasone is efficacious in the prophylaxis of a pain 
flare. Furthermore, they concluded it improved QoL by reducing nausea and increasing 
functional activity and appetite, without serious adverse effects. (121) These results need 
to be confirmed before implementing dexamethasone in daily clinical practice. Moreover, 
the optimal dosing schedule needs to be established. 
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Outline of this thesis
In this thesis, several unanswered research questions regarding patients with painful bone 
metastases, are addressed. For the analyses, the data of the Dutch Bone Metastasis Study 
(DBMS), the largest randomized radiotherapy trial in patients with painful bone metastases 
to date, were used. In this trial, between 1996 and 1998, 1157 patients were randomized 
between a single fraction of 8 Gray and six fractions of 4 Gray. The primary endpoint was 
pain response. The study proved equal effectiveness of both treatment schedules.  
In chapter 2 we assess the value of a simple tool to predict survival in patients with painful 
bone metastases, to assist both patients and physicians in making appropriate treatment 
decisions. Our goal was to create a model that would be simple and easy to use, to help 
physicians in their daily practice. Since the DBMS included patients in the late nineties and 
survival may have changed over the years, we validated this model externally with a more 
recent database. 
Chapter 3 describes the effectiveness and toxicity of two different radiotherapy treatment 
techniques (a single posterior field versus two opposing fields from anterior and posterior), 
used for patients with painful spinal metastases, to determine which technique should be 
preferred for individual patients in terms of toxicity. Both abdominal and skin complaints 
were studied. We compared both treatment techniques, different levels of the spinal 
column and fractionation schedules. Furthermore, we relate predictors to toxicity.  
Chapter 4 shows the course of psychological distress after radiotherapy for painful bone 
metastases. At baseline, we divided patients in groups with a high, intermediate or low 
level of distress and followed the course of psychological distress in these three groups. 
Furthermore, we created a model to help predict psychological distress, in order to be 
able to identify those patients most at risk and refer them in time for intervention.  
In chapter 5 we studied the course of quality of life after palliative radiotherapy in patients 
with painful bone metastases. We modelled the course of quality of life towards death, in 
order to inform both patients and physicians about the expected course of QoL. We 
studied the detailed course of QoL, separated into different domains, namely physical, 
psychosocial and functional status and general health, until a maximum of two years 
follow-up after treatment. We analyzed the influence of baseline and follow-up variables 
on the course of QoL. 
Chapter 6 shows the course of QoL after radiotherapy, comparing responding and 
non-responding patients, aiming to determine whether a pain response is related to a 
better QoL after treatment. A second objective of the study was to assess the value of 
prognostic factors to predict a pain response after radiotherapy in patients with painful 
bone metastases. We created a model to predict response to palliative radiotherapy, 
aiming to identify those patients who were highly likely to show a response and those 
who were not. Since response rates differ between primary tumor type, we also focused 
on primary tumor.  
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In chapter 7, we studied the effect of age in patients with painful bone metastases, to 
determine whether age should be taken into account when making treatment decisions 
for the individual patient. We showed the pain response in three age cohorts to see 
whether there were any differences in response rate. Furthermore, we created a model to 
predict pain response, to be able to determine whether age would predict for a pain 
response after palliative radiotherapy. Thirdly, we showed the course of QoL for three 
different age cohorts. 
The appendix contains the study protocol of the recent Dutch multicenter, double-blind 
placebo-controlled trial studying the efficacy of dexamethasone in the prevention of a 
pain flare, aiming to find a treatment strategy to prevent the occurrence of a pain flare. In 
total, 294 patients were included between January 2012 and March 2016. The database of 
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Purpose: Patients with bone metastases have a widely varying survival. A reliable estimation 
of survival is needed for appropriate treatment strategies. Our goal was to assess the value 
of simple prognostic factors, namely patient and tumor characteristics, Karnofsky performance 
status (KPS) and patient-reported scores of pain and quality of life, to predict survival in 
patients with painful bone metastases.
Methods and materials: In the Dutch Bone Metastasis Study 1,157 patients were treated with 
radiation therapy for painful bone metastases. At randomization, physicians determined 
the KPS; patients rated general health on a visual analogue scale (VAS-gh), valuation of life 
on a verbal rating scale (VRS-vl) and pain intensity. To assess the predictive value of the 
variables, we used multivariate Cox proportional hazard analyses and C-statistics for 
discriminative value. Of the final model, calibration was assessed. External validation was 
performed on a dataset of 934 patients, treated with radiation therapy for vertebral 
metastases. 
Results: Patients had mainly breast (39%), prostate (23%) or lung cancer (25%). After a maximum 
of 142 weeks follow-up, 74% of patients had died. The best predictive model included 
gender, primary tumor, visceral metastases, KPS, VAS-gh and VRS-vl (C-statistic 0.72, 95%CI 
0.70-0.74). A reduced model, with only KPS and primary tumor, showed comparable 
discriminative capacity (C-statistic 0.71, 95%CI 0.69-0.72). External validation showed a 
C-statistic of 0.72 (95%CI 0.70-.73). Calibration of the derivation and the validation dataset 
showed underestimation of survival. 
Conclusion: In predicting survival in patients with painful bone metastases, KPS combined 
with primary tumor was comparable to a more complex model. Considering the amount 
of variables in complex models and the additional burden on patients, the simple model 





Patients who have been diagnosed with bone metastases have a heterogeneous survival. 
Among other factors, this is related to primary tumor, its susceptibility to treatment and 
the presence of other metastases, mainly visceral. (1-3) An estimation of survival is 
important, because it is a vital element in decision making. (4-6) The physician relies on 
these estimates to decide on treatment options weighing time investment and expected 
toxicity versus effectiveness. Inaccurate estimations may lead to inadequate treatment 
decisions. In addition, it is important for patients and their relatives to be aware of the 
expected survival time, because it impacts their choice in treatments. (5-7)
Although some prognostic models in palliative radiation therapy exist, like the models 
developed by Chow, and van der Linden (1, 2, 8), these are infrequently used in practice (4). 
Existing models are often complicated in use and time-consuming for both doctor and 
patient. Physicians often rely on their own estimation of life expectancy, based on their 
clinical judgment. Unfortunately, it is difficult to make a correct estimation. Several studies 
report that health care professionals tend to overestimate survival. (4, 9-14) A performance 
status, like the Karnofsky performance status (KPS) (15), is a measure of a patients’ functional 
capacity and is commonly used. Several articles show the KPS to be significantly correlated 
with survival. (1, 8, 9, 12, 14, 16-20) A review of prognostic tools and prediction of physicians 
reported that the KPS was the best tool to estimate survival in terminally ill cancer patients. 
(9) However, another review showed little additive value of the KPS to the physicians’ 
clinical estimation of survival in these patients. (10) In a recent retrospective study in 
patients with painful bone metastases from non-small cell lung cancer, the KPS was not 
predictive for survival. (21) Survival estimates and performance status are mostly physi-
cian-based.  A recent review suggests that patients’ own ratings are better predictive tools 
than performance status. (22) Global quality of life scores have been shown to be 
correlated with survival in patients with several primary tumors in both a curative as well 
as a palliative setting. (22) Patient-reported pain scores may also predict survival. (22, 23) 
We aimed to assess the potential value of simple prognostic factors to predict survival in 
patients with painful bone metastases, to assist both patients and physicians in making 
appropriate treatment decisions. For that purpose, we used the prospectively collected 
dataset of the Dutch Bone Metastasis Study (DBMS), a large cohort of patients with a 
variety of primary tumors. (24) The aim of this study was to assess the prognostic value of 
the physician-rated KPS, as well as patient-reported pain and quality of life, in patients 
treated with radiation therapy for painful bone metastases. Secondly, we explored which 




The DBMS was a nationwide, randomized trial in patients with painful bone metastases. 
From March 1996 to September 1998, 1,157 patients with painful bone metastases were 
randomized between a single fraction of 8 Gy or 24 Gy in six fractions. The main endpoint 
was pain response. Detailed descriptions and outcomes of the study protocol have been 
published previously. (24) The Medical Ethics Committees of all participating institutions 
approved the study. All patients provided informed consent. In December 1998, survival 
data were retrieved from the medical records or from contacting the general practitioner. 
   
Scales
At randomization and follow-up, questionnaires were sent weekly, filled out at home and 
returned using self-addressed envelopes for twelve weeks and monthly thereafter until 
two years of follow-up, death or closure of the study in December 1998. The questionnaires 
consisted of the Rotterdam Symptom Checklist (RSCL) (25), a general health scale, a pain 
scale and medication intake. At randomization, the treating physician rated the 
performance status using the KPS. Patients rated their general health on a 100 mm visual 
analogue scale (VAS-gh), ranging from 0 to 100: the higher the score, the better the 
patients’ general health. One item from the RSCL is a verbal rating scale for overall valuation 
of life (VRS-vl), rated on a seven-point Likert-type scale, ranging from 1 (meaning the 
patient valuated life very high) to 7 (very low valuation of life). Pain was measured using an 
11-point numeric rating scale, ranging from 0 (meaning no pain) to 10 (meaning the worst 
pain imaginable). A pain score of at least 2 was required to enter the study. (24)
Statistical analyses
Based on the literature and availability in clinical practice, the following patient character-
istics were studied for their value in predicting survival: gender (male/female), age 
(dichotomized into ≤65/>65 years), primary tumor (breast, prostate, lung and other), 
visceral metastases (yes/no) and baseline scores for KPS (categorized into 20-60, 70-80, 
90-100), VAS-gh (0-33, 34-66, 67-100), VRS-vl (1-3, 4, 5-7) and pain score (2-5, 6-7, 8-10). KPS, 
VAS-gh, VRS-vl and pain score were clustered into subgroups to create categorical data 
with a sufficient amount of patients per subgroup. Gender, age, primary tumor and 
presence of visceral metastases were documented in all patients at study entry. The KPS, 
VAS-gh, VRS-vl and pain score at baseline were available for 99%, 92%, 94% and 99% of 
patients, respectively. We used single imputation to insert missing values. We only used 
the baseline measurement of these variables in order to be able to predict survival before 
treatment. Pearson’s correlation coefficients were assessed in order to assess the risk of 
multicollinearity of the potential predictors. Survival curves were estimated and assessed 




Univariate and multivariable Cox proportional hazard models were applied to relate 
candidate predictors to survival. For the development of the predictive model, we started 
with all candidate predictors (full model: gender, age, primary tumor, visceral metastases, 
KPS, VAS-gh, VRS-vl, pain score). Subsequently we eliminated the variables by backward 
selection. A threshold p-value of 0.20 was chosen to limit the loss of information and to 
also select weaker predictors. (26) Discriminative ability of the predictive models was 
assessed with the C-statistic. The C-statistic estimates the probability of concordance 
between predicted and observed responses. (27) A C-statistic ranges between 0.5 and 1.0, 
where a value of 0.5 means the model is no better than chance, while a value of 1.0 means 
perfect discrimination. By the use of bootstrapping, the shrinkage factor and optimism 
were calculated and used to correct the C-statistic. To assess the overall fit, the proportional 
hazards assumption and the Schoenfeld residuals were checked. A calibration plot was 
made to visualize the predictive accuracy of the model at 3, 6 and 9 months of follow-up. 
(27) For external validation of the final model (28), a retrospectively collected dataset was 
used, including 980 consecutive patients, receiving radiation therapy for vertebral meta- 
stases between 2001 and 2010 in one hospital in the Netherlands. (29) Data on survival 
were retrieved from the medical records or from contacting the general practitioner. 
In this dataset, KPS at baseline was missing for 46 (4,7%) patients. Therefore, we used the 
data of the 934 patients with complete data.
The effect of variables on survival was expressed as Hazard Ratio’s (HR) with 95% Confidence 
Intervals (95% CI). The dataset was analyzed using IBM SPSS statistics for Windows version 
20.0 (IBM Corp., Armonk, NY, USA). C-statistics were calculated in the R language environment 
for statistical computing, version 2.10 (freely available at http://cran.r-project.org). 
Results
In total, 1,157 patients were included into the DBMS (derivation dataset). Mean age was 65 
years (range 32-89). Fifty-four percent of patients was male. Most patients had breast 
(39%), prostate (23%) or lung cancer (25%). The remaining 152 patients had a variety of 
primary tumors, mostly bladder, colorectal or esophageal cancer. Visceral metastases 
were documented in 28% of patients. At baseline, mean scores (and ranges) for KPS, 
VAS-gh, VRS-vl and pain score were 70 (20-100), 46 (0-98), 4 (1-7) and 6 (2-10), respectively.
Survival data in derivation dataset
The median and mean survivals of the entire group were 30 and 49 weeks respectively, 
with a range of 0.3-142 weeks. At closure of the study, with a maximum follow-up of 2.7 years, 
860 (74%) patients had died. Figure 1 shows the survival of patients by categorized KPS, 
VAS-gh, VRS-vl and pain score. Table 1 shows that survival differed significantly between 
categories of different baseline variables (gender, age, primary tumor, visceral metastases, 
36
Chapter 2
KPS, VAS-gh, VRS-vl, pain score), but not between the treatment arms. There was no significant 
difference in survival between patients irradiated for vertebral metastases and patients 
irradiated for bone metastases elsewhere (data not shown). 
Figure 1   Survival by categorized baseline variables: Karnofsky performance status  
(KPS), visual analogue scoring of general health (VAS-gh), verbally rated scoring 
of overall valuation of life (VRS-vl), pain score.
Number of patients at risk 
90-100  221 174 115 76 46 23 11 
70-80 592 374 229 146 83 49 19  
20-60 344 145 73 47 21 10 6 
Number of patients at risk 
67-100  236 178 115 79 52 29 11 
34-66 530 328 190 116 64 31 15 
0-33 391 187 112 74 34 22 10 
Number of patients at risk 
1-3 350 240 152 97 59 29 13 
4 364 223 133 86 45 28 9  
5-7 443 230 132 86 46 25 13 
Number of patients at risk 
0-5 428 288 187 122 79 39 18  
6-7 362 212 119 71 35 17 8 




Table 1  Survival of patients by the different categorized baseline variables.
baseline variables n survival (weeks) p-value * in case of >2 groups:
difference between #median range
gender <0.001
male 624 (54%) 20.7 0.3-135.6
female 533 (46%) 49.9 0.6-142.0
Age 0.021
≤ 65 years 565 (49%) 34.6 1.0-141.0
> 65 years 592 (51%) 27.4 0.3-142.0
primary tumor < 0.001
breast 451 (39%) 68.7 1.1-142.0 breast-prostate (p < 0.001)
prostate 267 (23%) 39.7 1.4-135.6 breast-lung (p < 0.001)
Lung 287 (25%) 13.3 0.3-102.6 breast-other (p < 0.001)
other 152 (13%) 16.4 0.6-127.0 prostate-lung (p < 0.001)
prostate-other (p < 0.001)
visceral metastases <0.001
No 838 (72%) 35.0 0.3-142.0
Yes 319 (28%) 19.4 0.9-138.0
treatment arm n.s.
1x8 Gray 578 (50%) 32.9 0.7-142.0
6x4 Gray 579 (50%) 28.1 0.3-141.0
KPS < 0.001
90-100 221 (19%) 57.0 3.0-138.0 90-100 vs 70-80 (p < 0.001)
70-80 592 (51%) 34.6 1.7-142.0 90-100 vs 0-60 (p < 0.001)
20-60 344 (30%) 16.3 0.3-141.0 70-80 vs 0-60 (p < 0.001)
VAS-gh < 0.001
67-100 236 (20%) 50.6 1.7-141.0 67-100 vs 34-66 (p < 0.001)
34-66 530 (46%) 30.6 0.6-138.0 67-100 vs 0-33 (p < 0.001)
0-33 391 (34%) 19.4 0.3-142.0 34-66 vs 0-33 (p < 0.001)
VRS-vl < 0.001
1 – 3 350 (30%) 45.1 1.4-142.0 1-3 vs 4 (p = 0.007)
4 364 (31%) 31.7 1.0-135.6 1-3 vs 5-7 (p < 0.001)
5 – 7 443 (38%) 21.6 0.3-141.0 4 vs 5-7 (p = 0.004)
pain score < 0.001
2 – 5 428 (37%) 40.9 2.0-135.9 2-5 vs 6-7 (p < 0.001)
6 – 7 362 (31%) 27.9 0.6-141.0 2-5 vs 8-10 (p < 0.001)
8 - 10 367 (32%) 24.4 0.3-142.0
*: log-rank test,  #: the non-significant differences are not shown, n.s.: not significant, KPS: Karnofsky performance
status, VAS-gh: visual analogue score of general health, VRS-vl: overall valuation of life. KPS, VAS-gh:
the higher the score, the better the well-being. VRS-vl, pain score: the lower the score, the better the well-being
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Predictors for survival 
Univariate analysis showed that being male, being older than 65 years, having any primary 
tumor other than breast cancer, having visceral metastases, lower KPS, lower VAS-gh, 
higher VRS-vl and higher pain score were associated with a higher risk of death (Table 2). 
Next, we combined all relevant variables to investigate which combination would be 
most predictive for survival. In multivariate analysis (table 2), pain score did not contribute 
to the prediction of survival. The best predictive model included gender, primary tumor, 
visceral metastases, KPS, VAS-gh and VRS-vl, with a C-statistic of 0.72 (95% CI 0.70-0.74). 
A simplified model with only KPS and primary tumor, led to a comparable discriminative 
ability (C-statistic 0.71, 95% CI 0.69-0.72). Reduced models combining primary tumor with 
patient-rated variables VAS-gh or VRS-vl had worse predictive accuracy, with a C-statistic 
for both models of 0.69. Figure 2 shows the calibration plot of the reduced model. It shows 
estimations are overly pessimistic. In general, it predicts best in patients with lung cancer 
or with other primary tumors and a poor clinical condition. Table 3 shows the observed 
survival at three to eighteen months after treatment as a tool to use for physicians when 
consulting patients with painful bone metastases. 
External validation
The external dataset included 934 patients with a mean age of 65 years (range 33-95 
years). Fifty-two percent of patients was male and in 36% of patients visceral metastases 
were documented. Most patients had breast (29%), prostate (21%) or lung cancer (25%). 
These characteristics were the same in the full dataset. At the start of treatment, mean KPS 
was 70 (range 30-100). 
Survival data in validation dataset
At the time of data collection, with a maximum follow-up of 11.4 years, 95% of patients 
had died. Median and mean survival was 21 and 60 weeks, with a range of 0.1-594 weeks. 
For all primary tumor sites, survival differed significantly (p<0.001) between the KPS 
groups. Table 3 shows the median survival and observed survival in the different groups 
of patients by KPS and primary tumor. Some patient groups have a markedly better 
survival in the more recent dataset compared to the DBMS dataset. In the DBMS era 58% 
of patients with breast cancer and a KPS of 90-100 survived 18 months, versus 75% in the 
validation dataset. The difference is also noticeable in patients with prostate cancer and a 
KPS of 90-100, where 18 months survival in the DBMS and validation dataset was 30% and 
56% respectively. In lung and other primary tumors this difference is less marked. The 
C-statistic of our simple model, using KPS and primary tumor, was 0.72 (95%CI 0.70-0.73). 
The calibration plot of the model for the external validation set was almost identical to the 




Figure 2   Calibration plot of the predicted mortality at 3, 6 and 9 months after 
randomization versus the observed mortality in the studied patients. 
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Table 2   Univariate (UVA) and final multivariate (MVA) Cox regression analyses on 
potential baseline predictors for mortality after palliative radiation therapy 
for painful bone metastases.




female 0.47 (0.41-0.54) 0.75 (0.58-0.97)
age
≤ 65 years 1.00 #
> 65 years 1.17 (1.02-1.34)
primary tumor
breast 1.00 1.00
prostate 1.68 (1.40-2.02) 1.64 (1.19-2.25)
lung 4.27 (3.57-5.11) 3.67 (2.76-4.89)
other 3.49 (2.82-4.32) 2.86 (2.17-3.77)
visceral metastases
no 1.00 1.00
yes 1.53 (1.32-1.76) 1.66 (1.42-1.94)
KPS
90-100 1.00 1.00
70-80 1.51 (1.24-1.84) 1.37 (1.12-1.68)
20-60 2.77 (2.25-3.41) 2.39 (1.91-2.98)
VAS-gh
67-100 1.00 1.00
34-66 1.38 (1.15-1.67) 1.17 (0.95-1.43)
0-33 1.81 (1.49-2.19) 1.35 (1.07-1.71)
VRS-vl
1 - 3 1.00 1.00
4 1.27 (1.06-1.51) 1.07 (0.88-1.29)
5 - 7 1.60 (1.35-1.89) 1.27 (1.04-1.55)
pain score
2 - 5 1.00 #
6 - 7 1.37 (1.17-1.62)
8 - 10 1.39 (1.18-1.64)
95% CI: 95% confidence interval, UVA: univariate analysis, MVA: multivariate analysis,  
*: Cox regression analysis
#: did not remain in the final model, KPS: Karnofsky performance status, VAS-gh: visual analogue score of general 
health, VRS-vl: overall valuation of life. KPS, VAS-gh: the higher the score, the better the well-being; 































































































































































































































































































































































































































































































































































































































































To our knowledge, this is the first study that assessed the prognostic value of simple pa-
tient-reported outcomes and physician-based KPS to estimate survival in a large cohort of 
patients with painful bone metastases from a wide variety of primary tumors. Our best 
model with acceptable discrimination includes gender, primary tumor, visceral metastases, 
KPS, VAS-gh and VRS-vl. A simple model including only KPS and primary tumor showed 
comparable discrimination. We performed an external validation (28) in a large, more 
recent cohort of patients with vertebral metastases, and were able to confirm the initial 
results. Calibration of the model showed substantial underestimation of the actual survival 
of the patients in both the derivation and the validation dataset. Therefore, the model 
should be handled with caution. Generally, physicians tend to overestimate survival of 
their patients. We have no clear explanation why our model underestimates. Looking at 
the calibration plots per primary tumor (data not shown), our model predicted survival 
best in the worst prognostic groups, e.g. patients with lung cancer or with other primary 
tumors and a poor clinical condition. These patients were closest to their deaths. The KPS 
is relatively stable until the last weeks of life, when patients experience a rapid decline in 
performance status. (30) These are the patients in whom physicians are particularly 
interested to determine whether their remaining life would be too short for them to 
benefit from anticancer treatment. Therefore, our model functions best in patients for 
whom a correct estimation of survival is most relevant. Our survival table enables 
physicians to make an estimation of survival in patients referred for radiation therapy for 
painful bone metastases, based on primary tumor site and KPS. This is clearly helpful for 
daily clinical practice. It shows differences in survival between our dataset and the 
validation dataset. This may partly be due to the markedly longer follow-up times in the 
validation dataset, with a maximum of 11.4 years, versus a maximum of 2.7 years in the 
derivation dataset. Furthermore, the patients in the validation dataset all had vertebral 
metastases, which may be associated with a longer survival time. This does not explain 
the difference, as analysis of the DBMS showed no difference in survival between patients 
with vertebral metastases and patients with other bone metastases. Another explanation 
might be that patients referred after 2000 were in a better clinical condition. Our survival 
table shows, however, that patients in the validation dataset were generally even in a 
slightly worse clinical condition than the patients in the DBMS. Therefore, the differences 
in survival between our dataset and the validation dataset probably mostly reflect the 
changes in the effectiveness of systemic therapy over time, as it concerns mainly patients 
with breast or prostate cancer in a good clinical condition. 
Several other papers identified patient-reported factors predictive for survival in patients 
with advanced cancer. (14, 16, 31) Our study confirms this finding, but also observed that 
those patient-reported factors were inferior to physician-reported KPS. A review by Gotay 




ported outcomes were often better in predicting survival than performance status.  (22) 
They showed that in some studies performance status lost explanatory value after 
entering a patient-reported outcome into the model. This is in contradiction with our 
results, but might be explained by the different patient population. Other, smaller sized, 
studies in patients with metastatic cancer reported results similar to our study. Collette et 
al. showed in 391 patients with metastases from prostate cancer that patient-related 
symptoms were predictive for survival, but did not improve the predictive accuracy of 
several clinical variables, like performance status. (32) Efficace et al. studied 391 patients 
with advanced non-small-cell lung cancer and 219 patients with metastatic breast cancer. 
In the final models, patient-reported quality of life lost significance, while physician-rated 
performance status remained predictive for survival. (23, 33) 
In the past, several prognostic models using a combination of variables have been 
developed to predict prognosis and to aid physicians and patients in choosing treatment 
strategies, like the palliative prognostic score (34), palliative prognostic index (35) and the 
predictive models developed by Chow (2, 8), Gwilliam (36) and van der Linden (1). A survey 
among radiation oncologists showed that prognostic models are infrequently used in 
practice, while the KPS was frequently used. (4) These models contain many variables and 
some even use laboratory findings (34, 36), with the consequence of not being usable 
when one of these variables is missing. Because of the time these models consume, the 
amount of variables, the complexity and the additional burden on both patients and 
physicians, we consider these models not applicable for use in daily practice. Our own 
group developed a model, using a subset of patients with spinal metastases, including 
KPS, primary tumor and visceral metastases. (1) When comparing this model and their 
initial model (2), Chow concludes the DBMS-model to be easier to administer at the clinic. 
(37) This stresses the need for a simple model. The C-statistic of the more complex model 
by Chow et al. is comparable to our C-statistic, although they used six variables and no 
correction for optimism was performed. (2) Other models showed C-statistics between 
0.63 and 0.69. (8, 29, 36) All models, except the models from Chow (2, 8), did not meet 
current standards of methodology. (1, 34-36) 
Our study is based on a unique and large cohort of patients with bone metastases from 
the Netherlands. Our data originate from the late nineties, which may be considered a 
limitation of our analyses due to possible changes in patients and treatments. Therefore, 
we validated our model in a recent Dutch dataset showing identical results, which makes 
the model applicable to current patients with painful bone metastases. Although these 
patients were all treated for vertebral metastases, the predictive performance in both 
datasets is comparable, which is the most important. (38) Moreover, 65% of the patients in 
the validation dataset had extraspinal bone metastases when entering the database. (29) 
In the DBMS, 58% of patients had other bone metastases when entering the study. 
Furthermore, analysis of the DBMS showed no differences in KPS or primary tumor 
between patients with vertebral or other bone metastases. Obviously, there has been a 
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selection of patients in both the DBMS and the validation dataset, because patients in 
progressively declining conditions will in general not be referred for pain treatment. Thus, 
our results apply only for those patients with painful bone metastases who are deemed fit 
for radiation therapy. 
Conclusions
When predicting survival in patients with painful bone metastases, KPS combined with 
primary tumor has a similar predictive value compared to our best, more complex model, 
with reasonable discriminative ability. Using patient-rated variables instead of KPS did not 
increase the predictive value. Considering the amount of variables in the best, complex 
model and the extra burden on patients, the simple model is preferred for daily practice, 
despite underestimation of survival. In addition, a risk table for survival in these patients, 
based on primary tumor and KPS, is provided to assist both physicians and their patients 
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Background: Conventional radiotherapy for painful spinal metastases can be delivered with 
a single posterior-anterior (PA) or two opposed anterior-posterior fields (APPA). We studied 
the effectiveness and toxicity of both techniques and studied whether treatment technique 
was predictive for abdominal and skin toxicity.  
Patients and methods: Within the Dutch Bone Metastasis Study, 343 patients received 
8 Gray in a single fraction or 24 Gray in six fractions for painful spinal metastases. Treatment 
technique was not randomized. At baseline and weekly during follow-up, patients reported 
pain and other physical complaints. Any complaint increasing within four weeks after 
treatment was noted as a side-effect. Pain response was calculated according to inter- 
national standards, taking into account changes in pain score and medication. Repeated 
measurement analyses and multivariate logistic analyses were performed.
Results: Patients were mainly treated on the thoracic (34%) and lumbar (53%) spine and 
73% received a PA-field. Pain response was similar between both techniques (74%). In patients 
treated at the thoraco-lumbar and lumbar spine, with multiple fractions, significantly 
more abdominal complaints were noticed. In multivariate analysis, radiotherapy technique 
did not predict for side effects. 
Conclusion: Conventional radiotherapy of painful spinal metastases provides limited 
toxicity. Radiotherapy technique is not an independent predictor of abdominal and skin 
toxicity of irradiation.
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Introduction
For patients with painful bone metastases, radiotherapy is an effective treatment, with a 
pain response rate of more than 60%. The golden standard is to treat these patients with 
a single fraction of 8 Gray (Gy) [1-3], aiming at pain relief with minimal toxicity. 
In general, side effects from this treatment are mild and depend on factors like dose, field 
size and the anatomic area being irradiated. [1, 4-6] In several studies in patients treated 
with radiotherapy for painful bone metastases, toxicity rates between 35 and 46% are 
reported, consisting mainly of nausea and/or vomiting. [7-9] A recent study in 32 patients 
treated for painful bone metastases showed that over 50% of patients had complaints of 
nausea and/or vomiting, despite receiving prophylactic anti-emetic treatment. [10]
Radiotherapy to spinal metastases can be delivered with different treatment techniques. 
Highly conformal treatment techniques like intensity modulated radiotherapy (IMRT) and 
volumetric arc radiotherapy (VMAT) are used more and more, often to higher doses. Still, 
frequently used conventional techniques are a single posterior-anterior (PA) field or two 
parallel opposed fields from anterior and posterior (APPA). The advantage of a PA-field is 
the sparing of anterior organs like the bowel, although the coverage of the vertebrae 
might be suboptimal. [11] By using a PA-field, the dose to the posterior skin and paraspinal 
musculature can be high, which can be a problem for future surgical interventions. [12-14] 
The advantage of the APPA-technique is a better coverage of the vertebrae [11], while 
sparing the posterior skin and paraspinal musculature. A disadvantage is the higher dose 
in the anterior organs, possibly leading to more abdominal side effects. In the literature, 
however, no prospective data on the toxicity of both techniques have been published.
The aim of the present analysis is to study the differences in effectiveness and toxicity of 
PA and APPA techniques for the irradiation of painful spinal metastases and to identify 
factors predictive for side effects of treatment. We studied patients who received 
radiotherapy for painful spinal metastases within the randomized Dutch Bone Metastasis 
Study (DBMS). [1] 
Patients and Methods
Details of the patient population and study protocol of the DBMS were published 
elsewhere. [1, 15] In summary, the DBMS was a nationwide, randomized trial in patients 
with uncomplicated painful bone metastases. Between 1996 and 1998, a total of 1.157 
patients with painful bone metastases were randomized between a single fraction (SF) of 
8 Gy or 24 Gy in six fractions. The study showed equal effectiveness of a SF versus multiple 
fractions (MF) with regard to pain response, which was the primary endpoint. All patients 
provided informed consent and the Medical Ethics Committees of participating 




Patients with metastases in the cervical spine were excluded from the DBMS. [1, 15] In total, 
348 patients were treated for painful metastases in the thoracic, lumbar or sacral spine. 
Data on spinal location and treatment technique were available in 343 patients (99%). For 
spinal location, the treated level of the spine (i.e. thoracic, lumbar or sacral) was registered, 
without specification of the specific vertebra or vertebrae irradiated. Treatment was performed 
with conventional treatment techniques, using either a PA-field, or APPA-fields contributing 
each 50% of the total dose, no other techniques were used. The prescription depth for 
PA-fields was typically at 4 to 6 cm, depending on the depth of the vertebra. The choice 
for treatment technique was left to the decision of the treating radiation oncologist, and 
was mostly dependent on institutional policy. 
Questionnaires 
At randomization and during follow-up, patients filled out thirteen weekly questionnaires 
and monthly afterwards until two years of follow-up, death or closure of the study in 
December 1998. The questionnaires consisted, among others, of the Rotterdam Symptom 
Checklist (RSCL) [16], a pain scale, pain medication intake and questions about itching and 
painful skin. No data were available on the use of anti-emetics or anti-diarrhea medication. 
The following items were studied to determine toxicity: diarrhea, abdominal pain, nausea 
and vomiting. These scores were grouped into the variable ‘abdominal complaints’. 
Itching and painful skin were grouped into the variable ‘skin complaints’. All items were 
rated on a four-point Likert-type scale, ranging from 1 (no complaints) to 4 (severe 
complaints). To facilitate interpretation, all sum scores were standardized to the range of 0 
(no complaints) to 10 (severe complaints). Besides sum scores, the individual item scores 
were also studied. As radiotherapy of the lower spine is more likely to affect the bowel, we 
studied the individual abdominal items for the treated thoraco-lumbar, lumbar and 
lumbo-sacral vertebrae separately. Pain was measured using an 11-point numeric rating 
scale, ranging from 0 (no pain) to 10 (the worst pain imaginable). A pain score of at least 2 
was required to enter the study. [1]
Statistical analyses
Pain response was calculated according to international criteria, taking into account 
changes in pain medication and pain score. [17] No fixed time interval from the date of 
randomization was applied. A response was calculated if at least two successive follow-up 
pain scores were available, which was possible in 325 patients (95%). 
To compare the categorical variables at baseline, Chi-Square tests were used. To visualize 
and compare the course of side effects over time, we used repeated measurement 
analyses (mixed procedure), a longitudinal data analysis technique. Analyses were also 
performed adjusted for treatment institute to take into account potential confounding by 
indication by institutional choice for treatment technique. P-values are based on 2-sided 
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tests and considered significant if p<0.05. Figures were created based on the least square 
means of the repeated measurements. 
To assess which baseline variables were predictive for toxicity, the complaints variable was 
dichotomized into having or not having complaints. For that purpose, we compared 
the maximal complaint scores one to four weeks after treatment with the baseline scores. 
If a score was higher than the baseline score, the patient was considered as having side 
effects of radiotherapy. The time period of four weeks was chosen because by then most 
side effects would be present. 
We applied multivariate logistic regression analyses to relate candidate predictors to 
toxicity. First, we started with a full model, including all preselected variables. Subsequently, 
we eliminated the variables by a backward selection process with a threshold p-value of 
0.20, based on likelihood-ratio test results. The chosen p-value of 0.20 intends to limit the 
loss of information and to select also weaker predictors, although at the cost of including 
‘noise’ variables. [18] The preselected baseline variables, based on the literature and clinical 
experience, were primary tumor (breast, prostate, lung or other cancer), age (≤65 years or 
>65 years), gender (male or female), Karnofsky performance status (KPS) [19] (≤ 60, 70-80 
or 90-100), pain score (2-4, 5-7 or 8-10), presence of visceral metastases (yes or no), 
concomitant systemic therapy (yes or no), treatment arm (1 x 8 Gy or 6 x 4 Gy), opioids (yes 
or no), spinal localization (thoracic, thoraco-lumbar, lumbar or lumbo-sacral spine) and 
treatment technique (PA or APPA). 
The database was analyzed using IBM SPSS statistics for Windows version 20.0 (IBM Corp., 
Armonk, NY, USA) and SAS software (version 9.2, SAS Institute Inc, Cary, NC, USA).
Results
Baseline characteristics
In general, patients with spinal metastases did not differ from the entire population of 
1.157 patients with bone metastases. Table 1 shows baseline characteristics of the study 
population (n:343). Primary tumors were mainly breast (42%), prostate (24%) and lung (20%) 
cancer. The mean age was 65 years (range 32-89 years) and 52% was male. The majority of 
patients was in good to moderate condition, 71% had a KPS of 70 or higher. The mean pain 
score at baseline was 6.4 (range 2-10). Visceral metastases were documented in 28% of patients; 
55% of patients received concomitant systemic therapy at the time of randomization. 
250 patients (73%) were treated with a single PA-field and 93 patients (27%) with an APPA-
technique. The most frequently treated localization was the lumbar spine (53%), followed 
by the thoracic spine (34%). The remaining patients were treated at overlapping regions. 
Baseline characteristics did not differ between both treatment technique groups, except for 
systemic therapy. More patients in the group treated with a PA-field were treated with systemic 
therapy (59%), compared to patients treated with an APPA-technique (43%, p=0.009). 
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Table 1   Baseline characteristics of patients with painful spinal metastases,  






PA APPA difference  
PA vs APPA *
1157 343 250 93
primary tumor n.s.
breast cancer 451 (39%) 145 (42%) 110 (44%) 35 (38%)
prostate cancer 267 (23%) 83 (24%) 63 (25%) 20 (22%)
lung cancer 287 (25%) 68 (20%) 48 (19%) 20 (22%)
Other 152 (13%) 47 (14%) 29 (12%) 18 (19%)
Age n.s.
≤ 65 years 565 (49%) 167 (49%) 120 (48%) 47 (51%)
> 65 years 592 (51%) 176 (51%) 130 (52%) 46 (50%)
Gender n.s.
Male 624 (54%) 178 (52%) 125 (50%) 53 (57%)
Female 533 (46%) 165 (48%) 125 (50%) 40 (43%)
KPS n.s.
90 – 100 221 (19%) 67 (20%) 47 (19%) 20 (22%)
70 – 80 587 (51%) 176 (51%) 132 (53%) 44 (47%)
20 – 60 343 (30%) 100 (29%) 71 (28%) 29 (31%)
pain score n.s.
2 – 4 234 (20%) 71 (21%) 54 (22%) 17 (18%)
5 – 7 550 (48%) 155 (45%) 116 (46%) 39 (42%)
8 – 10 366 (32%) 117 (34%) 80 (32%) 37 (40%)
visceral metastases n.s.
No 838 (72%) 247 (72%) 178 (71%) 69 (74%)
Yes 319 (28%) 96 (28%) 72 (29%) 24 (26%)
systemic therapy 0.009
No 531 (46%) 156 (46%) 103 (41%) 53 (57%)
Yes 626 (54%) 187 (55%) 147 (59%) 40 (43%)
treatment schedule n.s.
1 x 8 Gy 578 (50%) 171 (50%) 129 (52%) 42 (45%)
6 x 4 Gy 579 (50%) 172 (50%) 121 (48%) 51 (55%)
pain medication n.s.
no opioids 667 (58%) 170 (50%) 123 (49%) 47 (51%)
Opioids 490 (42%) 173 (50%) 127 (51%) 46 (50%)
spinal localisation n.s.
thoracic spine 117 (34%) 90 (36%) 27 (29%)
thoraco-lumbar spine 32 (9%) 27 (11%) 5 (5%)
lumbar spine 183 (53%) 124 (50%) 59 (63%)
lumbo-sacral spine 11 (3%) 9 (4%) 2 (2%)
PA: posterior-anterior field, APPA: anterior-posterior and posterior-anterior field
KPS: Karnofsky performance score; Gy: Gray; n.s.: not significant; *: Chi-Square
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At baseline, the mean scores of the individual complaints items were low, varying from 1 
(no complaints) to 2 (minor complaints), on a scale from 1 to 4. The mean sum score of 
abdominal complaints was 1.3 (range 0-7.5, on a scale from 0 to 10) and the mean sum 
score of skin complaints was 0.7 (range 0-8.3, on a scale from 0 to 10). No baseline 
differences in items or sum scores between the two treatment groups were observed. 
A preference per treatment institute was noticed for treatment technique. Institute policy 
and preferences mainly determined the choice of technique, instead of individual patient 
characteristics.
Pain response
In total, 241 (74%) of the 325 evaluable patients had a pain response to radiotherapy, with 
no significant difference between the two treatment techniques (74% each). The pain 
response rate is comparable to that of the entire DBMS population. 
Side effects
Side effects were minor. In general, patients experienced more abdominal complaints 
than skin complaints. Four and eight weeks after treatment, respectively 264 (77%) and 
229 (67%) patients returned questionnaires. Figure 1 shows the course of complaints in 
the first weeks after treatment. Patients treated with an APPA-technique experienced 
more abdominal complaints compared to patients treated with a PA-field. This difference 
was temporary, abdominal complaints were comparable five weeks after treatment. Skin 
complaints increased minimally over time, irrespective of treatment technique (figure 1A). 
For both techniques, patients receiving multiple fractions experienced more abdominal 
complaints than patients receiving a single fraction (figure 1B). Differences in skin complaints 
were hardly noticed (figure 1C).
In patients treated with both techniques, the course of complaints was similar for all 
anatomical localizations, although most outspoken for the lumbar spine in patients 
treated with an APPA technique (figure 2). For skin complaints, only the two patients 
treated at the lumbo-sacral spine with an APPA-technique showed a distinctive increase, 
to a maximum mean score of 3.4 (scale of 0-10).    
Studying the separate side effects for all 343 patients, a trend was noticed towards more 
vomiting and abdominal pain in patients treated with the APPA-technique (p = 0.054 and 
p = 0.053 respectively). Patients treated with the APPA-technique had significantly more 
severe complaints of diarrhea (p = 0.044). No significant difference was noticed for nausea. 
Studying the abdominal side effects for the lower spine (all patients, excluding those 
treated on the thoracic spine only), there were statistically significant differences between 
treatment techniques. For all studied items (nausea, vomiting, abdominal pain and 
diarrhea), patients treated with the APPA-technique experienced more complaints than 
patients treated with the PA-technique (p-values all <0.009). 
56
Chapter 3
Figure 1   The course of complaints (range of score 0 to 10) after radiotherapy for  
painful spinal metastases. (A) abdominal and skin complaints per treatment 
technique, (B) abdominal complaints per treatment technique  















0 1 2 3 4 5 6 7 8 
skin, PA 
skin, APPA 










































Side effects of radiotherapy
3
Table 2 shows the results of the multivariate analyses. Treatment schedule and location 
were independent predictors for abdominal complaints. Patients treated with a single 
fraction had a lower risk of abdominal complaints (OR 0.49 (95% CI 0,29-0,81)) compared to 
multiple fractions. Patients treated at the thoraco-lumbar and lumbar spine had a higher 
risk of abdominal complaints (OR 2.51 (0.93-6.80) and 2.29 (1.34-3.93) respectively), 
compared to radiotherapy of the thoracic spine. For skin complaints (Table 2B), primary 
tumor and localization were predictive in multivariate analyses. Patients with lung cancer 
(OR 2.27 (1.20-4.30) compared to breast cancer) had a higher risk of skin complaints. 
Figure 2   The course of abdominal complaints (range of score 0 to 10) after radio - 
therapy for painful spinal metastases. To facilitate interpretation, subgroups 
with less than 10 patients were not shown in the figure (lumbosacral spine PA 
(n:9), thoracolumbar spine APPA (n:5), lumbosacral spine APPA (n:2)).  
(A) abdominal complaints using the PA-technique per location, (B) abdominal 
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Patients treated at the lumbo-sacral spine (OR 1.83 (0.52-6.49) compared to radiotherapy 
of the thoracic spine)  had a higher risk, while patients treated at the lumbar spine had a 
lower risk of skin complaints (OR 0.54 (0.32-0.91)) compared to the thoracic spine. 
Treatment technique did not predict for abdominal or skin toxicity after radiotherapy. 
When studying patients per treatment arm, treatment technique was not significantly 
associated with abdominal or skin toxicity. 
Table 2A   Analysis of potential predictors for developing abdominal complaints 
within four weeks after treatment for painful spinal metastases.
% of patients with Odds Ratio (95% CI)
baseline variables abdominal com-
plaints
UVA a MVA a
primary tumor
breast cancer 73% 1.00 #
prostate cancer 71% 0.90 (0.49-1.67)
lung cancer 69% 0.84 (0.43-1.64)
Other 64% 0.68 (0.33-1.42)
Age
≤ 65 years 70% 1.00 #
> 65 years 70% 1.01 (0.62-1.64)
gender
male 71% 1.00 #
female 70% 0.95 (0.59-1.54)
KPS
90 - 100 65% 1.00 #
70 - 80 73% 1.16 (0.61-2.20)
20 - 60 70% 0.78 (0.39-1.55)
pain score
2 - 4 69% 1.00 #
5 - 7 73% 1.22 (0.65-2.30)
8 - 10 68% 0.96 (0.49-1.86)
visceral metastases
no 69% 1.00 #
yes 74% 1.26 (0.72-2.22)
systemic therapy
no 73% 1.00 #
yes 68% 0.78 (0.48-1.27)
treatment schedule
6 x 4 Gy 78% 1.00 1.00
1 x 8 Gy 63% 0.49 (0.30-0.81) 0.49 (0.29-0.81)
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Table 2B   Analysis of potential predictors for developing skin complaints within  
four weeks after treatment for painful spinal metastases.
% of patients with Odds Ratio (95% CI)
baseline variables skin complaints UVA a MVA a
primary tumor
breast cancer 31% 1.00 1.00
prostate cancer 28% 0.87 (0.47-1.61) 0.95 (0.50-1.79)
lung cancer 49% 2.19 (1.17-4.11) 2.27 (1.20-4.30)
Other 36% 1.26 (0.61-2.62) 1.28 (0.61-2.70)
Age
≤ 65 years 39% 1.00 #
> 65 years 30% 0.66 (0.41-1.06)
Gender
Male 35% 1.00 #
Female 33% 0.92 (0.58-1.47)
KPS
90 – 100 34% 1.00 #
70 – 80 31% 0.84 (0.46-1.56)
20 – 60 40% 1.29 (0.66-2.51)
Table 2A   Continued.
% of patients with Odds Ratio (95% CI)
baseline variables abdominal com-
plaints
UVA a MVA a
pain medication
no opioids 71% 1.00 #
opioids 70% 0.95 (0.59-1.54)
spinal localisation
thoracic spine 60% 1.00 1.00
thoraco-lumbar spine 79% 2.44 (0.91-6.54) 2.51 (0.93-6.80)
lumbar spine 77% 2.22 (1.31-3.77) 2.29 (1.34-3.93)
lumbo-sacral spine 45% 0.56 (0.16-1.94) 0.65 (0.18-2.30)
treatment technique
PA 69% 1.00 #
APPA 75% 1.35 (0.76-2.37)
95% CI: 95% confidence interval, UVA: univariate analysis, MVA: multivariate analysis, KPS: Karnofsky performance 
status, PA: posterior-anterior field, AP-PA: anterior-posterior and posterior-anterior field a: logistic regression analysis, 




This study showed that treatment technique did not predict for abdominal nor skin 
complaints. Pain response rates did not differ between both treatment techniques.  In a 
multivariate model, fractionation schedule and treated localization were independent 
predictors of abdominal complaints. Primary tumor and treated location appeared to be 
predictors of skin complaints. 
Table 2B   Continued.
% of patients with Odds Ratio (95% CI)
baseline variables skin complaints UVA a MVA a
pain score
2 – 4 29% 1.00 #
5 – 7 34% 1.22 (0.65-2.31)
8 – 10 38% 1.48 (0.76-2.90)
visceral metastases
No 33% 1.00 #
Yes 38% 1.27 (0.76-2.14)
systemic therapy
No 38% 1.00 #
Yes 31% 0.75 (0.47-1.20)
treatment schedule
6 x 4 Gy 31% 1.00 #
1 x 8 Gy 37% 1.34 (0.84-2.15)
pain medication
no opioids 33% 1.00 #
Opioids 35% 1.09 (0.68-1.75)
spinal localisation
thoracic spine 42% 1.00 1.00
thoraco-lumbar spine 39% 0.91 (0.39-2.14) 0.95 (0.40-2.25)
lumbar spine 27% 0.52 (0.31-0.88) 0.54 (0.32-0.91)
lumbo-sacral spine 55% 1.69 (0.49-5.89) 1.83 (0.52-6.49)
treatment technique
PA 33% 1.00 #
APPA 37% 1.19 (0.70-2.02)
95% CI: 95% confidence interval, UVA: univariate analysis, MVA: multivariable analysis, KPS: Karnofsky 
 performance status, PA: posterior-anterior field, AP-PA: anterior-posterior and posterior-anterior field a:  
logistic regression analysis, none of the differences is statistically significant, using Chi Square,  
# : did not remain in the final model
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Although nowadays more conformal techniques and even stereotactic radiotherapy are 
frequently used in patients with painful bone metastases, the benefits of those techniques 
compared to the conventional techniques still remain to be proven. All available data 
show that a dose higher than 8 Gy is not superior to a single dose of 8 Gy in terms of pain 
control. [20] These techniques have the disadvantage that they are more time consuming 
in terms of preparation, additional imaging modalities (such as magnetic resonance 
imaging) needed and a more complex and technically demanding treatment planning. 
[21-23] Furthermore, they are more expensive than conventional treatment techniques 
[24] and treatment time is in general prolonged, which causes more inconvenience for the 
patients. Therefore, for the majority of patients, conventional techniques still remain the 
treatment of first choice. [25]
In general, the reported side-effect scores were relatively low. This does not imply that 
those side effects are not relevant, since even mild complaints might be burdensome. In 
a study among 368 patients receiving radiotherapy, patients with nausea, although with 
mild severity in 72% of patients, had a lower QoL and a lower overall level of wellbeing 
than patients without nausea. [26]
Our results showing more abdominal complaints with the multiple fraction treatment are 
in line with the results from Chow et al. in re-irradiated patients with painful bone 
metastases. [27] They described more vomiting, loss of appetite and diarrhea after 20 Gy 
in multiple fractions compared to a single fraction of 8 Gy. They also described more 
redness of the skin after multiple fractions, which was not noticed in our analyses, 
although redness was not specifically questioned. 
The abdominal side effects of the APPA-technique were more prominent in patients 
treated on the lower spine. In this part of the spine, the vertebrae are located relatively 
ventral. An APPA-technique gives a better dose coverage, due to the deep location of 
the target volume, with the anterior body of the fifth lumbar vertebra located at a mean 
depth of 12 cm. [11] A PA-technique might lead to a lower dose on the ventral part of 
the vertebral body, which can a disadvantage, since previous studies have shown that a 
dose of 8 Gy results in a higher pain response rate than lower doses. [28, 29] On the other 
hand, in this study population, the response rate does not differ between treatment 
techniques. 
Another disadvantage of the PA-technique at the lower spine might be the high skin dose 
when trying to cover the ventral part of the vertebral body. [11] We did not notice skin side 
effects related to treatment technique, but this might be due to the type of questions 
asked and the lack of an objective physical examination. An option could be to treat this 
location with a three field or intensity modulated technique, thereby avoiding bowel 
structures [30] and the skin. [31, 32] However, these conformal techniques are more time 
consuming, for patients and logistics [33], and not available in every institution. A more 
conformal, but efficient and easy technique is a single PA-field using 10MV, with the 
addition of a second AP-field, contributing less than 50% of the dose, to increase the dose 
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ventrally to at least 85% of the prescribed dose. In this way, side effects to the bowel can 
be minimized. 
In our multivariate analyses, we found that patients with bone metastases from lung 
cancer are at increased risk of skin complaints. We have no reason to believe that those 
patients are more sensitive to radiotherapy. We also found that patients treated at the 
lumbo-sacral spine have more skin complaints. An explanation might be the varying 
depth of lumbal and sacral vertebra [11] , possibly leading to more skin dose when trying 
to cover the entire vertebral bodies with a PA-field. However, we believe those skin 
complaints to be of minor relevance, due to the limited increase in complaints.  
A disadvantage of our analyses is, firstly, that we are not informed about the intake of 
anti-emetics and/or anti-diarrhea medication. It has been shown that the decision on 
prescribing medication differs per physician [34], so patients from some physicians might 
have had medication for side-effects, while others hadn’t.. Secondly, the choice of 
treatment technique was not randomized, increasing the risk of confounding by indication. 
We did notice a preference per treatment institute. Since institute policy and preferences 
mainly determined the choice of technique, instead of individual patient characteristics, 
we also adjusted our analyses for treatment institute as sensitivity analyses, which showed 
similar outcomes. Thirdly, patients reported their complaints once a week. Perhaps if 
reported with smaller intervals, minor, but relevant differences in toxicity would have 
been noted. Fourthly, only 93 patients were treated with the APPA-technique, with a 
subgroup of 51 patients treated with six fractions of 4 Gy and 42 patients with a single 
fraction of 8 Gy. Finally, no data were known about dose distribution. 
On the other hand, this dataset provides a unique insight in patients receiving palliative 
radiotherapy, due to the number of patients included and the frequency and contents of 
the prospective patient-reported follow-up. Although our data were collected from 1996 
until 1998, we believe the results presented here are still representative for current patients 
receiving palliative radiotherapy for spinal metastases, which is still delivered mainly using 
AP and APPA fields. And, while improvements in systemic therapy have occurred over the 
last years, the most frequent applied treatment for painful bone metastases is palliative 
radiotherapy, with a single fraction of 8 Gy as the golden standard [2]. Although medication 
might help to prevent the reported side effects [35], we believe it is better to try to avoid 
any side effects by using an optimal treatment technique, especially in this patient group 
with frequent co-medication and/or systemic therapies.
In conclusion, we advocate the use of a single fraction to treat patients with painful 
uncomplicated spinal metastases. Based on our analysis, when conventional techniques 
are used, there is no preference for either a PA or an APPA-technique. If higher total doses 
are needed, we advise to search for a more conformal treatment technique to avoid high 
doses to the abdomen, specifically when treating the lower spine.
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Screening for psychological distress  
before radiotherapy for painful  
bone metastases may be useful to identify 
patients with high levels of distress 
Westhoff PG, de Graeff A, Monninkhof EM, Berveling MJ, van Vulpen M, 
Leer JWH, Marijnen CAM, Reyners AKL, van der Linden YM. 





Background: Psychological distress (PD) has a major impact on quality of life. We studied the 
incidence of PD before and after radiotherapy for painful bone metastases. Furthermore, 
we aimed to identify factors predictive for PD.
Methods: Between 1996 and 1998, the Dutch Bone Metastasis Study included 1,157 patients 
with painful bone metastases. Patients were randomized between two fractionation 
schedules. The study showed a pain response of 74% in both groups. Patients filled out 
weekly questionnaires for 13 weeks, then monthly for two years. The questionnaires 
included a subscale for PD on the Rotterdam Symptom Checklist. We used generalized 
estimating equations and multivariable logistic regression analyses. 
Results: At baseline, 290 patients (27%) had a high level of PD. For the entire group, the level 
of PD remained constant over time. The majority of patients with a low level of PD at baseline 
remained at a low level during follow-up. In patients with a high level of PD at baseline, 
the mean level of PD decreased after treatment and stabilized around the cut-off level. 
Female patients, higher age, worse performance, lower pain score and worse self-reported 
QoL were associated with an increased chance of PD, although the model showed 
moderate discriminative power. 
Conclusion: A substantial proportion of patients had a high level of PD before and after 
radiotherapy for painful bone metastases. Most patients who reported high levels of PD 
when referred for palliative radiotherapy remained at high levels thereafter. Therefore, 






Radiotherapy is an effective treatment for patients with painful bone metastases. The pain 
response rate is above 60%, with the golden standard of a single fraction of 8 Gray (Gy). 
[1-3] Although reduction of pain is the main treatment goal, it is also important to focus on 
quality of life (QoL). [4] Painful bone metastases have a negative impact on the QoL of 
patients. [5, 6] Studies show that radiotherapy stabilizes or improves QoL. [7-15]  
Psychological distress (PD) has a major impact on QoL and is defined as a multi-determined 
unpleasant emotional experience that may interfere with the ability to cope effectively with 
cancer, its physical symptoms and treatment. [16] Symptoms such as nervousness, depressed 
mood, worrying, anxiety and irritability contribute to PD [17] and are quite common in 
patients with advanced cancer. Nervousness for example, is experienced by almost 50% 
of incurable cancer patients, according to a systematic review in 25.074 patients. [18] Other 
symptoms, such as depressed mood, worrying, anxiety and irritability are reported by 
39%, 36%, 30% and 30% of patients respectively. 
Up to 50% of patients suffer from PD, however only a small percentage of them is referred 
for intervention. [19, 20] Routine screening of distress in patients with disseminated cancer 
is uncommon [20], despite the fact that several interventions exist which can decrease PD, 
such as psychosocial interventions [21], cognitive therapy [22] or psycho-educational 
interventions [23, 24]. Some patients disclose the presence of PD to their health care providers 
spontaneously and are therefore easily identified. Other patients do not communicate or 
even recognize their PD and its impact. Patients and health care providers may also be 
unaware of the possibility of interventions to reduce PD. [19] It is therefore important to 
identify patients with high levels of PD early, to increase awareness of both patients and 
health care professionals on this topic, and, if wanted, to offer interventions. Most of the 
current literature on PD was acquired in patients with cancer treated with a curative intent. 
[19, 24-28] To our knowledge, no studies were performed so far specifically in patients with 
bone metastases. No studies reported the extensive course of PD, both in palliative and 
curative setting. 
In earlier publications we showed that total QoL and its separate domains, including the 
psychosocial domain, diminish towards death [14] and that patients responding to radio- 
therapy have a better QoL than non-responding patients [29]. The aim of the present 
analysis was to focus on the incidence of PD in patients with painful bone metastases and 
its course following palliative radiotherapy. We aimed to identify factors predictive for PD. 
For this purpose, the data from the randomized Dutch Bone Metastasis Study (DBMS) [1] 




The DBMS was a nationwide, randomized trial in patients with uncomplicated painful 
bone metastases. Between 1996 and 1998, 1.157 patients were randomized between a 
single fraction of 8 Gy or 24 Gy in six fractions. The mean age was 65 years (range, 32-89 
years). Fifty-four percent of the patients were male. Most patients had breast cancer (39%), 
prostate cancer (23%), or lung cancer (25%). At study  inclusion, the mean and median 
time since diagnosis of the primary tumor was more than three years and almost two 
years, respectively. The median and mean survivals of the entire group were 30 weeks 
and 49 weeks, respectively, with a range of 0.3 to 142 weeks. The study showed the equal 
effectiveness of both treatment schedules with regard to pain response, which was the 
primary endpoint. All patients provided informed consent and the Medical Ethics 
Committees of participating institutions approved the study. Further details of the DBMS 
and the study protocol were published elsewhere. [1, 30]
  
Questionnaires  
At randomization and during follow-up, patients filled out  weekly questionnaires for 
thirteen weeks  and then monthly until two years of follow-up, death or closure of the 
study in December 1998. The questionnaires were carried out by mail. The questionnaires 
consisted, amongst others, of the Rotterdam Symptom Checklist (RSCL) [17], a visual 
analogue general health scale (VAS-gh), a pain scale and pain medication intake. The RSCL 
consists of three subscales (psychological distress, physical symptom distress and activity 
level impairment) and a scale for overall valuation of life (on a seven-point Likert-type 
scale, with a low score indicating few or no complaints) (VRS-vl). All other RSCL-items were 
rated on a four-point Likert-type scale, ranging from 1 (no complaints at all) to 4 (many 
complaints). Sum scores were calculated conform to the manual of the RSCL, inserting the 
personal scale mean of the patient in cases where less than half of the items of the sum 
score were missing. [17] At baseline, the score for the RSCL-subscale for PD was available in 
94% of patients. In addition to the RSCL scales, a VAS-gh was noted on a line from 0 (no 
complaints) to 100 (worst general health possible). The advantage of the latter is that each 
individual patient valuates for himself the impact of his combined physical, psychological 
and functional condition on their overall perceived general health. Pain was measured 
using an 11-point numeric rating scale, ranging from 0 (no pain) to 10 (the worst pain 
imaginable). A pain score of at least 2 was required to enter the study. [1] 
Psychological distress
The PD subscale of the RSCL consists of seven items, namely irritability, worrying, 
depressed mood, nervousness, despairing about the future, tension and anxiety. Since all 
items are scored on a four-point Likert-type scale, the total sum score ranges from 7 (no 




patients, in order to screen for anxiety and depression. The RSCL performed well in 
patients with progressive disease. A cut-off point with good sensitivity and specificity for 
the presence of PD was determined at 16. [31] 
To determine whether patients with an intermediate level of PD at baseline might have 
more chance of converting to a high level of PD during follow-up, the patients below the 
cut-off value were divided into two groups: low (7-11) and an intermediate (12-16) level. 
Pain response
Pain response was calculated by taking changes in pain score and pain medication into 
account, according to international criteria. [32] No fixed time interval from the date of 
randomization was applied. A response was calculated if at least two successive follow-up 
pain scores were available.
Statistical analyses
Chi-Square tests were used to compare the categorical variables at baseline. To visualize 
and compare the course of PD over time, we used generalized estimating equations 
(GEE-measurements), a longitudinal data analysis technique. P-values are based on 
two-sided tests and considered significant if p<0.05. Figures were created based on the 
least square means of the repeated measurements. 
To assess which variables were predictive for PD at baseline, we dichotomized the patients 
into having or not having PD (sum score <17 and ≥17). We applied multivariable logistic 
regression analyses to relate candidate predictors for PD. First, a full model was used, 
including all preselected variables. Subsequently, we eliminated the variables by a 
backward selection process with a threshold p-value of 0.20, based on likelihood-ratio test 
results. The chosen p-value of 0.20 intends to limit the loss of information and to also 
select weaker predictors, although at the cost of including ‘noise’ variables. [33] The 
preselected baseline variables, based on the literature and clinical experience, were 
primary tumor (breast, prostate, lung or other cancer), age (≤65 or >65 years), gender 
(male or female), Karnofsky performance status (KPS) [34] (≤ 60, 70-80 or 90-100), baseline 
pain score (2-5, 6-7 or 8-10), VRS-vl (1-3 (good), 4 or 5-7 (bad)), VAS-gh (0-33 (good), 34-66 
or 67-100 (bad)), visceral metastases (yes or no), systemic therapy (yes or no), treatment 
arm (6x4 Gy or 1x8Gy), pain medication (no opioids or opioids), localization of pain 
(extremities, spinal column, pelvis or other) and time since diagnosis of primary tumor 
(continuous). To prevent that independent variables entered into the model were 
correlated with each other, especially those measuring daily living abilities and general 
health, we checked for multicollinearity. 
The database was analyzed using IBM SPSS statistics for Windows version 20.0 (IBM Corp., 




Relation between patient characteristics and PD at baseline
In 1084 (94%) patients, the level of PD at baseline could be calculated. The mean level of 
PD at baseline was 13.4 for the entire group, with a median of 12.0. Twenty-seven percent of 
patients had a high level of PD at baseline (score≥17). Table 1 shows baseline characteristics 
of the three baseline levels of PD. 
The mean age was 65 years (range 32 – 89 years). Within the different groups of primary 
cancer, 32% of patients with breast cancer had a high level of distress, compared to 21% of 
patients with prostate cancer and 22% of lung cancer patients. Twenty percent of male 
patients experienced a high level of distress, compared to 31% of female patients. There 
was a significant gender difference in the 285 patients with lung cancer and the fourth 
group consisting of 145 patients with other primary tumors and their level of PD at 
baseline. Thirty-seven percent of these women had a high level of PD, compared to 21% 
of male patients (p = 0.016). 
There were significant differences between the three groups in terms of primary tumor, 
gender, KPS, VRS-vl and VAS-gh. Patients with a high level of PD at baseline were more 
likely to have breast cancer, to be female and to have a low KPS. They had lower scores for 
their overall QoL, rated both visually and verbally. There was no relation between PD at 
baseline and mean pain score. 
Because we expected patients with a short survival to have high levels of PD, we analyzed 
this group separately; of the 405 patients who died within three months or did not 
respond anymore after twelve weeks, 24%, 32% and 44% had a high, intermediate or low 
level of PD at baseline, respectively. There was no significant correlation between PD at 
baseline and survival. 
Prediction of high levels of PD at baseline
In table 2, the results of multivariate analysis are shown. The final model to predict a high 
level of PD at baseline included age, gender, KPS, pain score, VRS-vl and VAS-gh. Female 
patients, higher age, lower performance status, lower pain score and worse self-reported 
QoL were associated with an increased chance of high levels of PD. The area under the 
curve of the final model was 0.710, indicating moderate discriminative power. The 
explained variance was 15.3%. 
Course of PD
Figure 1 shows the course of PD over time after treatment. Figure 1a shows the entire 
group of patients, in which the mean score of distress remained more or less constant 
over time. When excluding the 405 patients who did not return the questionnaires after 
three months, due to death (65%) or other reasons, possibly representing patients in a 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2   Univariate (UVA) and final multivariate (MVA) logistic regression analyses on 
potential baseline predictors for high level of psychological distress before 
palliative radiotherapy for painful bone metastases.
Baseline variables Odds ratio (95% CI)
UVA* MVA*
Primary tumor   
Breast 1.00 #
Prostate 0.57 (0.40 - 0.82)  
Lung 0.61 (0.43 - 0.87)  
Other 0.80 (0.53 - 1.22)  
Age   
≤ 65 years 1.00 1.00
> 65 years 1.08 (0.83 - 1.42) 1.28 (0.95 - 1.73)
Gender   
Male 1.00 1.00
Female 1.84 (1.40 - 2.42) 1.94 (1.44 - 2.62)
KPS   
90-100 1.00 1.00
70-80 1.83 (1.21 - 2.76) 1.44 (0.92 - 2.24)
20-60 2.83 (1.84 - 4.37) 1.67 (1.03 - 2.70)
Pain score   
2 – 5 1.00 1.00
6 – 7 0.85 (0.61 - 1.18) 0.65 (0.46 - 0.94)
8 – 10 1.10 (0.80 - 1.52) 0.60 (0.42 - 0.87)
VRS-vl   
1 – 3 1.00 1.00
4 1.66 (1.11 - 2.47) 1.40 (0.91 - 2.17)
5 – 7 3.94 (2.74 - 5.67) 2.54 (1.63 - 3.96)
VAS-gh   
0-33 1.00 1.00
34-66 1.86 (1.20 - 2.88) 1.43 (0.88 - 2.31)
67-100 4.73 (3.06 - 7.32) 2.64 (1.55 - 4.48)
Visceral metastases   
No 1.00 #
Yes 0.93 (0.69 - 1.26)  
Systemic therapy   
No 1.00 #
Yes 1.28 (0.97 - 1.68)  
Treatment arm   
6 x 4 Gy 1.00 #
1 x 8 Gy 1.11 (0.85 - 1.45)  
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scores (figure 1a).When separating the patients into three groups with low, intermediate 
and high PD at baseline, figure 1b shows that the course of distress was also rather stable 
for the low and intermediate group. For patients with a high level of distress at baseline, 
the mean level decreased in the first weeks after treatment and stabilized around 16 
(slightly below the cut-off level). 
Sixty percent of patients with an initially high level of PD never reached a period of several 
weeks with PD below the threshold value. Of the patients with low or intermediate PD 
at baseline, approximately 20% were above the cut-off value of 17 somewhere in the 
follow-up period. No major differences in the course of distress between the four different 
primary tumors groups were noticed.  
Figure 2 shows the proportion of patients with a high, intermediate or low level of PD. 
The percentage of patients with a high level of PD decreases slightly over time, but remains 
substantial during the follow-up. 
Table 2  Continued.
Baseline variables Odds ratio (95% CI)
UVA* MVA*
Pain medication   
No opioids 1.00 #
Opioids 1.32 (1.01 - 1.74)  
Localization of pain   
Extremities 1.00 #
Spinal column 1.12 (0.74 - 1.71)  
Pelvis 0.95 (0.63 - 1.42)  
Other 0.95 (0.58 - 1.54)  
Time since primary tumor   
(Continuous) 1.00 (1.00 - 1.00) #
95% CI: 95% confidence interval, UVA: univariate analysis, MVA: multivariate analysis, *: logistic regression analysis, 
#: did not remain into the final model, KPS: Karnofsky performance score, VRS-vl: overall valuation of life, VAS-gh: 




Figure 1   Mean scores of psychological distress (sum score ranges between 7 (low) and 
28 (high)) at baseline (measurement 0) and after radiotherapy for painful bone 
metastases in (A) All patients (n = 1084) and all patients who still returned 
their questionnaires after twelve weeks (n = 679) and (B) Patients with a high 
(n = 290), intermediate (n = 337) and low level (n = 457) of psychological 
distress at baseline. The first twelve measurements after baseline were taken 
weekly, thereafter monthly.








































































































































We conclude from our analyses that 27% of patients with advanced cancer referred for 
palliative radiotherapy for painful bone metastases, have a high level of psychological 
distress when measured on the Rotterdam Symptom Checklist. [17] Furthermore, we 
showed that female patients, older patients , those with a bad performance score, lower 
pain score and a low self-reported QoL are at risk for a high level of PD.
The course of PD following radiotherapy depends mainly on the level of PD at the start of 
treatment. In patients with high levels of distress at baseline the mean level of PD declined 
to a level just above the cut-off for having complaints. This might be due to (the 
expectation of) a pain response or the attention of caregivers at the radiotherapy 
department, even though, 19% of patients experienced high psychological distress a few 
weeks after treatment. There is little change in the level of distress after treatment in 
patients with intermediate and low levels of distress at baseline. 
Figure 2   Percentage of patients with a low, intermediate or high level of PD during 
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The results may be influenced by the loss of follow-up, as three months after treatment 
only 663 patients (57%) returned questionnaires. This is of course mainly due to the study 
population of patients with metastasized cancer and a limited life expectancy. Theoretically 
this might influence the results, since after a few months only the fittest patients remain, 
who may be less distressed than those patients approaching death. Therefore, in figure 1a, 
we excluded patients with a relatively short survival or those who were lost to follow-up 
three months after treatment. When excluding those patients, the course of PD remains 
similar, although this population has a slightly lower level of PD.     
The World Health Organization has defined palliative care as “an approach that improves 
the QoL of patients and their families facing the problem associated with life-threatening 
illness, through the prevention and relief of suffering by means of early identification and 
impeccable assessment and treatment of pain and other problems, physical, psychosocial 
and spiritual”. [35] In patients with advanced cancer, however, both patients and their 
health care provider are often focused on physical symptoms, with less attention for 
psychosocial problems. Although PD is a common problem among patients with cancer, 
many of those patients are not recognized and referred for interventions. [19, 20] Several 
interventions for coping with PD exist, such as individual psychological support, support 
groups or education programs. [20, 21, 36] Therefore, screening might be considered. 
A large recent review concluded that no specific screening tool for distress could be 
recommended [20]. A screening tool which is often used in Dutch hospitals, the distress 
thermometer (Lastmeter) [26], uses dichotomized questions such as ’do you feel distressed’, 
supplemented with the amount of distress on a scale from 0 to 10. A review including 
seven randomized trials showed that screening showed an effect on psychological well- 
being in four of the seven trials. [37] Furthermore, screening seems to improve communication 
between health care providers and patients and may enhance psychosocial referrals and 
facilitate discussions about QoL. [20] However, it is important to be aware that not all 
patients with a high level of PD want to be referred for an intervention. [26] In a study in 
302 cancer patients in the Netherlands, mostly treated with curative intent, 51% of 
distressed patients did not need an intervention directly after treatment and 25% were 
already receiving support. After two months, regardless of distress level, 10% of all 
screened patients reported an unmet need for intervention. The study showed that the 
need for an intervention was positively related to the level of distress. [28] In a study 
evaluating 361 referrals for psycho-oncological counseling, 20% of newly referred patients 
never attended counseling. These patients were mainly men and patients with lung 
cancer. [36] Therefore, although identification of distress is important in order to identify 
those patients who might benefit from intervention, referral should be discussed with the 
individual patient. A study in 1352 Dutch cancer patients found that single patients, 
patients not living with their partner and patients below 65 years most often wanted an 
intervention when highly distressed. [27]  In Switzerland, a study investigating the barriers 
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and predictors of patients accepting or declining psycho-oncological support has recently 
opened. The results of this trial should increase the insight into why not all patients with 
PD want to be referred for an intervention. [38]     
To our knowledge, no other papers regarding the incidence and course of PD in patients 
with bone metastases treated with palliative radiotherapy have been published, making it 
difficult to compare our results with other studies. A Japanese study in 85 patients with 
advanced non-small cell lung cancer, measured PD at diagnosis, after two and six months. 
Forty percent of these patients underwent radiotherapy. They showed that depression 
and anxiety decreased over time, while other dimensions of PD and the overall level of PD 
did not. A high level of complaints at baseline predicted for a high level of complaints 
during follow-up. Therefore, the authors recommended starting an intervention shortly 
after diagnosis. [39] These findings are largely in line with our results, although we notice 
a decrease in overall level of PD in patients with a high level of PD at baseline. 
A study among 149 married cancer patients, mainly with advanced disease, showed that 
female patients reported a higher overall distress than male patients. [40] In the earlier 
mentioned Dutch study in 302 cancer patients, female patients and younger patients were 
at higher risk of having a high level of PD. [28] In another paper studying 2.776 patients 
with cancer visiting a tertiary cancer center in Canada, significant gender differences were 
found; female patients reported depressive symptoms more frequently than male patients 
and were more likely to receive psychosocial support. [19] Contrary to our results, they also 
found younger patients to be at a higher risk of PD [19], as did a recent study among breast 
cancer patients in Morocco [25].  This might be related to the study populations, namely 
patients with all stages of cancer, where the disruption of social life might be different 
compared to patients in the palliative phase.    
Surprisingly, the three groups of PD had comparable pain scores at baseline. One would 
expect a higher pain score to be a risk factor for PD, leading to more anxiety, worrying or 
depression. Accordingly, in a study among 106 palliative patients a higher pain score was 
correlated with increased distress. [41] In contrast, we found that a lower pain score 
predicted for a higher level of PD. We have no clear explanation for this finding.  
Our data were collected in the late nineties, which might be considered as a limitation of 
our study, since changes in treatment and subsequent survival may have altered the 
course of the disease. Nevertheless, it is based on a unique and large cohort of patients 
with bone metastases. Although the systemic treatment has changed over time, the 
standard local treatment for patients with painful bone metastases has remained palliative 
radiotherapy, with a single fraction of 8 Gy. [2] Therefore, we believe these results are still 
applicable to current patients with painful bone metastases. Another possible shortcoming 
could be that we did not study patients with painful bone metastases who did not receive 
radiotherapy. The course of PD could be a result of progressive disease. 
In conclusion, over 25% of patients referred for palliative radiotherapy for painful bone 




following treatment. Although palliative radiotherapy is an effective treatment for pain, 
these patients still experience distress. Therefore, we would like to increase awareness in 
referring medical specialists and radiation oncologists on the presence of PD. We advise 
them  to screen patients for PD and, if present, to make the topic discussable. If wished for, 
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Purpose: To study the course of quality of life (QoL) after radiation therapy for painful bone 
metastases
Methods: The Dutch Bone Metastasis Study randomized 1157 patients with painful bone 
metastases between a single fraction of 8 Gray and six fractions of 4 Gray between 1996 
and 1998. The study showed a comparable pain response of 74%. Patients filled out 
weekly questionnaires for 13 weeks, then monthly for two years. In these analyses, physical, 
psychosocial and functional QoL domain scores and a score of general health were 
studied. Mixed modeling was used to model the course of QoL and to study the influence 
of several characteristics. 
Results: In general, QoL stabilized after a month. Psychosocial QoL improved after 
treatment. The level of QoL remained stable, steeply deteriorating at the end of life. For 
most QoL domains, a high pain score and intake of opioids were associated with worse 
QoL, with small effect sizes (-0.11 to -0.27). A poor performance score was associated with 
worse functional QoL, with a medium effect size (0.41). There is no difference in QoL 
between patients receiving a single fraction of 8 Gray and six fractions of 4 Gray, except for 
a temporary worsening of physical QoL after six fractions.
Conclusion: Although radiation therapy for painful bone metastases leads to a meaningful 
pain response, most domains of QoL do not improve after treatment. Only psychosocial 
QoL improves slightly after treatment. The level of QoL is related to the actual survival, 
with a rather stable course of QoL for most of the remaining survival time and afterward a 
sharp decrease, starting only a few weeks before the end of life. Six fractions of 4 Gray lead 
to a temporary worse physical QoL compared with a single fraction of 8 Gray.  
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Introduction
Radiation therapy is an effective treatment for patients with painful bone metastases, with 
a pain response rate of more than 60%. Several randomized trials have shown an equal 
effectiveness in pain response of a single fraction of 8 Gray (Gy) compared to multiple 
fractions. Therefore, the golden standard is to treat these patients with a single fraction of 
8 Gy. (1-3) Although reduction of pain is the main aim of treatment in patients with painful 
bone metastases, it is also important to focus on other goals of treatment. In the palliative 
setting, the traditional oncological treatment endpoints, like disease control or survival are 
often less or even not appropriate. The treating physician has to weigh the impact of 
treatment against the benefit it provides for the individual patient. Therefore, palliative 
treatments focus on maintaining or improving quality of life (QoL). (4) 
Health-related QoL is defined as a multidimensional construct encompassing perceptions 
of both positive and negative aspects of physical, emotional, cognitive and social functions, 
due to the sequelae of a disease and its treatment. (5) Painful bone metastases have a 
negative impact on the QoL of patients. (6, 7) Despite this, few of the numerous randomized 
trials that were published since the late nineties documented the impact of bone meta- 
stases and its treatments on QoL. If patients and their treating doctors have a better 
understanding of the expected course of QoL, this may help them to make decisions about 
treatment of painful bone metastases in the context of a possibly short life expectancy.
Some studies reported that radiation therapy improved QoL, mainly in patients 
experiencing a pain response. (8-14) Two of these publications had a very short follow-up 
of only one month (10, 11) and only two studies were randomized (12, 13). One of the latter 
studies compared different treatment schedules and found that improvements of QoL 
were of similar magnitude irrespective of fractionation schedule (single or multiple 
fractions). (12) The second, more recent, randomized study compared two treatment 
schedules for re-irradiation of painful bone metastases and found a better QoL two 
months after retreatment in responders compared to non-responders. (13) None of these 
studies reported the course of specific domains of QoL after treatment. 
Initial analyses of the Dutch Bone Metastasis Study (DBMS), the largest randomized trial 
comparing the effect of single versus multiple fractions on pain response, found no 
differences in global QoL between patients treated with a single fraction and multiple 
fractions. (1, 15) More recent analyses report that patients responding to radiation therapy 
have a better QoL during the first three months after treatment than non-responding 
patients. (16) The aim of our current analysis was to study the detailed course of the 
physical, psychosocial and functional domains of QoL and general health after radiation 
therapy for painful bone metastases with a maximum of two years follow up after 
treatment, and to create a model of its course. We also analyzed the influence of baseline 




The DBMS was a nationwide randomized controlled trial in 17 out of the 21 radiation 
therapy institutions for patients with painful bone metastases in the Netherlands. Between 
1996 and 1998, a total of 1157 patients with painful bone metastases were randomized 
between a single fraction of 8 Gy or 24 Gy in six fractions. The main endpoint of the study 
was pain response. Detailed descriptions of the study protocol have been published 
previously. (1) The Medical Ethics Committees of participating institutions approved the 
study and all patients provided informed consent. The database was updated for survival 
and closed in December 1998.
Questionnaires
At randomization and during follow-up, patients filled out weekly questionnaires for 
thirteen weeks and monthly thereafter until two years of follow-up, death or closure of the 
study. These questionnaires contained in total 43 items, including items from the 
Rotterdam Symptom Checklist (RSCL) (17), three questions about possible side-effects of 
radiation therapy and two questions from the European Organization for Research and 
Treatment of Cancer (EORTC) Core Quality of life Questionnaire (QLQ)-C30 (18), whether 
physical condition or medical treatment influenced family life or social activities. 
Furthermore, questionnaires consisted of a visual analogue general health scale (VAS-gh) 
and a question on the intake of pain medication. At randomization, the treating physician 
rated the performance using the Karnofsky performance status (KPS) (19). Pain was 
measured using an 11-point numeric rating scale, ranging from 0 (no pain) to 10 (worst 
pain imaginable). A pain score of at least 2 was required to enter the study. (1) The VAS-gh 
is a self-reported global assessment of general health, which was noted on a line from 0 
(no complaints) to 100 (worst general health possible). Missing data were imputed using 
the expectation maximization algorithm, when patients filled out at least half of the 
questionnaires. Of all questionnaires, 67.5% were filled out completely, without missing 
values. Twenty-two percent of all questionnaires were missing only one value. 
Quality of life analyses
In total, data of 1115 patients (96,4%) were used. The remaining 42 patients were not 
analyzed, since they never filled out a (complete) questionnaire. Principal component 
analysis with oblique rotation was used to reduce the number of QoL items from the 
questionnaires into components (or domains). Principal component analysis is considered 
a valid method to summarize data into factor scores. The advantage of this method is that 
we were able to convert individual items from the different questionnaires that were used 
in the DBMS into clinically meaningful and relevant sum scores. Three domains were 
found and labeled as: physical health, psychosocial health and functional status. Table 1 
presents the rotated and standardized component loadings, with a score for the contributive 
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ability of the item on the domain. As shown in table 1, some of the items contribute to 
two or three domains, while others contribute to a single domain. The domain scores 
were standardized to scores (z-scores), with a mean of 0 and a standard deviation of 1, 
to facilitate interpretation of the subsequent regression analyses. The domain z-scores 
were used for further analyses. A multilevel regression analysis was used to study the 
course of QoL (the three domain scores and the VAS-gh) during follow-up and to create 
a model based on these patient data. The higher the total score, the better the QoL. 
The multilevel model enables the analysis of all available data, as opposed to only 
complete data. The repeated measures have a first-order autoregressive covariance 
structure. We studied the influence of the following baseline variables on the course of 
QoL: age, gender, KPS, primary tumor (breast, prostate, lung cancer, and other) and 
treatment arm (1x8Gy, 6x4Gy). In addition, we studied the influence of two variables 
varying over time: pain score and intake of opioids. An alpha level of 0.05 was used to 
judge statistical significance of effects. As both predictors and outcome variables have 
been standardized, the regression coefficients can be interpreted as effect size r and d for 
continuous and dichotomous predictors respectively. Regression coefficients for binary 
predictors can be interpreted as effect size Cohen’s d, with values of 0.2-<0.5, 0.5-<0.8, and 
≥0.8 indicating small, medium and large effect sizes, and regression coefficients for 
continuous predictors can be interpreted as effect size r, with values of 0.1-<0.3, 0.3-<0.5, 
and ≥0.5 indicating small, medium and large effect sizes. (20, 21) Negative values indicate 
a negative effect on QoL, positive values a positive effect.
Survival groups for the course of QoL
To identify the course of QoL in relation to remaining survival, we divided patients into five 
separate survival groups, with an observed survival of less than 3, 3-<6, 6-<12, 12-<18 and 
18-<24 months. QoL was  modeled as a composite of two latent curves, modeling both 
time since the first measurement and time to death. This model thus takes into account 
the impact of impending death, as this can have a marked impact on QoL. The database 




Table 1   Allocation of the variables to the three QoL domains, with accompanying 
standardized component loadings.
Source Items physical psychosocial functional






lack of energy 0.34 0.46
low back pain 0.41
nervousness 0.83
nausea 0.62
despairing about future 0.90




decreased sexual interest 0.25
tension 0.85






tingling hands or feet 0.43
difficulty concentrating 0.26 0.45
sore mouth/pain when swallowing 0.49
loss of hair 0.20
burning/sore eyes 0.44
shortness of breath 0.31
dry mouth 0.53 0.21
care for myself (wash etc.) 0.82
walk about the house 0.83
light housework/household jobs 0.84
climb stairs 0.85
heavy housework/household jobs 0.85
walk out of doors 0.88
go shopping 0.86
overall valuation of life 0.40 0.28 0.29
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The primary results of the DBMS were already published. (1, 15) In short, of the 1115 
evaluable patients, the mean age was 65 years (range 32-89 years) and 46% of patients 
was female. The mean KPS was 70 (range 20-100) and in 28% of patients visceral metastases 
were documented. The most common primary tumors were breast (39%), prostate (23%) 
and lung cancer (25%). The overall pain response rate was 74%, with no difference between 
the two treatment schedules. The median and mean survivals were 30 and 49 weeks 
respectively, with a range of 0.3-142 weeks. After one year, 320 patients (28%) were still 
alive and returning questionnaires. At closure of the study, with a maximum follow-up of 
142 weeks (≈ 2.7 years) 860 (74%) patients had died.
Quality of life
Figure 1 shows the modeled course of the QoL domains physical health, psychosocial 
health and functional status and of the VAS-gh in patients surviving less than 3, 3-<6, 
6-<12, 12-<18 and 18-<24 months after randomization, respectively. The level of QoL is 
related to the actual survival, with a rather stable course of QoL for most of the remaining 
survival time and afterwards a sharp decrease, starting several weeks before the end of 
life. In general, treatment with radiation therapy does not lead to an improvement of QoL. 
After start of treatment, immediate deteriorations in the first week of the physical domain, 
the functional domain and VAS-gh are noticed. For the physical domain only, an improvement 
is seen after this initial decline. In both other domains, the deterioration flattens until it 
further decreases near death. Only in the psychosocial domain an improvement after 
treatment occurs, which persists until the steep decline towards death. 
Table 1   Continued.
Source Items physical psychosocial functional
QLQ-C30 interference with family life 0.31 0.34





bone pain 0.37 0.20
To facilitate interpretation of the domains, we only display items with a factor loading equal to  
or larger than 0.20, RSCL: Rotterdam Symptom CheckList; QLQ-C30: European Organization for 
Research and Treatment of Cancer Core Quality of life Questionnaire
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Figure 1   The modeled course of QoL after radiation therapy for painful bone 
metastases, represented in survival groups (patients surviving less than 3, 
3-<6, 6-<12, 12-<18 and 18-<24 months after randomization). The x-axis 
represents the months after treatment, where month 0 is the baseline 
measurement before treatment and month 1 the first months after treatment. 
The y-axis reflects the domain score of QoL, where the average is 0, with a 
standard deviation of 1. The higher the score, the better the QoL. (A) physical 
domain. (B) psychosocial domain. (C) functional domain. (D) VAS-gh.
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Figure 1   Continued.
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Impact of baseline and follow-up variables on QoL
Table 2 describes which baseline and follow-up variables influenced the course of the 
different QoL domain scores and the VAS-gh, including the effects sizes. Higher pain score 
and intake of opioids are associated with lower levels of QoL for almost all domains, with 
varying effect sizes. There are small, but clinically relevant, effects of intake of opioids on 
the physical and functional domain and on VAS-gh (-0.27, -0.21 and -0.21 respectively) and 
of pain score on the physical and psychosocial domain and on VAS-gh (-0.14, -0.11 and 
-0.24 respectively). The largest effect size is for the influence of KPS on the functional 
domain, with a medium effect size of 0.41. Age has a small effect on the functional domain, 
of -0.12. Thus, a lower baseline performance score or higher age is associated with 
significantly worse functional status. Furthermore, primary tumor has a small effect on the 
physical and functional domain, with patients with prostate cancer having worse 
functional and physical QoL after radiation therapy, while patients with breast cancer have 
a worse functional QoL, compared to patients with other types of cancer. Other effect 
sizes are smaller and therefore not considered clinically relevant. 
Impact of treatment schedule on QoL
Patients receiving either 8 Gy in a single fraction or six fractions of 4 Gy have comparable 
QoL outcomes, except for the physical domain (Figure 2). Treatment with six fractions of 4 
Gy leads to a temporary worsening of QoL on the physical domain during the first four 
weeks after treatment, compared to a single fraction of 8 Gy. This is represented in the 
difference between the dotted and the solid line in figure 2, with superimposing lines 
afterwards (effect size each week below 0.2, indicating a minor effect, p<0.001, table 2). 
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Our analyses describe the detailed course towards death of different QoL domains after 
radiation therapy in patients with painful bone metastases. QoL initially remains stable 
after treatment, until a steep deterioration occurs near the end of life. It is an important 
finding for both patients and physicians to be aware of the rather stable QoL, until several 
weeks before death. This stabilization may reflect the benefit of treatment, since a decline 
can be expected without treatment in most patients. However, since untreated patients 
were not studied, it may also reflect the natural course of the disease in these patients. The 
course of QoL towards death is in accordance with the pattern described by Murray. (22) 
His paper, which is frequently cited in palliative care, shows a distinctive pattern for cancer 
Figure 2   The modeled course of the physical domain twelve weeks after randomization, 
represented in survival groups (patients surviving less than 3, 3-<6, 6-<12, 
12-<18 and 18-<24 months after randomization). The temporary difference 
between both fractionation schemes is shown in the dotted line (1x8 Gray) and 
the solid line (6x4 Gray). The x-axis represents the weeks after start of treatment. 
The y-axis reflects the physical domain score, where the average is 0, with a 
standard deviation of 1. The higher the score, the better the physical QoL.
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patients versus patients with other life threatening diseases, such as COPD and cardiac 
failure. Cancer patients show a predictable pattern, characterized by an initial rather stable 
course of QoL, followed by a short and swiftly declining phase towards death. Our model, 
based on actual patient data, therefore confirms the hypothesis by Murray also for patients 
with painful bone metastases.   
There seems to be a discrepancy in our results that, although 74% of patients experienced 
a pain response, most domains of QoL of these patients did not improve after radiation 
therapy. This is in line with the fact that we found little effect in the multilevel regression 
analyses of pain score on the QoL domains. The main reason for this is probably the 
influence of many other variables on QoL, like the presence of other symptoms these 
patients suffer, related to their advanced disease and possibly also side effects from 
medication and/or systemic therapies. Concerns about end-of-life and worrying about 
the future might also influence QoL. (23) These concerns are not likely to resolve after 
radiation therapy for painful bone metastases. Nevertheless, in a population like this, even 
stabilization of QoL may be considered very meaningful to patients. Without treatment, 
QoL might have deteriorated sooner. The improvement in psychosocial status after 
treatment, might be due to the care given by doctors and nurses at the radiation therapy 
department, in combination with the hope and expectation of a beneficial treatment 
outcome. Notable is the temporary decline of physical health after six fractions of 4 Gy, 
which does not occur after a single fraction of 8 Gy, although with a minor effect size. The 
difference may be due to more treatment side effects and the burden of five additional 
visits to the radiation therapy facility. 
On the one hand, our results, indicating no apparent improvement of QoL after radiation 
therapy for painful bone metastases, are in line with the results from Caissie et al (8). They 
prospectively studied the QoL of a cohort of 178 patients with uncomplicated painful 
bone metastases, using the EORTC-QLQ-C15-PAL questionnaire at one, two, four and eight 
weeks after treatment. Unfortunately, at three out of the four time points a maximum of 
40% of patients returned the questionnaires. The pain response rate was 65% after two 
months. They reported no improvement of total QoL up to two months after radiation 
therapy, while pain, insomnia and constipation improved. In a recent randomized study 
on retreatment for painful bone metastases, in 528 evaluable patients, no clinically relevant 
improvement of global QoL was noticed after a pain response. (13) 
The results of the present study seem to be in contradiction with our earlier analyses 
showing that responders have a better QoL compared to non-responders. However, this 
difference is mainly caused by a deterioration of QoL in non-responders. Apparently, it is a 
matter of selection: the patients without a pain response are patients with a poorer QoL, 
both before and after treatment, and an observed shorter survival.(16, 24) The temporary 
decrease in physical health in the multiple fraction regimen we found in our current 
analyses, might be in line with some increase in fatigue the first two weeks after treatment, 
which was described in another paper, prospectively studying 518 patients. (9) 
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On the other hand, our results contradict several other studies, stating that radiation 
therapy leads to improvement of QoL. (9-13) However, these other studies have some 
limitations. For example, they only studied QoL at a limited amount of time points (10, 11, 
13), focused on limited items (9, 12) or included small patient numbers (11). Moreover, 
statistically significant improvement of QoL does not necessary reflect clinically relevant 
improvement. 
Although our study is based on a unique and large cohort of patients with bone 
metastases from the Netherlands, the data originate from the late nineties, which may be 
considered a limitation due to changes, in systemic and symptomatic treatments in the 
past years, which have altered the course of the disease. On the other hand, in the current 
paper we showed that, irrespective of  survival, the pattern of QoL is similar in all patient 
groups. QoL remains stable for a long period and only deteriorates briefly before the end 
of life. Although the systemic treatment of patients with painful bone metastases and 
their survival has changed over time, the standard local treatment has remained palliative 
radiation therapy, with a single fraction of 8 Gy (3). Therefore, we believe these QoL results 
are still applicable to current patients with painful bone metastases. The RSCL and EORTC 
QLQ-C30 questionnaires that were used, are not specifically designed for patients with 
painful bone metastases. Therefore, small, but meaningful differences might have been 
missed by these global QoL questionnaires. For future studies, we would recommend 
using a bone metastases specific questionnaire, like the EORTC QLQ-BM22, which contains 
22 questions, relevant to patients with bone metastases. Moreover, we would advise the 
EORTC PAL15 questionnaire instead of the C30. (25) Another possible limitation is that 
follow-up data may be biased, since patients with a good QoL and good performance 
status will be more likely to complete a questionnaire than patients in poor physical 
condition. However, since 74% of the patients died during follow up, we believe that the 
results towards death provide a meaningful outcome. A final shortcoming might be that 
we did not study patients with painful bone metastases who did not receive radiation 
therapy. Therefore, we cannot determine whether the stabilization of QoL is a benefit of 
treatment, although it seems reasonable to conclude that without treatment QoL would 
have deteriorated sooner.  
Conclusion
Although radiation therapy for painful bone metastases often leads to a meaningful pain 
response, most domains of QoL do not improve after treatment. Only psychosocial QoL 
improves slightly after treatment. The level of QoL is related to the actual survival, with a 
rather stable course of QoL for most of the remaining survival time and afterwards a sharp 
decrease, starting several weeks before the end of life. For most QoL domains, a high pain 
score and intake of opioids are associated with worse QoL. A poor performance score is 
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associated with worse functional QoL. There is no difference in QoL between patients 
receiving a single fraction of 8 Gray and six fractions of 4 Gray, except for a temporary 
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for painful bone metastases 
Westhoff PG, de Graeff A, Monninkhof EM, Pomp J, van Vulpen M, Leer JWH, 
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Purpose: To study quality of life (QoL) in responders and nonresponders after radiation 
therapy for painful bone metastases; and to identify factors predictive for a pain response. 
Methods: The prospectively collected data of 956 patients with breast, prostate, and lung 
cancer within the Dutch Bone Metastasis Study were used. These patients, irradiated for 
painful bone metastases, rated pain, QoL and overall health at baseline and weekly 
afterward for twelve weeks. Using generalized estimating equations analysis, the course 
of QoL was studied, adjusted for primary tumor. To identify predictive variables, proportional 
hazard analyses were performed, taking into account death as a competing risk, and 
C-statistics were calculated for discriminative value.  
Results: In total, 722 (76%) patients responded to radiation therapy. During follow-up, 
responders had a better QoL in all domains compared with nonresponders. Patients with 
breast or prostate cancer had a better QoL than patients with lung cancer. In multivariate 
analysis, baseline predictors for a pain response were breast or prostate cancer as primary 
tumor, younger age, good performance status, absence of visceral metastases, and using 
opioids. The discriminative ability of the model was low (C-statistic: 0.56). 
Conclusions: Responding patients show a better QoL after radiation therapy for painful 
bone metastases than nonresponders. Our model did not have enough discriminative 
power to predict which patients are likely to respond to radiation therapy. Therefore, 
radiation therapy should be offered to all patients with painful bone metastases, aiming 
to decrease pain and improve QoL.
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Introduction 
Radiation therapy, with a single fraction of 8 Gray (Gy), is an effective treatment for patients 
with painful bone metastases, with a durable pain response rate of more than 60%. (1-3) 
Since painful bone metastases have a major impact on quality of life (QoL) in patients with 
advanced cancer (4, 5), reducing pain is likely to improve QoL. Although a few studies 
showed that radiation therapy for painful bone metastases contributes to improvement 
of QoL, no thorough studies have been published focusing on the course of QoL after 
radiation therapy. (4, 6-8) These patients frequently have other contributing factors that 
influence QoL, like visceral metastases, deteriorating physical condition, psychosocial 
issues or side-effects from systemic treatments. (4, 9) Furthermore, adequate treatment of 
pain at one site might unmask pain at other sites, resulting in migrating pain. As a consequence, 
it is unsure to what extent a response to palliative radiation therapy leads to improvement 
of QoL. To determine the effect of palliative radiation therapy for painful bone metastases 
on QoL, it is relevant to study the difference in QoL between responding patients and 
nonresponding patients. To our knowledge only one publication  compared QoL in 22 
responding patients versus 8 nonresponders. (8) 
Moreover, it would be helpful to identify the remaining 30-40% of patients who will not 
respond to radiation therapy, in order to prevent overtreatment and loss of valuable time. 
These patients might benefit more from a change in pain medication (10) or other treatments, 
such as radiopharmaceuticals (11), bisphosphonates (12, 13), minimally invasive surgery (14, 
15) and/or systemic therapy. In addition, psychological interventions might be helpful, 
using pain education or other supportive measures (16). Several studies have tried to 
identify factors predictive for pain response after palliative radiation therapy, like primary 
tumor type, radiographic imaging features, size of radiation therapy fields and baseline 
pain score. (17-23) However, the results are inconsistent, probably related to the small 
number and selection of patients and the variables studied. A validated predictive model 
for response to radiation therapy for painful bone metastases has not been published yet. 
The aim of the present study is to study the course of QoL in responding versus non- 
responding patients, who received radiation therapy for painful bone metastases within 
the randomized Dutch Bone Metastasis Study (DBMS). In this study, in 1157 patients, 
no differences in pain response were seen between a single fraction of 8 Gy and six 
fractions of 4 Gy. (1, 24, 25) A second objective of the present study was to assess the value 




Patients and methods 
The DBMS was a nationwide, randomized controlled trial in patients with painful bone 
metastases. From 1996 to 1998, 1157 patients with painful bone metastases were randomized 
between a single fraction of 8 Gy or 24 Gy in six fractions, in 17 out of the 21 radiation 
therapy institutions in the Netherlands. The main endpoint was pain response. Single and 
multiple fraction schedules were equally effective in reducing pain, with a pain response 
in 73-75% of patients and no specific patient subgroups benefitting from the higher total 
dose. (1, 24-27) Detailed descriptions of the study protocol have been published previously. 
(1, 28) The Medical Ethics Committees of all participating institutions approved the study. 
All patients provided informed consent. In December 1998, the database was updated 
for survival and closed.
Study population
For the present analyses, patients were grouped into three groups of the most common 
tumor sites: breast cancer, prostate cancer and lung cancer, with a total of 1005 patients. 
The remaining group of 152 patients had a variety of primary tumors, mainly bladder, 
colorectal, esophageal cancer and unknown primary tumor. We considered this group too 
heterogeneous, while the outcome would not be easily translatable into daily clinical 
practice. Therefore, we excluded those patients from the present analysis.
Scales
At randomization and during follow-up, patients filled out weekly questionnaires for 
twelve weeks and monthly thereafter until two years of follow-up, death or closure of the 
study. At randomization, the treating physician rated the performance status using the 
Karnofsky performance score (KPS) (29). The questionnaires consisted of, among others, 
a pain scale, medication intake, the Rotterdam Symptom Checklist (RSCL) (30) and a visual 
analogue general health scale (VAS-gh). Pain was measured using an 11-point numeric 
rating scale, from 0 (no pain) to 10 (worst pain imaginable). A pain score of at least 2 was 
required to enter the study. (1, 28) The RSCL consists of three QoL-subscales (psychological 
distress, physical symptom distress and activity level impairment) and a scale for overall 
valuation of life (on a seven-point Likert-type scale) (VRS-vl). Sum scores were calculated in 
accordance with the RSCL manual. (30) All QoL-scores were standardized to the range of 
0 to 100, 0 representing the best possible and 100 representing the worst possible 
condition. The VAS-gh was noted on a line from 0 (no complaints) to 100 (worst general 
health possible). In general, a difference of ten points on a 100 point scale is considered to 
be clinically relevant. 
At baseline, the RSCL-domains, VRS-vl and VAS-gh were available in 97%, 97% and 96% of 
patients, respectively. After six weeks, those numbers were 75%, 73% and 73%, respectively. 
After twelve weeks, 61% of patients filled out each of those items. Responding patients 
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had a better compliance than nonresponders, at six weeks 42-45% of nonresponding 
patients filled out the items, versus 82-85% of responding patients. At twelve weeks after 
treatment, 79% of patients were alive. 816 patients (85%) completed all questionnaires up to 
4 weeks before their death. So, therefore, most missing data is due to (approaching) death.
Following international criteria (31), pain response was defined as a decrease in the initial 
pain score by at least two points, without analgesic increase, or an analgesic decrease 
without an increase in pain score. No fixed time interval from the date of randomization 
was applied. Response analysis was possible in 956 patients, because 49 patients (5%) did 
not return at least two successive follow-up pain scores, which was needed to determine 
response.
Statistical analysis
To compare the categorical variables at baseline, Chi-Square tests were used. Survival 
curves were estimated using the Kaplan Meier method and differences between curves 
were assessed with the log-rank test. For comparing the course of QoL-domains over time 
between responders and nonresponders, we used generalized estimating equations 
(GEE-measurements), a longitudinal data analysis technique. Since primary tumor type is 
related to the chance of a pain response, it might be a confounder. Therefore, the QoL 
analyses were adjusted for this factor. 
Effects of the different variables on the prediction of response were quantified using 
proportional hazard analyses according to the method of Fine and Gray. (32) This method 
takes into account all type of events, without assuming independency between the time 
to each of those events, but the effect depends on the magnitude of the risk of other 
competing events. 
The vast majority of responses (97%) appeared within twelve weeks after randomization. 
Therefore, we considered all deaths within those twelve weeks as competing risks.
On the basis of the literature and clinical experience, the following baseline variables 
were studied for their value in predicting response: primary tumor (breast, prostate or 
lung cancer), age (≤65 years or >65 years), KPS (≤ 60, 70-80 or 90-100), baseline pain score 
(2-4, 5-7 or 8-10), presence of visceral metastases (yes or no), concomitant systemic therapy 
(yes or no), baseline pain medication (no opioids or use of opioids), painful localization 
(extremities, spinal column, pelvis or other). We used single imputation method to impute 
missing values of KPS (in six patients) and pain score (in three patients) at baseline. 
Correlation between variables was assessed using Pearson’s correlation coefficients in 
order to assess the risk of multicollinearity of the potential predictors. Gender was not 
included into the model, since gender and primary tumor were highly correlated (Pearson 
correlation coefficient of 0.8). In a prognostic study, variables that are not significant in 
univariate analyses, should not be excluded for multivariate analyses. (33) Therefore, we 
started with all preselected variables for the development of the predictive model. 
Subsequently, we eliminated the variables by backward selection with a threshold p-value 
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of 0.20, until the model fit decreased significantly. The chosen p-value of 0.20 intends to 
limit the loss of information and to select also weaker predictors, although at the cost of 
including ‘noise’ variables. (34) In the regression analyses per primary tumor, we studied 
the full model, except for localization, since the degrees of freedom were limited in this 
analysis. In the analysis per primary tumor, gender was only studied in patients with lung 
cancer, due to the abovementioned correlation in patients with breast and prostate cancer. 
Discrimination of the predictive models was assessed with the C-statistic. A C-statistic is a 
measure for the discriminative ability of the model to distinguish between patients with 
a pain response and patients without pain response. A C-statistic ranges between 0.5 
and 1.0. A value of 0.5 means that the model is no better than chance, while a value of 1.0 
means perfect discrimination. (35) 
The database was analyzed using IBM SPSS statistics for Windows version 20.0 (IBM Corp., 
Armonk, NY, USA) and SAS software (version 9.2, SAS Institute Inc, Cary, NC, USA). The Fine and 
Gray competing risks and the C-statistics were calculated in the R language environment 
for statistical computing, version 2.10 (freely available at http://cran.r-project.org). 
Results
Pain response
In total, 722 (76%) of 956 patients experienced a pain response after treatment. Median 
time to response was 3 weeks. 
Quality of life
At baseline, there was a statistically significant difference in activity level impairment and 
VAS-gh between responders and nonresponders. Baseline psychological distress, physical 
symptom distress and VRS-vl did not differ significantly between responders and non-
responders. Figure 1 shows the course of QoL for responders and nonresponders during 
the first twelve weeks of follow-up. The curves differ significantly between responders 
and nonresponders, with a higher score (reflecting more complaints) for nonresponders 
in all QoL domains (all p-values <0.001). Psychological distress, physical symptom distress, 
VAS-gh and VRS-vl deteriorate in nonresponders but improve in responders.  Activity level 
impairment remains rather stable in responders but deteriorates in nonresponders. Figure 1 
shows that the differences were small in the first weeks after treatment, but increased with 
time, becoming clinically relevant. 
For all QoL domains, patients with prostate cancer had significantly better scores than 
patients with lung cancer. The average difference over time ranged between 2.2 points in 
physical symptom distress (p= 0.03) and 11.3 in activity level impairment (p<0.0001). 
Patients with breast cancer had a significantly better QoL than patients with lung cancer 
with regard to physical symptom distress, VRS-vl and VAS-gh.  
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Responders versus nonresponders
Table 1 shows the baseline characteristics of responding and nonresponding patients. 
No significant difference in response rate between the two treatment arms was noted. 
Of the patients with breast, prostate and lung cancer, 82%, 79% and 62% responded, 
respectively. Nonresponding patients more frequently had lung cancer and visceral meta- 
stases. The mean age differed significantly between responding and nonresponding 
patients: 64 years and 67 years respectively. Responding patients were in a better physical 
condition: 74% of responders had a pretreatment KPS of 70-100, compared to 64% of 
nonresponders. Patients with a KPS of 90-100, 70-80 and 20-60 responded in 84%, 76% 
and 69%, respectively. Baseline pain scores were comparable in responding and non- 
responding patients. Nonresponders were less likely to receive systemic therapy prior to 
radiation therapy. Responding patients lived significantly longer than nonresponders: 
median survival was 35 weeks for the entire cohort, 16 weeks for nonresponders, and 
45 weeks for responders (p<0.001). At closure of the study, 67% of responding patients 
and 87% of nonresponding patients had died.
Figure 1   Course of pain and QoL in responders and nonresponders during twelve weeks 
after palliative radiation therapy. Dark line represents responders, grey line 
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Table 1   Baseline characteristics of patients with and without response to 
radiation therapy.
baseline variables pain response to radiotherapy difference  
responders - 
nonresponders *
all patients response no response
n 956 722 234  
primary tumor     <0.001
breast 434 355 (82%) 79 (18%)  
prostate 253 200 (79%) 53 (21%)  
lung 269 167 (62%) 102 (38%)  
age (years)     0.009
≤ 65 years 463 367 (79%) 96 (21%)  
> 65 years 493 355 (72%) 138 (28%)  
gender     0.002
male 482 343 (71%) 139 (29%)  
female 474 379 (80%) 95 (20%)  
KPS     0.001
90 - 100 200 168 (84%) 32 (16%)  
70 - 80 488 370 (76%) 118 (24%)  
20 - 60 268 184 (69%) 84 (31%)  
pain score     0.762
2 - 4 198 152 (77%) 46 (23%)  
5 - 7 457 347 (76%) 110 (24%)  
8 - 10 301 223 (74%) 78 (26%)  
visceral metastases     0.04
no 722 557 (77%) 165 (23%)  
yes 234 165 (71%) 69 (29%)  
systemic therapy     <0.001
no 379 262 (69%) 117 (31%)  
yes 577 460 (80%) 117 (20%)  
treatment arm     0.525
1x8 Gy 483 369 (76%) 114 (24%)  
6x4 Gy 473 353 (75%) 120 (25%)  
pain medication     0.217
no opioids 556 428 (77%) 128 (23%)  
opioids 400 294 (74%) 106 (27%)  
painful localization     0.462
extremities 139 98 (71%) 41 (29%)  
spinal column 292 220 (75%) 72 (25%)  
pelvis 389 298 (77%) 91 (23%)  
other 136 106 (78%) 30 (22%)  
* : Pearson Chi-Square, KPS: Karnofsky performance score, Gy: Gray
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Model
In total, 72 (8%) patients, who died within twelve weeks without experiencing a pain 
response, were considered as having a competing event.
Table 2 shows the results of the analyses of predictors for a pain response. The final model 
included primary tumor, age, Karnofsky performance score, presence of visceral metastases 
and use of opioids. The analysis showed that breast or prostate cancer, younger age, good 
performance status, no visceral metastases and opioids were associated with an increased 
chance of a pain response. However, the C-statistic of this final model was only 0.56, 
indicating low discriminative power. Table 3 shows the analysis of the predictors for a pain 
response per primary tumor. Only for breast cancer, two variables appeared to add to the 
prediction of a pain response, with a C-statistics of 0.55. The multivariate analysis in patients 
with breast cancer showed that younger age and no visceral metastases were associated 
with a higher chance of responding to radiation therapy. For patients with prostate or 
lung cancer, no additional predictors were identified. 
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Table 2   Analysis of factors predictive for a pain response to radiation therapy  
for painful bone metastases.
baseline variables % of patients  
with response
Hazard Ratio (95% CI)
UVA * MVA *
primary tumor    
breast 355 (82%) 1.00 1.00
prostate 200 (79%) 0.96 (0.82-1.11) 0.94 (0.79-1.11)
lung 167 (62%) 0.67 (0.56-0.79) 0.67 (0.56-0.81)
age     
≤ 65 years 367 (79%) 1.00 1.00
> 65 years 355 (72%) 0.86 (0.75-0.98) 0.88 (0.76-1.01)
KPS     
90 - 100 168 (84%) 1.00 1.00
70 - 80 370 (76%) 0.87 (0.75-1.02) 0.88 (0.75-1.03)
20 - 60 184 (69%) 0.78 (0.65-0.94) 0.81 (0.66-0.99)
pain score     
2 - 4 152 (77%) 1.00 #
5 - 7 347 (76%) 1.03 (0.87-1.21)  
8 - 10 223 (74%) 1.01 (0.84-1.21)  
visceral metastases     
no 557 (77%) 1.00 1.00
yes 165 (71%) 0.83 (0.70-0.97) 0.81 (0.69-0.96)
systemic therapy     
no 262 (69%) 1.00 #
yes 460 (80%) 1.22 (1.06-1.40)  
pain medication    
no opioids 428 (77%) 1.00 1.00
opioids 294 (74%) 0.99 (0.86-1.13) 1.12 (0.96-1.29)
painful localisation    
extremities 98 (71%) 1.00 #
spinal column 220 (75%) 1.14 (0.92-1.42)  
pelvis 298 (77%) 1.14 (0.93-1.41)  
other 106 (78%) 1.23 (0.95-1.58)  
95% CI : 95% confidence interval, UVA : univariate analysis, MVA : multivariate analysis, *: competing risk analysis 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In the present analysis of the Dutch Bone Metastasis Study database on the effect of 
radiation therapy on QoL, we showed that response resulted in better QoL for all domains 
compared to non-response. Although the average differences were relatively small, the 
separating curves in figure 1 indicate a progressive clinically relevant difference between 
responding and nonresponding patients over time. Therefore, the average difference 
might not be the best measure to determine differences in QoL between responding and 
nonresponding patients.
The difference in QoL between responders and nonresponders was most outspoken in 
activity level impairment, VRS-vl and VAS-gh at 12 weeks. To our knowledge, only one 
small study in 59 patients has been published that compared QoL in 22 responders, 8 
nonresponders and 29 patients with indeterminate response, using the QLQ-BM22 and 
the QLQ-C30. Even in such a small number of evaluable patients, they found significant 
differences after one month between responders and nonresponders in pain, painful site, 
painful characteristics, functional interference, physical functioning and role functioning. 
(8) Our results are in line with the studies by Cramarossa and by Wu, who found that less 
pain predicted for improved QoL, in patients receiving radiation therapy for painful bone 
metastases. (4, 7) 
Secondly, we attempted to create a model to predict which patients with painful bone 
metastases are most likely to respond to palliative radiation therapy. Such a model, if 
predictive enough, might assist both clinicians and patients when choosing appropriate 
treatments for painful bone metastases. Despite the number of variables studied and the 
large number of included patients, the discriminative ability of the model was very low 
(C-statistic 0.56). Therefore, its clinical relevance is only minor. 
Previous studies also tried to identify predictive factors for a favorable pain response after 
radiation therapy for painful bone metastases. In a non-randomized single center study 
from Italy in 205 patients, an effect of total dose and baseline performance score on pain 
response was found, with lower response rates in patients with lower doses and worse 
performance scores. (17) Other studies, all from a large research group in Canada, found 
no correlation between pain response and the size of the radiation field (18), computed 
tomography imaging features of spinal metastases (21), location within the spinal column 
or dose fractionation (22). They found no significant difference in response rate between 
69 patients with bone metastases from gastrointestinal cancers and patients with bone 
metastases from other primary tumors. (19) Furthermore, they noticed no effect of painful 
localization, spinal versus non-spinal metastases, on response rate in 386 patients. (23) In 
a dataset of 1053 patients, they concluded that patients with mild/moderate pain at 
baseline had a comparable chance of having a pain response as patients with severe pain. 
At different time points after treatment, primary tumor was significantly related to the 
chance of having a pain response, with higher chances for prostate or breast cancer. (20) 
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Some of these studies have limitations, like assessing only one or two specific variables 
(18, 19, 23), including a small number of patients (19, 21, 22), retrospective collection of data 
(17) or not using state-of-the-art methods (33) for prognostic modeling (17). Although 
their joint results suggested that total radiation dose, performance status and primary 
tumor might be predictors for response, these studies did not present the discriminative 
ability of these variables using C-statistics or other similar statistical test outcomes. In our 
analyses, primary tumor and performance status were confirmed as variables predicting 
response. The study by Arcangeli et al., that concluded those variables to be predictors, 
was a non-randomized single center study in which 65% of patients received a dose 
above 30 Gy in at least ten fractions. (17) In addition, they only studied complete response 
in their multivariate analysis and the definition of response was not according to the more 
recent international criteria also taking into account changes in analgesic intake (31). In 
conclusion, the literature and our results do not consistently demonstrate any clear factors, 
other than primary tumor and performance status, predicting a pain response after 
radiation therapy for painful bone metastases. 
Some methodological aspects of our present analysis require discussion. The Dutch Bone 
Metastasis Study dataset provides a unique insight in cancer patients receiving palliative 
radiation therapy, due to the large number of patients included and the frequency and 
contents of follow-up. A disadvantage of our database is that it contains no items on 
concomitant comorbidities or medication, which might also effect the course of QoL. The 
compliance in responders and nonresponders differed. GEE analysis was chosen to be the 
best statistical method, considering this difference. (36) 
Although our data were collected from 1996 until 1998, we believe the characteristics and 
outcome after treatment of these patients are still representative for current patients 
receiving radiation therapy for painful bone metastases. While improvements, for example 
in systemic therapy have occurred over the last years, the most frequent applied treatment 
for painful bone metastases is still palliative radiation therapy, with a single fraction of 8 Gy 
as the golden standard. (3) 
Conclusion
Patients responding to radiation therapy for painful bone metastases had a better QoL 
than nonresponders during the first three months after treatment. We were unable to 
develop a model to accurately predict pain response to radiation therapy. Therefore, since 
76% of studied patients responded, radiation therapy should be offered to all patients 
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Effect of age on response to palliative 
radiotherapy and quality of life in patients 
with painful bone metastases
Westhoff PG, de Graeff A, Monninkhof EM, Bollen L, Dijkstra PDS, van der Steen EM, 
van Vulpen M, Leer JWH, Marijnen CAM, van der Linden YM. 





Background: Multimorbidity and declining performance in elderly cancer patients may 
result in less treatment benefit. We investigated whether age is a predictor for pain 
response and quality of life (QoL) after radiotherapy in patients with painful bone 
metastases.
Methods: The database of the Dutch Bone Metastasis Study was used (1996-1999). 1157 
patients, irradiated for painful bone metastases, rated their pain, QoL-domains and overall 
health at baseline and during follow-up. Response was calculated taking into account 
changes in pain score and medication. Patients were grouped into three age cohorts: A: 
<65 (n=520), B: 65-74 (n=410) and C: ≥ 75 years (n=227). 
Results: No significant difference existed in pain response between cohorts: 78% in 
cohort A, 74% in B and 67% in C. When assessing baseline QoL, a significant difference in 
activity level was noticed, with more impairment in elderly compared to younger patients 
(C versus B (p=0.01), C versus A (p<0.001)). Other QoL-domains were similar at baseline and 
during follow-up among cohorts. A pain response was significantly associated with 
improvement of health-related QoL (OR 3.74, 95% CI 2.66-5.25). 
Conclusions: The majority of elderly patients with painful bone metastases responded to 
radiotherapy and showed comparable overall QoL compared to their younger 





The incidence of cancer increases with age. 1-3 Data from the last decades show that for 
the most common cancers, the percentage of patients aged 65 years and older is over 
50%. 2 The number of elderly cancer patients is increasing due to a longer life expectancy, 
improved cancer treatments and increased tumor-specific survival. 2,3 Moreover, the aging 
of the babyboom era is coming. The number and proportion of elderly patients with 
cancer is thus expected to increase dramatically 3, with up to 42% of cancer patients in the 
United States in 2050 being 75 years and older. 2 Elderly patients with cancer represent a 
different and more fragile population than younger patients, with specific age-related 
problems and needs, related to multimorbidity and poorer physical or cognitive condition. 
They are frequently excluded from or underrepresented in clinical trials. 4 Therefore, trial 
outcomes and subsequent choices for medical treatments may not be applicable to this 
group. Studies show that elderly cancer patients receive different treatments than younger 
patients. 5-8 In both Canada and the United States, for example, elderly patients were less 
likely to be referred even for an effective palliative treatment such as radiotherapy. 9-11
Painful bone metastases have a major impact on quality of life (QoL) of cancer patients. 12,13 
Radiotherapy with a single fraction of 8 Gray (Gy) is considered the standard treatment for 
patients with painful bone metastases, with a pain response rate of more than 60%. 14-17 
The Dutch Bone Metastasis Study (DBMS) is the largest trial contributing to these 
outcomes, with 1157 patients included. 14,17 Both single and multiple fraction schedules 
were equally effective in treating pain, with a pain response in 73-75% of patients and no 
specific patient subgroups benefitting from higher total doses. 14,17-20  
To determine whether palliative radiotherapy is justified in elderly patients with painful 
bone metastases, the DBMS database was used. We investigated whether age is a 
predictor for pain response and QoL after radiotherapy for painful bone metastases.
Patients and methods  
The DBMS was a nationwide, randomized controlled trial in patients with painful bone 
metastases. From 1996 to 1998, 1157 patients with painful bone metastases were 
randomized between a single fraction of 8 Gy or 24 Gy in six fractions. The main endpoint 
of the study was pain response. Detailed descriptions of the study protocol have been 
published previously. 14,17 The Medical Ethics Committees of all participating institutions 
approved the study. All patients provided informed consent.  
Questionnaires
At randomization and during follow-up, patients filled out weekly questionnaires for 
twelve weeks and thereafter monthly until two years of follow-up, death or closure of the 
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study in December 1998. These questionnaires contained a pain scale, QoL-related questions 
from the Rotterdam Symptom Checklist (RSCL) 21, a visual analogue general health scale 
(VAS health) and medication intake. 
Analyses
For the present analyses, we used the pain scale, QoL scores of the RSCL and VAS health 
for twelve weeks after randomization. This time frame was chosen to limit the influence 
from tumor progression or other treatments. To study the effect of age, patients were 
grouped into three age cohorts: A: patients under 65 years, B: 65 to 74 years and C: 75 years 
and older. 
Pain response analyses
Pain was measured on an 11-point numeric rating scale, from 0 (no pain) to 10 (worst pain 
imaginable). Following international criteria 22, pain response was defined as a decrease in 
the initial pain score by at least two points, without analgesic increase, or analgesic decrease 
without an increase in pain score. No fixed time interval from the date of randomization 
was applied. A response was calculated if at least two successive follow-up pain scores 
were available. Response analysis was possible in 1099 patients, because 58 patients (5%) 
did not return enough questionnaires to determine response. 
Quality of life analyses
The RSCL consists of three QoL-subscales (psychological distress, physical symptom 
distress and activity level impairment, on a four-point Likert-type scale) and a scale for 
overall validation of life (on a seven-point Likert-type scale). 21 Sum scores were calculated 
in accordance with the manual of the RSCL. 21 We reversed the scores of activity level 
impairment, with a high score indicating a high level of impairment. All QoL-scores were 
standardized to the range of 0 to 100, with 0 representing the best possible and 100 
representing the worst possible condition. The VAS health was noted by patients on a line 
from 0 to 100, with 100 representing a poor general health situation. At baseline, the 
RSCL-domains, overall validation of life and VAS health were available in 94%, 94% and 
92% of patients, respectively. 
To assess the effect of palliative radiotherapy on health-related QoL, we compared the 
VAS health eight weeks after treatment with the VAS health at baseline. If this score was 
missing at eight weeks, we used the previous score at week seven or six. This time period 
was chosen because by then most responders had already noticed the effect of treatment, 
while possible transient side-effects had passed. Any decrease in VAS health, compared to 
baseline, was considered an improvement of QoL. If patients did not return their questionnaire 





The database was analyzed using IBM SPSS statistics for Windows version 20.0 (IBM Corp., 
Armonk, NY, USA) and SAS software (version 9.2, SAS Institute Inc, Cary, NC, USA). 
For the categorical variables at baseline, Chi-Square tests were used. For continuous 
variables we used the one-way ANOVA, with Bonferroni post-hoc testing. Correlation 
between variables was studied using Pearson’s correlation coefficients. To assess survival, 
we used Kaplan Meier method with a log-rank test. P-values are based on 2-sided tests 
and considered significant if p<0.05. To identify which variables predicted pain response 
and in particular to determine whether age is a predictor, Cox proportional hazard models 
were used. The preselected baseline variables, based on literature and clinical knowledge, 
were age (cohorts A/B/C), gender (male/female), Karnofsky performance score (KPS) 23 (90-
100/70-80/≤ 60), pain score (2-4/5-7/8-10), primary tumor (breast/prostate/lung cancer/
other types), presence of visceral metastases (yes/no) and concomitant systemic therapy 
(yes/no). The full model contained all preselected variables. Subsequently, we eliminated 
the variables by backward selection with a threshold p-value of 0.20, until the model fit 
decreased significantly. The chosen p-value of 0.20 intends to limit the loss of information 
and to select also weaker predictors, although at the cost of including ‘noise’ variables. 24
For comparing the course of the QoL-domains over time between age cohorts, we used 
generalized estimating equations (GEE-measurements), a longitudinal data analysis 
technique. In all models, the outcome variables (RSCL-subscales and VAS health) were 
analyzed as a dependent variable using age cohort as a key independent variable. To 
identify predictors of improvement of health-related QoL (dichotomized into yes or no) 
and to determine whether age is a predictor, logistic regression was used. All preselected 
variables (at baseline: age, primary tumor, pain score, visceral metastases, gender, KPS and 
systemic therapy and during follow-up: pain response (yes/no)) were analyzed with a 
backward selection process with a threshold p-value of 0.20. 
Results
Patient characteristics
Table 1 shows patient characteristics by age cohort. The mean age was 65 years (range 32 
– 89 years). Cohort A (<65 years) consisted of 520 patients (45%), B (65-74 years) of 410 
patients (35%) and C (≥75 years) of 227 patients (20%). There were significant differences in 
gender and primary tumor between age cohorts. Patients older than 64 years were more 
likely to be male and to have prostate cancer, while patients in cohort A were more often 
females with breast cancer. At baseline, there were significant age differences in KPS 
(p = 0.004), the percentage of patients with KPS 20-60 being 26% in cohort A, 29% in 
cohort B and 39% in cohort C. Baseline pain scores were not significantly different between 
cohorts. Visceral metastases were more frequently present in patients younger than 65 
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years: 35% in cohort A compared to 24% in cohort B (p<0.001) and 17% in cohort C 
(p<0.001). Younger patients lived significantly longer than elderly patients: median survival 
was 35 weeks (cohort A), 27 weeks (B) and 27 weeks (C) respectively (p=0.047). 
Pain response 
The overall pain response rate was 74%. Response was not significantly different between 
age cohorts: 78% in A versus 74% in B (p=0.42) and 67% in C (p=0.07). Mean time to 
response did not differ between cohorts (A: 3.6 weeks, B: 3.8 weeks, C: 3.1 weeks). Table 2 
shows the results of the analysis of predictors for pain response. The final model included 
primary tumor and visceral metastases and showed that having breast cancer and the 
absence of visceral metastases were associated with an increased chance of pain response. 
Age was not an independent predictive factor for pain response. When analyzed per 
fractionation schedule, both models eliminated age as a predictor.
Quality of life
At baseline, activity level impairment was significantly different between age cohorts: 
mean score 48.6 in cohort C compared to 40.9 in B (p = 0.01) and 37.5 in A (p < 0.001). The 
other QoL subscales did not differ significantly between age cohorts. Figure 1 shows the 
course of QoL for age cohorts. These curves were largely superimposable, with a slight, 
statistically significant, but clinically irrelevant improvement over time, except for mean 
activity level impairment. GEE analysis showed a significant difference in the course of 
activity level impairment between the youngest cohort (A) and the oldest cohort (C) 
(p < 0.001) and between cohort B and C (p = 0.0032) (Figure 1). Table 3 lists the factors 
predictive for improvement of health-related QoL. The final model included pain response, 
primary tumor, visceral metastases and KPS. Having a pain response was predictive for 
improvement of health-related QoL. Patients with breast cancer or prostate cancer more 
frequently had improvement than those with lung cancer and other tumors. No difference 




Table 1   Baseline characteristics for the three age cohorts  
(A: <65 years, B: 65-74 years, C: ≥ 75 years) of patients included in the  
Dutch Bone Metastasis Study (n=1157).





< 65 yrs 65-74 yrs ≥ 75 yrs
520 410 227
gender < 0.001
male 198 (38%) 267 (65%) 159 (70%) A-B (p < 0.001)
female 322 (62%) 143 (35%) 68 (30%) A-C (p < 0.001)
Karnofsky performance score 0.004 c
90 - 100 102 (20%) 85 (21%) 34 (15%) A-C (p = 0.001)
70 - 80 283 (54%) 203 (50%) 101 (45%) B-C (p = 0.021)
20 - 60 134 (26%) 120 (29%) 89 (39%)
pain score n.s. c
2 - 4 105 (20%) 91 (22%) 38 (17%)
5 - 7 231 (44%) 202 (49%) 117 (52%)
8 - 10 184 (35%) 115 (28%) 71 (31%)
primary tumor < 0.001
breast cancer 277 (53%) 115 (28%) 59 (26%) A-C (p < 0.001)
prostate cancer 49 (9%) 123 (30%) 95 (42%) B-C (p = 0.009)
lung cancer 117 (23%) 124 (30%) 46 (20%)
other 77 (15%) 48 (12%) 27 (12%)
visceral metastases < 0.001
no 337 (65%) 313 (76%) 188 (83%) A-B (p < 0.001)
yes 183 (35%) 97 (24%) 39 (17%) A-C (p < 0.001)
systemic therapy n.s.
no 232 (45%) 203 (50%) 96 (42%)
yes 288 (55%) 207 (51%) 131 (58%)
treatment schedule n.s.
1 x 8 Gy 257 (49%) 206 (50%) 118 (52%)
6 x 4 Gy 263 (51%) 204 (50%) 109 (48%)
Gy : Gray, n.s. : not significant, a Pearson Chi-Square, b non-significant differences are not shown, c also tested as a
continuous variable, using one-way ANOVA and Bonferroni post-hoc testing
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Table 2   Univariate (UVA) and final multivariate (MVA) Cox regression analysis on 
potential baseline predictors for pain response to palliative radiotherapy in 
patients with painful bone metastases.
baseline variables % of patients
with response
Hazard Ratio (95% CI)
UVA a Final MVA a
age
< 65 years 78% 1.00 b
65-74 years 74% 0.94 (0.81-1.10)
≥ 75 years 67% 0.84 (0.69-1.02)
gender
male 70% 1.00 b
female 79% 1.14 (1.00-1.31)
Karnofsky performance score
90 - 100 82% 1.00 b
70 - 80 75% 0.93 (0.78-1.11)
20 - 60 68% 0.91 (0.74-1.11)
pain score
2 - 4 75% 1.00 b
5 - 7 73% 1.01 (0.84-1.21)
8 - 10 74% 1.09 (0.90-1.33)
primary tumor
breast cancer 82% 1.00 1.00
prostate cancer 79% 0.96 (0.81-1.14) 0.92 (0.77-1.10)
lung cancer 62% 0.76 (0.63-0.91) 0.74 (0.62-0.90)
other 64% 0.71 (0.56-0.89) 0.72 (0.57-0.91)
visceral metastases
no 76% 1.00 1.00
yes 69% 0.87 (0.74-1.02) 0.88 (0.74-1.03)
systemic therapy
no 68% 1.00 b
yes 79% 1.16 (1.01-1.33)
95% CI : 95% confidence interval, UVA : univariate analysis, MVA : multivariate analysis,
a Cox regression analysis, b did not remain in the final model 
MVA: the full model contained all variables. We eliminated the variables by backward selection,
with a threshold p-value of 0.20, until the model fit decreased significantly and the final model remained.
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Effect of age
7Figure 1   Quality of life in the first twelve weeks after palliative radiotherapy. On the 
X-axis week numbers, week 0 indicating baseline, number 1 the first week 
after treatment et cetera. All scores range from 0-100, with 100 indicating 
maximum amount of complaints.
Cohort A (<65 years)
Cohort B (65-74 years)



















































































weeks from randomization 
weeks from randomization 
0 1 2 3 4 5 6 7 8 9 10 11 12 
A - psychological distress 
B – physical symptom distress 
C – activity level impairment 
D – overall validation of health 
E – visual analogue scoring of health 
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Table 3   Univariate (UVA) and final multivariate (MVA) logistic regression analysis  
of potential predictive variables for improvement of health-related quality  
of life (defined by VAS health) six to eight weeks after radiotherapy.




Odds Ratio (95% CI)
UVA a Final MVA a
age
< 65 years 39% 1.00 b
65-74 years 39% 0.98 (0.75-1.28)
≥ 75 years 36% 0.87 (0.63-1.20)
gender
male 35% 1.00 b
female 43% 1.41 (1.11-1.79)
Karnofsky performance score
90 - 100 37% 1.00 1.00
70 - 80 41% 1.22 (0.89-1.68) 1.52 (1.08-2.13)
20 - 60 34% 0.88 (0.62-1.26) 1.31 (0.90-1.92)
pain score
2 - 4 39% 1.00 b
5 - 7 38% 0.97 (0.71-1.32)
8 - 10 39% 1.03 (0.73-1.44)
primary tumor
breast cancer 46% 1.00 1.00
prostate cancer 44% 0.93 (0.68-1.25) 0.90 (0.64-1.25)
lung cancer 25% 0.38 (0.28-0.53) 0.46 (0.33-0.66)
other 30% 0.49 (0.33-0.73) 0.59 (0.39-0.90)
visceral metastases
no 41% 1.00 1.00
yes 32% 0.68 (0.51-0.89) 0.74 (0.55-1.01)
systemic therapy
no 31% 1.00 b
yes 44% 1.78 (1.38-2.24)
pain response
no 18% 1.00 1.00
yes 48% 4.08 (2.93-5.68) 3.74 (2.66-5.25)
95% CI : 95% confidence interval, UVA : univariate analysis, MVA : multivariate analysis, 
a logistic regression analysis, b did not remain in the final model 
MVA: the full model contained all variables. We eliminated the variables by backward selection,





The present analyses of the DBMS database show that 67% of elderly patients (≥ 75 years) 
with painful bone metastases respond to palliative radiotherapy. Our study showed an 
11% lower response rate in the elderly cohort. This difference did not reach statistical 
significance at a level of p≤ 0.05. In multivariate analysis, age was not an independent 
predictive factor for pain response or QoL after radiotherapy. Even if multivariate analysis 
would have shown age to be a predictor of pain response, there would still be no reason 
to treat elderly patients differently and to withhold palliative radiotherapy. Our results are 
in line with the outcomes of Campos et al, showing response to palliative radiotherapy for 
painful bone metastases to be independent of age. 25 These outcomes are important, 
since cancer disproportionally strikes elderly. 2,3 However, several studies show that elderly 
frequently receive different medical treatments than younger patients 5-11, because of fear 
of higher toxicity and expected lower effectiveness. Moreover, our analysis shows that 
pain response is an important factor leading to improvement of QoL. Caissie et al. 
prospectively studied the course of QoL in 178 patients treated with radiotherapy for 
painful bone metastases. They also showed pain response is associated with improvement 
of QoL. 26 
In the literature, inconsistent results concerning QoL in elderly patients with cancer have 
been reported. 27-29 One could argue their QoL is less than that of younger cancer patients, 
because of multimorbidity, increased physical and/or mental impairment 25,28 or diminished 
social support networks 29. On the other hand, they might be better able to cope with 
their limitations than younger people, because of life experience and different expectations 
of remaining life, resulting in an equal or better QoL. 27,30 Our study supports the latter 
thought, with only a difference in activity level impairment between elderly and younger 
patients and equivalent other QoL-scores.
In our study population, 39% of the patients aged 75 years or older had a KPS of ≤ 60 
against 26% of the patients under 65 years. A difference in performance status between 
elderly and younger patients was also seen in a study by Campos. 25 In a population of 558 
patients who received radiotherapy for painful bone metastases, they showed that 
younger patients had higher KPS. Remarkably, our study shows patients with a lower KPS 
(<70) had a comparable pain response and improvement of QoL compared to patients 
with a higher KPS. So a lower KPS should not be a reason to restrain palliative radiotherapy, 
even if patients are elderly. Since KPS is associated with activity level impairment, the 
lower performance status in the elderly cohort is probably reflected in the difference we 
found in activity level impairment. 
In order to study QoL in elderly patients with cancer, a separate EORTC-QLQ-ELD15 
questionnaire has been developed. 31 When patients were asked what items they thought 
to be important and relevant, elderly people considered mobility to be more important 
and relevant than younger patients. 31 It is therefore most important that our data show 
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that, despite more activity level impairment, elderly patients did not evaluate their overall 
QoL different compared to younger patients. The aforementioned life experience and 
adjusted expectations might enable those elderly to cope more easily with limitations 
without lowering overall valuation of life.
Some methodological aspects of our study require discussion.
Our choice for division in age cohorts is arbitrary. The literature shows different cut-offs in 
defining the elderly population. 31,32 Because in The Netherlands 65 years was, at the time 
of the study, the age people retired from work, cohort A represents the potentially working 
population. Patients aged 75 years and older are separated because of increased 
multimorbidity and frailty. 
This dataset provides a unique insight in cancer patients receiving palliative care, due to 
the number of patients included, the percentage of elderly and the frequency and 
contents of follow-up. Although our data were collected from 1996 until 1998, we believe 
these patients are still representative for current patients receiving palliative cancer care. 
While improvements in systemic therapy have occurred over the last years, the most 
frequent applied treatment for painful bone metastases is still palliative radiotherapy, with 
a single fraction of 8 Gy as the golden standard. 16 This analysis provides no reason to treat 
elderly differently. One could argue that the aforementioned improvements in systemic 
therapies might also affect QoL. However, although almost half of the patients in our 
population received systemic therapy at randomization, systemic therapy was not an 
independent prognostic factor for pain response or improvement of QoL. 
Conclusion
The majority of elderly patients showed a meaningful pain response to radiotherapy. 
Response to palliative radiotherapy leaded to improvement of QoL. Age was not a 
predictor for pain response or QoL. Elderly patients did not evaluate their overall QoL 
inferior compared to younger patients. Therefore, higher age should not be a reason to 
withhold palliative radiotherapy. In view of the increasing proportion of elderly patients in 
palliative care and the underrepresentation in clinical trials, future studies should focus on 
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Discussion and future perspectives
8
The research in this thesis focuses on several aspects of quality of life in patients with 
painful bone metastases who were treated with palliative radiotherapy. Knowledge of 
quality of life, in relation to radiotherapy and the natural course of the disease, is important 
for patients and physicians. It impacts  decision making and personalization of treatment. 
Research questions we tried to answer in this thesis involve estimation of survival, 
side-effects of radiotherapy, course of quality of life after radiotherapy, both in general 
and related to a pain response, and the effect of age on a pain response. 
Impact of the Dutch Bone Metastasis Study on 
knowledge about bone metastases
For the analyses presented in this thesis, we used the data of the Dutch Bone Metastasis 
Study (DBMS), a study that included 1157 patients with painful bone metastases between 
1996 and 1998 and randomized between a single fraction of 8 Gray (Gy) and six fractions 
of 4 Gy. (1,2) The first analyses of this study have led to an important increase of knowledge 
worldwide about effectiveness of radiotherapy, in general, but also in long and short 
survivors. Furthermore, papers were published studying cost-effectiveness, factors 
influencing retreatment, assessment of the fracture risk, survival prediction in patients 
with vertebral metastases and health care utilization in the palliative phase. (1-9) 
For the further analyses presented in this thesis, we again used this dataset because of its 
largeness and uniqueness, with follow-up data on pain, quality of life (QoL) items and side 
effects. The main outcome of the DBMS, that a single fraction of 8 Gy is as good as a 
treatment schedule with multiple fractions in terms of pain relief, was confirmed by many 
other, but smaller, randomized studies, all published between 1986 and 2009. Several 
meta-analyses were performed, all confirming that there is no dose-response effect in 
radiotherapy for uncomplicated painful bone metastases (figure below). (10-13)
Therefore, the golden standard in treating patients with painful bone metastases, is a 
single fraction of 8 Gy. In 2014 the results of a large randomized trial in patients re-irradiated 
for painful bone metastases, were published. This trial demonstrated non-inferiority of 
a single fraction of 8 Gy compared to multiple fractions in terms of a pain response in 
previously treated patients. (14) As a consequence, a single fraction of 8 Gy is also the 
standard in retreatment.
Durability of DBMS outcomes
A comment on the durability of the outcomes of the DBMS could be that changes in 
systemic anticancer therapies and the widespread introduction of bone modifying agents 
such as zoledronic acid have occurred over the years. These changes should be reflected 
in survival times. In one of the studies in this thesis, we validated our prognostic survival 
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model with a more recent cohort of patients, treated between 2001 and 2010. It shows 
that survival times have not improved dramatically in the meantime. Furthermore, little is 
known about the effect of systemic treatments on pain in patients with painful bone 
metastases. In patients with metastatic prostate cancer, the effect of systemic treatment 
on pain has been reported in several studies. For example for docetaxel, a reduction in 
pain has been documented. (15) For cabazitaxel and mitoxantrone improvement of pain 
in less than 20% of patients was noted, while pain worsened in more than 30% of patients, 
after a median follow-up of 25 months. (16) A relatively new therapy for patients with 
breast cancer with bone metastases, is trastuzumab. To our knowledge, no data on pain 
response are known, since pain and analgesic use are not routinely assessed in trials 
involving trastuzumab. A French study included 128 patients with at least three-year 
Figure 1   Overall response rates for single versus multiple fractions for  
intention-to-treat patients.
Source: Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radio- 
therapy trials for bone metastases. Clin Oncol (R Coll Radiol) 2012 Mar;24(2):112-124.Used with permission.
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progression free metastatic breast cancer after using trastuzumab, therefore representing 
a favorable subset of patients. Of those 128 patients, 43% had initial bone metastases and 
the study showed bony disease progression in 24% of cases, without data on pain. (17) 
Although no comparative studies are available, radiotherapy seems to have more effect 
on pain due to bone metastases than systemic therapy. To our knowledge, no data exist 
that suggests that current systemic treatments have more effect on pain than the systemic 
treatments in the era of the DBMS. 
Synchronizing methodology of trials
In research related to the treatment of bone metastases, using similar endpoints is important, 
in terms of pain response and other outcomes. Therefore, in 2000 an International Bone 
Metastases Consensus Working Party on endpoint measurements was established, with 
the purpose to define an international consensus on endpoints and to formulate remaining 
questions.  In 2002 the consensus was published, with an update in 2012. These endpoints 
take into account both pain scores and pain medication, in determining a pain response. 
Furthermore, advices on re-irradiation timing, use of questionnaires, follow-up, pain 
measurement, analgesic treatment et cetera are given in this consensus. (18,19) Those 
endpoints and recommendations should be followed for future trials in patients with 
painful bone metastases, for all treatment modalities, to define the real effect of treatment 
without the influence of changes in pain medication. Furthermore, it will simplify comparison 
between trials and treatment modalities. Since the first international consensus agreement 
was published after the initial publication of the DBMS (2), in 2004 a further analysis was 
published, using those international standards in terms of pain response and taking into 
account the effect of retreatment. (1) Unfortunately, many trials do not follow those 
international endpoints, making it difficult to compare the trials and determine which 
treatment modality is better in terms of pain response than others. 
Prognostic models
More and more, also in palliative settings, prognostic models are developed in order to 
help patients and their caregivers to balance treatment options and to individualize 
treatment by weighing benefits and disadvantages. These models should have prognostic 
accuracy, validation in a different dataset and calibration and discrimination should be 
evaluated. (20,21) In addition, simplicity of those tools is preferred, in order to be feasible 
in daily clinical practice. Regrettably, in palliative care, many models exist that have not 
been properly tested, hampering use in clinical practice. As a result, those models might 
even guide decision making in the wrong direction. Thus, when a treatment decision 
140
Chapter 8
depends on or is influenced by a model, physicians should ensure themselves that the 
model has sufficient predictive power and that is has been developed in accordance with 
methodological guidelines. (20) Unfortunately, this subject is not yet covered in the most 
recent consensus of the IBMCWP, but will hopefully be discussed in the following update. 
Current models mainly predict outcomes like survival, risk of fracture and chance of 
response. In the future, further attention should be paid to models predicting outcomes 
like QoL or patient-related outcome measurements (PROMs). Nevertheless, due to the 
importance and the increase in use of these models, critical use of prognostic models 
should be covered in the education programs of oncologists, general practitioners and 
other physicians.
Important outcomes of this thesis
Survival  
An adequate estimation of survival is important for both patients and physicians to 
carefully weigh the time and effort needed to achieve treatment effect against the 
remaining survival time. In chapter 2, we developed an easy tool to predict survival of 
patients with painful bone metastases, and validated the model in a different, more recent 
cohort. (22) These two datasets from different treatment periods show that, despite 
changes in systemic treatment, survival times have only improved for patients with bone 
metastases of breast cancer and prostate cancer who are in a good clinical condition. Our 
goal was to facilitate physicians to estimate survival time for their individual patient, which 
may help patients and physicians in deciding about different treatment options, like 
radiotherapy or more invasive (such as surgery) or time consuming (such as stereotactic 
radiotherapy) treatments. In order to make the tool usable for daily clinical practice, we 
determined the predictive value of variables that are easily obtained in daily clinical 
practice. Our data show that the median survival of patients with a Karnofsky Performance 
Status below sixty, with other primary tumors than breast or prostate cancer, is roughly 
two months. Since mean time to response is three to four weeks (1), treatment of these 
specific patients is doubtful. This model  can guide daily clinical decision making, despite 
not being highly accurate. Hopefully, in the future, more accurate and simple models will 
be developed helping physicians and their patients in providing adequate palliative care. 
Quality of life (QoL) 
Health-related QoL is defined as a multidimensional construct encompassing perceptions 
of both positive and negative aspects of physical, emotional, cognitive and social 
functions, due to the sequelae of a disease and its treatment. (23) Palliative care should 
focus on improving QoL by preventing or relieving suffering by assessing and treating 
pain and other problems, physical, psychosocial and spiritual. (24) Since painful bone 
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metastases have a negative impact on the overall QoL of patients (25,26), treatment may 
improve or at least maintain QoL. Still, the expected treatment effect on QoL should be 
taken into account when deciding about treatment in the palliative phase. 
QoL after radiotherapy
Few studies have been published about the course of QoL after palliative radiotherapy, 
with a limited amount of data and follow-up. (27) Being aware of the expected course of 
QoL is important for both patients and physicians, to avoid incorrect expectations and to 
assist in treatment decisions. In chapter 5, we studied QoL after radiotherapy for painful 
bone metastases. We noticed a pattern with a rather stable level of QoL, regardless of 
survival time, deteriorating shortly before death. 
A review of the available literature showed that patients who experienced a pain response 
also reported improvement of QoL. (27) Since QoL is a multidimensional concept (23), one 
could on the other hand imagine that a response to palliative radiotherapy does not 
impact QoL very much, since other complaints might appear and mainly the physical 
dimension of QoL is affected by reducing pain. Secondly, since many patients have 
multiple bone metastases, a shift in pain might appear when one site of metastases is 
treated. In chapter 6, we studied QoL after radiotherapy in relation to a pain response, 
using the Rotterdam Symptom Checklist (28). During follow-up we noticed that 
responding patients had a better QoL than non-responding patients, for all domains of 
QoL. In general, QoL of responding patients improved after treatment, although the 
difference was less than ten points on a 0-100 scale, indicating little clinical significance. 
QoL of non-responding patients further declined after treatment, causing an increasing 
difference in QoL between both groups. 
The questionnaires used (the RSCL and two questions from the European Organization for 
Research and Treatment of Cancer (EORTC) Core Quality of life Questionnaire (QLQ)-C30 
(29)) are not specifically developed for patients with bone metastases. With more specific 
questionnaires, such as the later developed EORTC QLQ-Bone Metastases 22 (BM22) (30), 
larger differences in QoL might have been found. For future trials, we would recommend 
using the EORTC-QLQ-BM22. 
We also tried to identify those patients who were likely to experience a pain response after 
treatment. The predictive accuracy of the final predictive model, consisting of five 
variables (primary tumor, age, performance status, visceral metastases and the use of 
opioids), was very low, with a C-statistic of 0.56. Thus, the minority of patients who do not 
respond to radiotherapy cannot reliably be predicted beforehand. All patients with painful 
bone metastases should therefore be considered for palliative radiotherapy, of course 
taking into account the expected survival as mentioned before. It is however important to 
discuss the expected outcome with patients, to make sure they can weigh for themselves 
the expected effect and the disadvantages. Patients are nevertheless often motivated to 
undergo every possible treatment, but it is the physician’s duty to determine whether this 
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is justified. For example a rapidly declining performance status can be a sign that the end 
of life is near. In general, when survival is estimated less than one month, radiotherapy 
should not be considered. This is often the case in patients with a different primary tumor 
than breast or prostate cancer, who are no longer able to fully take care of themselves. 
QoL in elderly patients
The population of cancer patients is ageing (31,32). Studies show that elderly patients are 
less likely to receive palliative radiotherapy than younger patients. (33-35). Therefore, in 
chapter 7 we studied the effect of age in palliative radiotherapy for painful bone 
metastases. At baseline, elderly patients (75 years and older) had a significantly lower 
performance score, as is to be expected since elderly patients represent a more fragile 
population than their younger counterparts. However, age did not independently predict 
for a  pain response. Furthermore, the course of QoL after treatment was similar in elderly 
compared to younger patients for almost all domains, except for activity level impairment, 
which was higher in elderly, reflecting age specific limitations and not of the effect of 
radiotherapy. Thus, age does not have an effect on pain response or QoL after palliative 
radiotherapy. Therefore, there is no argument not to refer elderly patients for palliative 
radiotherapy, based only on age.   
A limitation of our study could be referral bias, with only elderly patients in a good clinical 
condition being referred for radiotherapy. In our analyses, 20% of patients was 75 years or 
older, of which 39% was in a bad clinical condition, not being capable of taking care of 
themselves. So apparently, also elderly in a bad clinical condition were referred for 
treatment.  Therefore, we believe this study is representative enough to conclude that age 
cannot be the reason not to refer patients for palliative radiotherapy. 
Psychological distress
Psychological distress (PD) in patients with cancer is defined as a multi-factorial unpleasant 
emotional experience that may interfere with the ability of patients to cope effectively 
with their disease, its physical symptoms and treatment. (36) Psychological distress has a 
negative impact on QoL. (37) The Dutch guideline for psychosocial support in cancer 
patients aims to identify patients with high levels of distress who may be in need of an 
intervention, by using a screening instrument, the so-called “Lastmeter”. The guideline 
states that early identification can prevent severe problems and have a positive impact on 
quality of life. (38) In chapter 4, we studied psychological distress before and after palliative 
radiotherapy, in order to be able to identify patients with a high level of psychological 
distress and offer them appropriate interventions. At baseline, 27% of patients had a high 
level of psychological distress. We found no relation between psychological distress at 
baseline and pain response. Only 15% of the variance in PD at baseline was explained by 
gender, age, performance status, pain score and self-reported QoL. However, we were not 
informed about some factors that might influence PD, like marital status, socio-economi-
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cal status, level of education et cetera. The level of distress at baseline determined the 
level of distress after treatment, implying  that physicians can identify high risk patients by 
screening at the referral for radiotherapy. However, having a high level of distress does not 
immediately imply a patients’need for referral for psychosocial support. (39) For 
radiotherapy departments, a specialized nurse might be useful, to screen for distress, 
speak with the patients and select those patients needing an intervention and willing to 
be referred.
Education
Education about (indications for) palliative radiotherapy and its effect on QoL should be 
incorporated in the training program of residents in any field of oncology. Studies among 
general practitioners show that the more knowledge they have of palliative radiotherapy, 
the higher the referral rate. (40,41) In Australia for example, only 78-80% of general 
practitioners would refer their patients with painful bone metastases and a prognosis of 
at least four months for palliative radiotherapy. (42) In the Netherlands, most general 
practitioners were aware of the effectiveness of radiotherapy for painful bone metastases. 
Nevertheless, only 47% ever referred patients for palliative radiotherapy, while 56% knew 
about possible side-effects. The most important reasons for not referring patients, were 
general condition, presumed discomfort of treatment and wish of the patient. (43) 
Hopefully our data will help other physicians determine whether their individual patient 
might benefit from palliative radiotherapy, inform them on the expected outcome and, 
when appropriate, refer those patients.
Past and current developments in radiotherapy for 
painful bone metastases 
We studied the course of side-effects after treatment for painful spinal metastases in 
chapter 3, comparing two simple conventional treatment techniques, namely a single 
posterior-anterior (PA) field and two parallel opposed fields from anterior and posterior 
(APPA). The analyses demonstrated that radiotherapy technique is not an independent 
prognostic factor for abdominal or skin toxicity after treatment. However, after the DBMS, 
several developments took place.
Developments after the DBMS
Diagnostic imaging with computed tomography (CT) scans or MRI scans is nowadays 
standard of care. Simulation protocols, with the widespread use of computed tomography 
scans, have evolved over time. This gives opportunity to depict the actual radiation dose 
on the scans, making it possible to visualize the actual dose to target tissue and surrounding 
organs at risk. Furthermore, in the era of conventional radiography, margins were in 
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general set one vertebra above and below the metastasis. Since imaging and positioning 
verification have also improved over the years, margins for treatment can theoretically be 
reduced. (44) With current imaging techniques the metastasis and its clinical target 
volume can be delineated, following the guidelines of the International Spine Radiosurgery 
Consortium (45). However, patients often indicate a painful region or the majority of the 
spine is affected. Therefore it is debatable whether smaller field sizes will provide equal 
pain response rates as in the era of the DBMS. 
Although conventional techniques are still frequently used to treat painful vertebral 
metastases, more advanced techniques, such as intensity modulated radiotherapy (IMRT) 
or volumetric modulated arc radiotherapy (VMAT), become standard of care. These 
techniques facilitate a more conformal dose delivery and non-target tissues can be spared, 
in line with the ALARA-principle (“as low as reasonably achievable”). (46) Unfortunately, no 
studies are published comparing simple techniques with more conformal techniques, in 
terms of pain control, cost-effectiveness, QoL and patient satisfaction. When pain control, 
QoL and patient satisfaction are equal, these more conformal techniques are a better 
treatment option, although being more expensive and time consuming than the simple 
techniques. The advantages of more conformal dose distributions and sparing of organs 
at risk outweigh those disadvantages. 
Nevertheless, little is known about the effect of the reduction in margins and smaller field 
sizes. This development should therefore be carefully monitored, data on pain response 
and retreatment rates should be gathered. Using cohorts of patients is a method 
becoming increasingly popular. An example is the OPTIMAL cohort, which is a prospective 
multicenter cohort collecting data on quality of life and pain in patients after radiotherapy 
and/or surgery of metastases of the long bones (see clinicaltrials.gov). 
Another example is the PRESENT cohort (47) which is currently recruiting patients with 
painful bone metastases treated at a department of radiotherapy of a university hospital. 
This cohort collects information about baseline characteristics, pain, response to treatment, 
quality of life et cetera. In the future, cohorts like these will answer a variety of remaining 
questions in this patient group. They will probably also answer the question whether 
treatment of smaller fields results in comparable pain response rates as with conventional 
techniques. 
In the appendix, we describe the study protocol of a randomized trial looking at preventing 
a temporary increase in pain, the so-called pain flare, after palliative radiotherapy. We studied 
two dose schedules of dexamethasone and placebo. (48) Inclusion was completed in 
March 2016, but was much slower than expected, since many patients met exclusion criteria, 
like the use of opioids, treatment of multiple sites or optimization of pain medication before 
treatment. Furthermore, the low inclusion rate was partially due to competing trials and 
the upcoming use of stereotactic radiotherapy. Slow inclusion rates seem to be a problem 
in studies in palliative patients. Therefore, the upcoming use of cohorts might boost the 
research in palliative care. The Canadian trial, comparing 8 milligrams of dexamethasone 
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with placebo, was already published. They showed a reduction in pain flare after treatment 
with dexamethasone in 298 patients treated with palliative radiotherapy. The incidence of 
a pain flare was 26% after dexamethasone and 35% with placebo. (49) Our database is 
currently updated and analysed, the results of our trial are expected soon.
Ongoing developments
Currently, other treatment techniques are emerging. 
- Stereotactic radiotherapy 
Stereotactic radiotherapy is an emerging treatment option for patients with painful bone 
metastases. Because of the steep dose gradient, the dose to the surrounding organs at 
risk, like the spinal cord, can be limited, while the dose at the target lesion can be 
intensified. (50,51) Single doses up to 16-24 Gy have been reported, with high radiologic 
tumor control rates of over 85%, without data on the pain response, since mainly local 
control was studied and the international definition of a pain response was not followed. 
(52,53) Toxicity rates, like radiation-related fractures or radiation-induced spinal cord 
toxicity, appear to be low. (53-56)
- Protons
Protons have a theoretical benefit over photons, due to the Bragg peak with rapid falloff 
of dose directly distally from the target, a sharp lateral penumbra and a low dose proximally 
from the target, thereby allowing also high and conformal dose depositions. Due to its 
characteristics, protons have potential benefits for patients, intensifying the dose to the 
target volume and lowering the dose to organs at risk. (57,58)  So far, few patients with 
bone metastases have been treated with protons. 
- MR linear accelerator
A recent development is a linear accelerator (linac) combined with a magnetic resonance 
imaging (MRI) scanner, the so-called MR-linac. The MRI provides optimal soft-tissue contrast 
and can therefore allow very accurate image-guidance during treatment. A possible 
benefit in patients with painful bone metastases might be dose escalation, mostly due to 
a better visualization of organs at risk, like the spinal cord. (59) Currently, few patients have 
been treated with the MR-linac for bone metastases. 
Indications
The abovementioned techniques may have benefits in certain situations:  
- Dose
A higher local dose might theoretically lead to a longer or better local control of the lesion. 
However, in a systematic review on treatment schedules in painful bone metastases, 
including schedules with 20 fractions of 2 Gy and 10 fractions of 3 Gy, a higher total dose 
did not lead to significantly higher pain response rates, neither in the group as a whole nor 
in subgroups (figure 1). (10,11) There seems to be a threshold below which treatment is less 
effective in terms of a pain response. This was shown in a randomized trial comparing a 
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single fraction of 4 Gy, 6 Gy and 8 Gy in patients with painful bone metastases. Patients 
treated with 6 or 8 Gy had a significantly higher pain response rate (73% and 78% 
respectively) than patients treated with a single fraction of 4 Gy (59%). The difference in 
pain response between a single fraction of 6 or 8 Gy was not significant. There was no 
difference in duration of a pain response or the rate of retreatment between those three 
doses. (60) A more recent trial compared a single fraction of 4 Gy with a single fraction of 
8 Gy, in 651 patients with painful bone metastases. This trial showed a pain response after 
four weeks of 68% versus 80% for 4 and 8 Gy respectively. (61) To our knowledge, only one 
randomized trial compared a single fraction of 10 Gy with multiple fractions, showing an 
equal pain response rate. Of the 129 patients treated with a single fraction, pain response 
rate was 83,7%, but the amount and possible changes of pain medication were not taken 
into account. (62) In a systematic review by Tree on stereotactic radiotherapy in patients 
with oligometastatic disease, local control rates around 80% were noted, no data on pain 
response were given. Unfortunately almost all data were from single institution series and 
none of the studies was a randomized trial. (63) Nevertheless, no data are known showing 
that a dose higher than 8 Gy provides better pain control. Therefore, the optimal dose of a 
single fraction for painful bone metastases seems to be somewhere between 6 and 8 Gy. 
So, in the future, trials on higher doses delivered with aforementioned techniques in 
patients with bone metastases should report on pain response and QoL, instead of just 
local control rates. Furthermore, randomized trials in patients with painful bone metastases 
comparing conventional radiotherapy and those new techniques are important to 
determine the added value of stereotactic radiotherapy, protons or the MR-linac. 
- Retreatment
When complaints of painful bone metastases return after previous radiotherapy, retreatment 
should be considered. However, the tolerance of surrounding normal tissue, like the spinal 
cord in vertebral metastases, limits the dose that can still be given locally, particularly when the 
interval between treatments is relatively short. Due to the aforementioned steep dose 
gradient, the dose to organs at risk can be reduced in stereotactic radiotherapy or protons, 
enabling retreatment in the future, which is most relevant in patients with a longer life 
expectancy.
- Oligometastatic disease 
Patients with oligometastases (in bone or elsewhere) represent a relatively new group of 
patients with a maximum of four to five metastases, mostly limited to one site (e.g. bone, 
liver or lung), representing a subset of patients with a longer survival time than patients 
with more metastases. The focus of treatment is not only maintaining or improving quality 
of life, but also control of disease, prevention of local recurrences, delaying progression 
and possibly even leading to cure. (63-65) Therefore, this may be a subset of patients that 
particularly benefits from more advanced radiotherapy techniques. However, the presumption 
that more intensive treatment in patients with oligometastatic disease leads to better 
survival, remains to be proven.  
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Disadvantages
The main disadvantage of stereotactic radiotherapy, protons or the MR linac is the time 
investment it takes to prepare and deliver a treatment plan. Due to the steep dose 
gradients, image guidance during treatment is needed. Furthermore, additional imaging 
modalities are frequently needed such as MRI and the treatment planning is more 
complex and technically demanding. (50,51) As a result of this complexity, a one stop 
treatment, with intake, preparations and treatment within a few hours and thus just one 
hospital visit for the patient, is not possible with those techniques. Moreover, the costs are 
significantly higher compared to conventional treatment techniques (57,66) and treatment 
time is in general prolonged, which causes more inconvenience for the patients. Finally, 
these techniques, especially protons and the MR linac, are not widely available.   
Ongoing trials 
To our knowledge, two trials comparing stereotactic radiotherapy with conventional 
radiotherapy for painful bone metastases are currently ongoing. The Dutch RACOST trial 
is including patients with painful spinal metastases, randomizing between a single 
fraction of 20 Gy stereotactic radiotherapy and a single fraction of 8 Gy conventional 
radiotherapy. The primary objective is to investigate whether stereotactic radiotherapy 
leads to improved pain reduction compared to conventional radiotherapy without an 
increase of treatment related side-effects. Secondary endpoints are duration of the pain 
response, time to pain response and/or pain progression, toxicity, quality of life and the 
risk of spinal fractures. (67) In the RTOG 0631 trial, patients with painful spinal metastases 
are randomized between a single fraction of 8 Gy conventional radiotherapy and a single 
fraction of 16-18 Gy stereotactic radiotherapy. The dose of the stereotactic treatment, 16 
or 18 Gy, is left to the decision of the treating physician. (68) The primary endpoint is pain 
response, but unfortunately this is not defined according to the international standards 
(18), making comparison with other trials difficult. Secondary endpoints include time to 
response, duration of a response, toxicity of treatment and quality of life. 
Conclusion 
Altogether, those new techniques sound like promising treatment options for selected 
patients, but their value still remains to be proven. Selection of patients needs to be 
clarified, to determine which patients benefit from these new treatments. Until the results 
of randomized trials are known, treatment of uncomplicated painful bone metastases 
with stereotactic radiotherapy should be performed in studies and otherwise be reserved 
for specific cases. 
For the other two techniques, clinical trials should be performed confirming the benefits 
(69) and first results of clinical use should be awaited (59). For the majority of patients, a 
single fraction of 8 Gy conventional radiotherapy is the appropriate treatment of choice. 
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New developments outside radiotherapy 
Apart from radiotherapy, other treatment strategies for bone metastases have emerged 
the last two decades after publication of the results of the DBMS. 
Bisphosphonates
Bisphosphonates prevent bone resorption by reducing the number and activity of 
osteoclasts and are used to reduce the frequency and severity of skeletal-related events, 
like fractures, spinal cord compression, need for radiotherapy and hypercalcemia. (70) 
A recent systematic review studied the analgesic effect in patients with painful bone 
metastases and concluded that the evidence does not support the use of bisphospho-
nates to reduce existing pain. (71) 
In the RIB trial, a single fraction of 8 Gy with conventional radiotherapy was compared with 
a single infusion of a bisphosphonate, ibandronate, in 470 prostate cancer patients with 
painful bone metastases. Overall, there was no difference in pain response after twelve 
weeks: 56,7% of patients treated with ibandronate versus 60,2% of patients treated with 
radiotherapy. However, pain response was more rapid after palliative radiotherapy, with a 
significant difference in response rates after four weeks, disappearing at the following 
time points. Toxicity, spinal cord compression, fractures, quality of life and survival were 
not different between treatment groups. (72) As a result of this trial, the golden standard 
remains a single fraction of 8 Gy, but when radiotherapy is not available or no option due 
to previous treatments, ibandronate seems a reasonable alternative. In the future, it would 
be interesting to study whether the combination of bisphosphonates and radiotherapy 
might further improve pain response rates and/or duration. 
Radiopharmaceuticals
Radionuclides are administered intravenously and accumulate in sites of increased bone 
turnover. Subsequently, radiation is delivered at the osteoblastic metastatic sites, with the 
possible side-effect of bone marrow suppression. In a systematic review in patients with 
castrate-resistant metastatic prostate cancer, 36 articles were identified studying the 
effect of radiopharmaceuticals in patients with painful bone metastases, but an overall 
pain response could not be determined since different definitions of a pain response were used. 
In general, pain decreased in 50-60% of patients, while toxicity was mainly hematological. 
(73) For patients with metastatic breast cancer, limited evidence supports an effect of 
treatment. No well-designed trials showed superiority of radio-isotopes versus placebo 
and no trials showed non-inferiority or superiority of radio-isotopes versus radiotherapy 
or opioids in those patients. (74) The Cochrane review published in 2011, studied 15 
randomized controlled trials in patients with metastatic bone pain and showed isotopes 
were effective in terms of pain relief. International criteria were not followed, any decrease 
in pain score was considered a pain response. Furthermore, only three of the trials were 
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considered to have low risk of bias. (75) The recently published ALSYMPCA trial randomized 
patients with bone metastases and no visceral metastases from castration- resistant 
prostate cancer between placebo and Radium-223. It showed a longer interval until the 
first symptomatic skeletal-related event and less use of external beam radio - therapy. 
Furthermore, an improvement in survival of three months was observed. Unfortunately, 
no data on pain scores were collected. (76) Currently, the α-RT trial is including patients, 
comparing Radium-223 combined with radiotherapy versus radiotherapy alone in patients 
with castration- resistant prostate cancer and painful bone metastases. The primary 
endpoint is the time to radiological progression, pain control is one of the secondary 
outcomes. The results of this trial will determine whether combining both treatments can 
be considered a treatment option for patients with metastasized prostate cancer and painful 
bone metastases. In conclusion, radionuclides are an effective treatment option, mainly in 
patients with multiple painful metastases. The major disadvantages are that only osteo- 
blastic metastases respond to this treatment and the hematological toxicity. 
Other local treatments
Surgical treatment, using internal fixation or intramedullary nailing of metastases in the 
long bones and/or pelvis, has been shown to provide pain relief, although the quality of 
the evidence is moderate. Treatment-related morbidity, like thrombosis or infection, is 
described in up to 21% of patients, depending on the type of procedure, with a 
perioperative mortality of up to 9% of patients. Furthermore, recovery time after surgery 
can be extensive, which can lead to a reduction of QoL. (77) Due to the high morbidity 
and mortality, this is mainly a treatment option in patients with (impending) fractures and 
a relatively long survival.
In local surgical procedures, like vertebroplasty or kyphoplasty, cement is inserted into 
the involved vertebra, using either an injection or a balloon respectively. The aim is to 
strengthen and restore the height of a collapsed vertebra. In a systematic review, 987 
patients with bone metastases treated with vertebroplasty were studied. Pain reduction 
ranged between 47 and 87%. A pain response according to the international consensus 
could not be determined. Although the treatment is mostly performed using local 
anesthesia and considered safe, the review showed 5 deaths, attributable to the treatment, and 
19 serious complications, mainly neuropathy. (78) In a recent publication, kyphoplasty in 
31 patients with spinal metastases or multiple myeloma was studied. The authors noticed 
a pain reduction in all patients, but a pain response could not be determined. As a 
complication, on 13 treated levels, cement leakage appeared. (79) In conclusion, local surgical 
treatment seems a reasonable option in patients in whom the pain is caused by collapse of 
a vertebra due to bone metastases. Due to the limited evidence, in the Netherlands this 
treatment is not covered by insurance, which might play a role in decision making. 
Radiofrequency ablation (RFA) is a minimally invasive treatment option, using thermal 
ablation which causes necrosis. Several small studies, with a maximum of 55 patients, 
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were published showing a decrease in pain after this treatment in patients with painful 
bone metastases. (80-82) In one of these studies, RFA was combined with cement 
augmentation, which appeared to be safe and effective in terms of decrease in pain score. 
(80) Disadvantages of RFA are the limitation of size of the metastasis and the need for 
sedation. Since the effect of RFA depends on distance to the tip of the electrode, RFA is 
often less efficacious at the border of the lesion..An interesting feasibility study compared 
radiotherapy with RFA followed by radiotherapy, in 45 patients with painful osteolytic 
bone metastases. This trial used the international criteria for response and documented 
an overall response rate of 93.3 % for the combined treatment, compared with 59.9% for 
radiotherapy alone (p:0.048). (83) Altogether, this sounds like a promising treatment option 
in selected patients in a good clinical condition, but results of larger trials have to be 
awaited.  
High intensity focused ultrasound (HIFU), preferably with MRI guidance (MR HIFU), heats 
the target tissue. This leads to local elevation of the temperature and tissue destruction, 
indirectly ablating the periosteum and tumor tissue. (84) Several small single arm studies 
in patients with bone metastases were published. (85) The only randomized controlled 
single-blind trial showed a higher pain response after MR HIFU than placebo treatment. 
(86) No studies comparing MR HIFU with radiotherapy were published. Altogether, MR 
HIFU does not appear to be a replacement of palliative radiotherapy, due to the long 
treatment time, use of sedation, availability of the machine and the amount of patients 
that are ineligible for the treatment. (86,87) 
 
Conclusion 
In general, radiotherapy remains the golden standard for patients with painful bone 
metastases. In selected cases, for example patients who are ineligible for radiotherapy or 
have impending fractures or compression of the spinal cord, other treatment options, in 
particular surgery, may be considered. The value of other techniques remains to be proven 
in randomized trials.
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Concluding remarks
This thesis focuses on several aspects on quality of life in patients with uncomplicated 
painful bone metastases, treated with palliative radiotherapy. The majority of patients will 
have a pain response after a single fraction of 8 Gy. 
Since shared decision making and treatment individualization is important nowadays, it is 
insightful for both patients and physicians to be aware of the expected course of QoL in 
order to make individual treatment choices. Currently, it is not possible to predict which 
patients are not likely to benefit from treatment. Treatment of the great majority of patients 
with painful bone metastases is indicated, irrespective of factors like age and survival. 
The only group of patients in whom referral should be carefully considered, are those 
with a very low life expectancy, i.e. patients in a bad clinical condition. There are several 
new radiotherapy techniques, but their superiority over more conventional treatment 
techniques for irradiating painful bone metastases remains to be proven. It is likely that 
only a minority of patients with painful bone metastases will benefit from those new 
treatment strategies. 
For future trials, it is of upmost importance to follow the guidelines from the international 
consensus, to be able to determine the pure effect of treatments on pain and to compare 
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Background: Radiotherapy has a good effect in palliation of painful bone metastases, with 
a pain response rate of more than 60%. However, shortly after treatment, in approximately 
40% of patients a temporary pain flare occurs, which is defined as a two-point increase of 
the worst pain score on an 11-point rating scale compared to baseline, without a decrease 
in analgesic intake, or a 25% increase in analgesic intake without a decrease in worst pain 
score, compared to baseline. A pain flare has a negative impact on daily functioning and 
mood of patients. It is thought to be caused by periostial edema after radiotherapy. 
Dexamethasone might diminish this edema and thereby reduce the incidence of pain 
flare. Two non-randomized studies suggest that dexamethasone reduces the incidence of 
a pain flare by 50%. The aim of this trial is to study the effectiveness of dexamethasone to 
prevent a pain flare after palliative radiotherapy for painful bone metastases and to 
determine the optimal dose schedule. 
Methods and Design: This study is a three-armed, double-blind, placebo-controlled multi- 
center trial. We aim to include 411 patients with uncomplicated painful bone metastases from 
any type of primary solid tumor who receive short schedule radiotherapy (all conventional 
treatment schedules from one to six fractions). Arm 1 consists of daily placebo for four 
days, arm 2 starts with 8 mg dexamethasone before the (first) radiotherapy and three days 
placebo thereafter. Arm 3 consists of four days 8 mg dexamethasone. The primary endpoint 
is the occurrence of a pain flare. Secondary endpoints are pain, quality of life and side- 
effects of dexamethasone versus placebo. Patients complete a questionnaire (Brief Pain 
Inventory with two added questions about side-effects of medication, the EORTC 
QLQ-C15-PAL and QLQ-BM22 for quality of life) at baseline, daily for two weeks and lastly 
at four weeks.
Discussion: This study will show whether dexamethasone is effective in preventing a pain 
flare after palliative radiotherapy for painful bone metastases and, if so, to determine the 
optimal dose.
This study is registered at ClinicalTrials.gov: NCT01669499
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Background
Radiotherapy, with a single fraction of 8 Gray as the gold standard, has a good effect in 
palliation of painful bone metastases, with a pain response rate of more than 60%. (1) 
However, a possible side-effect is a transient progression of pain, the so-called pain flare. 
This pain flare is defined as a two-point increase of the worst pain score on an 11-point 
rating scale, compared to baseline, without a decrease in analgesic intake, or a 25% 
increase in analgesic intake without a decrease in worst pain score. A pain flare is 
distinguished from progression of pain by requiring the worst pain score and analgesic 
intake to return to baseline levels after the flare. (2) 
Two prospective observational studies show that approximately 40% of patients 
experience a pain flare. (3, 4) Hird studied 111 patients with uncomplicated painful bone 
metastases and showed an incidence of pain flare of 40%, with no difference between 
single or multiple fractions. The median duration of a pain flare was 1.5 days, while 25% of 
patients had more than one pain flare. Most of the pain flares occurred during the first five 
days after treatment. A pain flare occurred in 52% of patients with breast cancer and in 
25% of patients with prostate cancer. (3) Loblaw studied 44 patients and found, with an 
adjusted, underestimating definition of a pain flare, an incidence of 41%, with a significant 
difference between single and multiple fractions (57% and 24% respectively). (4)
A survey among patients who experienced a pain flare showed that having a pain flare 
had a negative effect on daily functioning of patients and on their mood. (5) Most patients 
tried to manage their pain flare by increasing their pain medication, at the cost of possible 
side-effects. The majority of patients who experienced a pain flare stressed the need for 
prevention of this pain flare instead of managing it with breakthrough medication. 
The pain flare is thought to arise through edema of the periostium of the irradiated bone. 
Dexamethasone, an anti-inflammatory drug decreasing edema, may be an effective drug. 
Two small studies were performed to study the effect of dexamethasone on the incidence 
of pain flare. (6, 7). In the study by Chow a single dose of 8 mg dexamethasone was 
prescribed one hour before the single fraction radiotherapy. This study included 33 
patients and showed an overall pain flare incidence of 24%. Most of the observed pain 
flares commenced after the half-life of dexamethasone (7), suggesting that a longer 
treatment time might be useful. Dexamethasone was well tolerated. A subsequent study, 
with 41 evaluable patients, used 8 mg dexamethasone before single fraction radiotherapy 
and then daily for three consecutive days. It showed an overall incidence of pain flare of 
22%, with a median duration of one day. (6) 
Both studies concluded that randomized trials are necessary to study the effectiveness of 
dexamethasone for prevention of a pain flare. No randomized trials have been published 
so far. Therefore, the aim of this trial is to study the effectiveness of dexamethasone to 
prevent a pain flare after palliative radiotherapy for painful bone metastases and to 





This three-armed, prospective, randomized, placebo-controlled multicenter study is 
being led by the University Medical Center Utrecht. The study is supported by grants from 
the Dutch Cancer Society and ZonMw. It is registered at ClinicalTrials.gov: NCT01669499. 
The study compares two different dose schedules of dexamethasone with a placebo 
(Figure 1). The aim is to study the effectiveness of dexamethasone to prevent the occurrence 
of a pain flare after radiotherapy for painful bone metastases and to define the optimal 
schedule of dosing. Secondary endpoints are pain scores, quality of life and side-effects of 
placebo and dexamethasone. In addition, the predictive value of a pain flare for response 
to the palliative radiotherapy will be studied. 
Patients
The study includes patients with uncomplicated painful bone metastases from a solid 
tumor, who are referred for a short course of palliative radiotherapy. Short course 
radiotherapy encompasses all conventional treatment schedules from one to six fractions 
of radiotherapy. The full inclusion and exclusion criteria are listed in Table 1. Patients are 
randomized between the three treatment arms (Figure 1), after stratification for center 
and treatment schedule: single or multiple fractions. Randomization is performed by 
telephone at the Comprehensive Cancer Center The Netherlands. Double-blind 
randomization is guaranteed by only communicating the number of the medication box 
to patients and physicians.
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Participating centers
In total, 12 out of the 21 radiotherapy departments in the Netherlands participate in this 
nationwide study. Patients are asked for participation at these departments. Participating 
centers are:
University Medical Center Utrecht, Utrecht; Leiden University Medical Center, Leiden; 
MAASTRO Clinic, Maastricht; Medical Center Haaglanden, den Haag; The Netherlands 
Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam; Medical Spectrum Twente, 
Enschede; Erasmus Medical Center, Rotterdam; ARTI Institute for Radiation Oncology 
Arnhem, Arnhem; Institute Verbeeten, Tilburg; Catharina Hospital, Eindhoven; Zeeuws 
 Radiotherapeutic Institute, Vlissingen; Reinier de Graaf Gasthuis, Delft
Ethics, informed consent and safety
The protocol has been approved by the medical ethics committee of the University 
Medical Center Utrecht. In the participating centers, local medical ethics committees have 
Table 1   Full inclusion and exclusion criteria.
Inclusion Patients of 18 years or older
Uncomplicated painful bone metastases 
Primary malignancy is a solid tumour
Pain intensity on a numeric rating scale of 2-8
No immediately expected change in the analgesic regimen.
Indication for single or short course radiotherapy
Able to fill out Dutch questionnaires
Able to follow instructions
Informed consent provided
Exclusion Patients with haematological malignancy
Multiple sites to be irradiated
Patients who have been treated before with palliative radiotherapy 
for painful bone metastases to the same bony localisation
Current use of steroids (dexamethasone, prednisolone or other), use up to less
than a week before randomization or expected use within 2 weeks after 
start of radiotherapy (e.g., as part of anti-emetic regimen for chemotherapy)
Contraindications for the use of dexamethasone (to be judged by the radiation- 
oncologist) 
Long-term schedule radiotherapy (>6 fractions)
Life expectancy shorter than 8 weeks
Karnofsky Performance Score of 40 or less
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approved the protocol. The study is conducted in accordance with the Declaration of 
Helsinki. Written informed consent, signed and dated, is obtained before randomization. 
Serious adverse events (SAE) or suspected unexpected serious adverse reactions (SUSAR), 
as defined in the study protocol, are reported to the central medical ethics committee and 
to the central committee of medical research involving human subjects. 
Endpoints and analysis
Participating patients fill out a questionnaire at baseline (the start of treatment, defined as 
day 1), then daily until day 15 and a final questionnaire at day 29. The questionnaire 
contains the Brief Pain Inventory (8), which notes the level of pain on a 11 point pain scale 
ranging from 0 (no pain) to 10 (worst imaginable pain). Two questions are added about 
side-effects of the study medication (‘Do you have appetite?’ and ‘Do you feel restless?’). 
To assess quality of life, the EORTC QLQ-C15-PAL (9) and the EORTC QLQ-BM22 (10) are 
added (both at baseline, day 8, 15 and 29). Reminder telephone calls are performed twice 
during the study. The researchers contact participants who do not return their questionnaires. 
The occurrence of a pain flare, the primary endpoint of the study, is determined using the 
daily noted pain scores and pain medication. Pain response and side-effects of placebo 
and dexamethasone are assessed by the daily questionnaires. 
Analysis will be by intention-to-treat. Patients who have received at least one fraction of 
radiotherapy, irrespective of study medication intake, and have returned questionnaires 
are evaluable. Descriptive analyses of baseline characteristics will be performed. 
Comparison of occurrence of pain flare between the three arms will be assessed using the 
Chi-Square test. Comparison of pain intensity, quality of life items and side effects at 
baseline and over time between the three arms will be done using multilevel analysis. 
Since the risks of the study using well-known medication are considered minimal, an 
interim analysis will not be performed. 
Power calculation
Assuming a reduction of 50% (from 40 to 20%) of the occurrence of a pain flare by 
administering a single dose of 8 mg dexamethasone, a total of 411 patients are necessary 
(137 per arm) to reach a power of 90% given a significance level of 5% (2-sided), and 
assuming a drop-out of 20% during follow-up. In the Netherlands, around 3000 patients 
are eligible for this study yearly. With 12 out of 21 institutions participating and an 
estimated participation rate of 20%, the total study time needed is about 2 years.
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Discussion
Up to 40% of patients experience a pain flare after palliative radiotherapy for painful bone 
metastases.(3, 4) A pain flare severely impacts functional activity and mood of patients. (5) 
Therefore, it is clinically important to prevent the occurrence of a pain flare. Earlier 
publications suggest an effect of dexamethasone on the incidence of pain flare. (6, 7) 
Although side-effects of a short course and relative low dosage of dexamethasone are 
considered minimal, the beneficial effect in this patient population should be proven 
before integrating dexamethasone medication into daily clinical radiotherapy practice. 
A prolonged schedule of dexamethasone might be better in preventing a pain flare. 
Therefore, in the present trial, we study different schedules, to be able to determine which 
one is the optimum schedule.
A recent publication from Chiang et al. (published after the initiation of our study) in 
patients treated with stereotactic radiotherapy for painful bone metastases showed an 
incidence of pain flare of 68%. However, this might be an overestimation. Firstly, they did 
not mention to require pain score and analgesic intake to return to baseline, to distinguish 
it from progression. Secondly, initiation of corticosteroids during or after treatment was 
considered to be indicative of a pain flare (11) Nevertheless, these results give rise to the 
assumption that this group of patients might also benefit from our treatment results. 
However, the results of our study are not directly applicable to patients who are treated 
with stereotactic radiotherapy for painful bone metastases, since they represent a highly 
selected group of patients who receive much higher total doses of radiotherapy (e.g. 1x 20 
Gy, or 3x 8 Gy).
Using consensus definitions of endpoints in literature is important, to be able to compare 
studies.(12)  Most published studies concerning pain flare after palliative radiotherapy use 
the definition by Chow (2), incorporating pain scores, analgesics intake and returning to 
baseline to distinguish it from progression. Loblaw et al.(4) used a different definition for 
pain flare. They tried to convert it into the definition by Chow (2), but since they used a 
different pain scale, this was not completely possible, which made it difficult to interpret 
and compare these results with other published studies. We chose to also use the 
definition by Chow (2), to enable comparison with other studies. 
In conclusion, if this study proves the effectiveness of dexamethasone in the prevention 
of a pain flare after palliative radiotherapy for painful bone metastases, this should lead to 
a change in supportive care. Since we use a commonly accepted definition of pain flare, 
comparison between our results and future results from other trials may be possible. It 
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In the majority of patients with metastasized cancer, the focus of treatment is no longer 
cure, but other treatment goals, such as local control, relieving symptoms, prolonging life 
and maintaining or improving quality of life (QoL). Bone metastases are common in those 
patients and may lead to pain, fractures, neurologic deficits and/or hypercalcemia. Pain is 
reported in over 70% of patients with bone metastases and has a negative impact on QoL. 
Pain control is therefore very important. Pharmacological treatment is the first treatment 
option, although this may not reduce the pain sufficiently or cause too many side effects. 
Another important treatment option is palliative radiotherapy, used in almost 75% of 
patients with bone metastases. The largest randomized trial worldwide is the Dutch Bone 
Metastasis Study (DBMS), which studied pain response after a single fraction of 8 Gray (Gy) 
versus six fractions of 4 Gy in 1157 patients with uncomplicated painful bone metastases. 
The study was first published in 1999 and showed equal effectiveness, with a pain 
response rate of 71%. After publication of international standards in clinical trials on bone 
metastases in 2002 (redefining a pain response), a re-analysis was performed in 2003, 
taking into account changes in pain medication. This analysis showed a pain response of 
71% and 73% for the single and multiple fractions respectively. The equal effectiveness of 
a single fraction compared to multiple fractions was confirmed in several systematic 
reviews and no differences in toxicity were observed. Furthermore, the DBMS has shown 
that a single fraction is also preferred in terms of cost utility benefits. A prognostic model 
was developed for patients with painful vertebral metastases, to be able to determine for 
which patients invasive treatments like surgery are indicated. For patients with femoral 
metastases, the amount of axial cortical involvement turned out to be predictive for the 
chance of developing a fracture, leading to a better selection of patients in whom 
prophylactic surgery may be indicated. Other analyses showed that a single fraction is 
also preferred for patients with a long survival. For patients who did not achieve a pain 
response after radiotherapy or who experienced progression after an initial response, 
retreatment can be considered. A recent randomized trial in retreated patients, studying a 
single fraction of 8 Gy versus 20 Gy in multiple fractions, reported a pain response of 
around 45-50% in both groups. In conclusion, in the majority of patients with 
uncomplicated painful bone metastases, a single fraction of 8 Gy is the golden standard 
for both primary treatment and for retreatment. Despite this overwhelming evidence, 
research shows that in daily clinical practice, patients are still treated with a variety of 
treatment schedules, or no treatment at all. The goal of this thesis is to increase insight in 
palliative radiotherapy for painful bone metastases. Furthermore, we aimed to help 




In chapter 2 we describe the development of a prognostic model for patients with painful 
bone metastases. Estimating prognosis is important for both patients and their caregivers, 
for example to make treatment decisions and weigh the time investment and toxicity of a 
treatment against the expected benefit and the duration of and to this effect. Several 
prognostic models exist, but these are infrequently used in daily clinical practice, mainly 
due to complexity or use of variables that are not commonly available. Our goal was to 
develop a simple prognostic tool to aid patients and physicians in decision making.  We used 
the data of the DBMS and, for external validation, a more recent cohort of 934 patients 
treated with radiotherapy for painful vertebral metastases between 2001 and 2010. 
The mean age in the DBMS was 65 years. Most patients had breast (39%), prostate (23%) 
and lung cancer (25%). The mean Karnofsky performance status was 70. Median and mean 
survival were 30 and 49 weeks respectively. Univariate analysis showed that being male, 
being older than 65 years, having any primary tumor other than breast cancer, having 
visceral metastases, lower performance score, lower score for general health, worse valuation 
of life and higher pain score were associated with a higher risk of death. In multivariate 
analysis, the best predictive model included gender, primary tumor, presence of absence 
of visceral metastases, performance score and scores for general health and valuation of 
life, with a C-statistic of 0.72. This is considered a reasonable discriminative ability. Since the 
aim was to develop a simple tool, we simplified the model to two widely available 
variables, namely performance status and primary tumor. This model had a comparable 
discriminative ability (C-statistic of 0.71). The calibration plot indicated that the model was 
overly pessimistic and predicted best in patients with a poor prognosis, namely patients 
with other primary tumors than breast or prostate cancer and a bad performance score. 
This is the patient group in whom physicians are particularly interested to determine 
whether they will live long enough to benefit from treatment. In the external dataset, 934 
patients were included, with a mean age of 65 years, having mainly breast (29%), prostate 
(21%) or lung cancer (25%). The mean performance status was 70. Median and mean 
survival were 21 and 60 weeks respectively. The simple model with only primary tumor 
and performance status, showed a C-statistic of 0.72 and an almost identical calibration 
plot.  The final model, including primary tumor and Karnofsky performance status, shows 
a reasonable discriminative ability. The survival table, based on those two variables, 
provides insight for physicians enabling them to make treatment decisions together with 





Side-effects from radiotherapy on painful bone metastases are in general mild. Rates of 
side-effects of  around 50% are reported, consisting mainly of nausea and/or vomiting. 
The side-effects depend largely on location of the radiation field. In patients with painful 
vertebral metastases, two conventional treatment techniques are frequently used, namely 
a single posterior-anterior (PA) field and two opposing anterior-posterior and posterior- 
anterior (APPA) fields. In chapter 3 we describe the toxicity of both treatment techniques. 
Data of 343 patients treated for vertebral metastases within the DBMS were used. Patients 
filled out thirteen weekly extensive questionnaires on pain, medication, physical complaints 
and quality of life, followed by monthly questionnaires afterwards, until two years of 
follow-up, death or closure of the study. Of the 343 studied patients, 250 were treated with 
a PA field, 93 patients (27%) with an APPA technique. Treated locations were the lumbar 
spine (53%), the thoracic spine (34%) or overlapping locations (13%). Treatment technique 
depended on treatment institute and not on individual patient characteristics. Baseline 
characteristics did not differ between treatment groups, with one exception: patients 
treated with a PA field more frequently received systemic therapy than those treated with 
an APPA technique (59% versus 43%). The pain response rate was 74% and comparable 
between both groups. In general, side-effects were minor. Patients treated with APPA 
fields showed slightly more abdominal complaints than those treated with a PA field, 
namely significantly more diarrhea, with a trend for more vomiting and abdominal pain. 
In multivariate analysis, treatment schedule and location were predictive for abdominal 
complaints. For skin complaints, primary tumor and location were predictive. Treatment 
technique did not predict for skin or abdominal complaints after treatment. Although 
more conformal treatment techniques are available nowadays, the benefits of these new 
techniques have not yet been proven. Furthermore, these new techniques are, in general, 
more time consuming in terms of treatment planning and delivery and more expensive. 
Therefore, conventional techniques using a single fraction of 8 Gy will continue to be 
used, without a preference for a PA or APPA field. 
Psychological distress
Psychological distress (PD) has a major impact on patients and is associated with symptoms 
like nervousness, worrying, anxiety and depression. Those symptoms are experienced by 
almost 50% of incurable cancer patients. Although several interventions exist, like psychosocial 
interventions, cognitive therapy or psycho-educational interventions, only a minority of 
patients is referred. This may partly be due to under-identification of those patients with a 
high level of PD. In chapter 4, we studied the incidence and course of PD in patients 
treated with radiotherapy for painful bone metastases in the DBMS. The Rotterdam 
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Symptom Checklist from the questionnaires was used, which consists of a subscale for PD, 
including irritability, worrying, depressed mood, nervousness, despairing about the future, 
tension and anxiety, and ranges from 7 (no PD) to 28 (maximum amount of PD). The mean 
level of PD at baseline was 13.4, with a median of 12.0. Twenty-seven percent of patients 
had a high level of PD at baseline (≥17). Patients with high PD were mainly female, had 
breast cancer, had a low Karnofsky performance status and low scores for QoL. The 
multivariate analysis showed that age, gender, Karnofsky performance status, pain score 
and scores for QoL were predictive for PD. Female patients, higher age, worse performance 
status, lower pain score and worse self-reported QoL were associated with an increased 
chance of high levels of PD. The area under the curve was 0.71, indicating moderate 
discriminative ability. When studying the course of PD, the mean score for the entire group 
remained constant over time. For those patients with a high level of PD at baseline, the 
mean level of PD decreased the first weeks after treatment and stabilized around the 
threshold value. When studying only those patients still returning questionnaires after 
three months, representing patients in a better clinical condition, the course of PD 
remained similar, although with slightly better scores. In conclusion, over 25% of patients 
experiences PD before treatment and stays around the threshold level after treatment. 
Screening might be helpful to identify those patients most in need for interventions, in 
order to improve or maintain QoL.
Quality of life   
Health-related QoL is a multidimensional construct, taking into account both positive and 
negative aspects of physical, emotional, cognitive and social functioning, in relation to the 
sequelae of a disease and its treatment. Although QoL of patients is an important endpoint 
in palliative care, few of the randomized trials in palliative radiotherapy for painful bone 
metastases, document the impact of bone metastases and its treatment on QoL. The 
studies that reported about QoL have limitations, like a short follow-up or only studying 
general QoL instead of the separate domains. In chapter 5 we studied and modeled the 
detailed course of different domains of QoL after radiotherapy for painful bone metastases, 
using the data of the DBMS. Furthermore, we analyzed the influence of several baseline 
and follow-up variables on the course of QoL. All QoL items in the QoL questionnaire 
(mainly consisting of the RSCL) were studied, using principal component analysis to define 
clinically meaningful and relevant sum scores. We identified three domains, namely 
physical health, psychosocial health and functional status. We found that the level of QoL 
was related to the actual survival. After treatment with radiotherapy, in the first week a 
deterioration occurred for the physical and functional domain and in perceived general 
health, which stabilized afterwards for the latter two and which improved for the physical 




treatment. Afterwards, the course of QoL remained quite stabile for most of remaining life 
span, with a steep deterioration of QoL several weeks before the end of life. This pattern 
was noticed for all QoL domains. Higher baseline pain score and intake of opioids were 
associated with lower levels of QoL for almost all domains, with varying effect sizes. 
A lower baseline performance status and a higher age were associated with a worse 
functional QoL. Compared to patients with other types of primary tumor, patients with 
prostate cancer had a lower physical and functional QoL, while patients with breast cancer 
had a lower functional QoL, although this effect was small. Radiotherapy schedule was 
not related to QoL, except for the physical domain: patients treated with six fractions of 4 Gy 
showed a temporary worsening of physical QoL during the first weeks after treatment, 
compared to patients treated with a single fraction of 8 Gy. Thus, in general, QoL stabilized 
after palliative radiotherapy for painful bone metastases. Stabilization might be the effect 
of treatment, since without treatment deterioration could be expected in most patients. 
Although the majority of patients experienced a pain response, QoL did not clearly 
improve after treatment, which is possibly due to the multidimensional concept of QoL, 
not only involving physical complaints like pain, but also psychosocial and functional 
problems. Furthermore, in metastasized cancer, QoL is influenced by many other physical 
symptoms, due to the disease and/or its treatment. Nevertheless, in a population like this, 
stabilization of QoL is an important and meaningful outcome. In chapter 6 we studied 
QoL in relation to a pain response, since one might expect a better QoL in patients with a 
pain response compared to patients who did not experience a pain response. Our 
secondary goal was to identify factors predictive for a pain response after radiotherapy for 
painful bone metastases, to determine who should and who should not be offered 
palliative radiotherapy. So far, it is unsure to what extent a response to radiotherapy leads 
to an improvement of QoL. We used the data of all 956 patients with breast, prostate and 
lung cancer within the DBMS, in whom a pain response could be determined. We 
excluded patients with other primary tumors, since this group was considered too 
heterogeneous. Studied QoL domains were psychological distress, physical symptom 
distress, activity level impairment, perceived general health and a score for general 
valuation of life. In total, 722 (76%) of 956 patients experienced a pain response after 
radiotherapy, with a median time to response of three weeks. At baseline, non-responders 
had significantly more activity level impairment and a worse perceived general health 
compared to responding patients. Other QoL subscales did not differ at baseline. In the 
twelve weeks after radiotherapy, non-responding patients showed a worse QoL for all 
domains compared to responding patients. Most QoL domains improve in responding 
patients and deteriorate in non-responding patients. Only activity level impairment 
remained stable in responding patients, but deteriorates in non-responding patients. The 
differences between both groups were small during the first weeks after treatment, but 
increased over time, becoming clinically relevant. At baseline, non-responding patients 
were more likely to have lung cancer, visceral metastases and a worse physical condition 
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and less likely to receive systemic therapy prior to radiotherapy. Responding patients had 
a significantly better survival than non-responding patients, with a median survival of 
16 weeks compared to 45 weeks for responding patients. The final model predicting a 
pain response after palliative radiotherapy included primary tumor, age, performance 
status, presence of visceral metastases and use of opioids. Breast or prostate cancer, 
younger age, good performance status, no visceral metastases and use of opioids were 
associated with a higher chance of responding to treatment. However, the discriminative 
ability of the model was very low (C-statistic of 0.55), making it useless for daily clinical 
practice. Analyzing by tumor type, in patients with breast cancer, younger age and no 
visceral metastases were associated with a higher chance of pain response after radio- 
therapy. For patients with prostate or lung cancer, no additional predictors were identified.
In conclusion, patients responding to radiotherapy for painful bone metastases show a 
better QoL afterwards than patients without a pain response. Patients with poor QoL at 
baseline are less likely to have a pain response. We were unable to develop a model to 
accurately predict which patients are most likely to achieve a pain response.  
Effect of age
The number of elderly cancer patients increases, due to several factors, like a longer life 
expectancy, ageing of the baby boom era and improved cancer treatments. Elderly cancer 
patients represent a different population than younger patients, in general they are more 
fragile, with age-specific needs, related to multimorbidity and poorer physical and/or 
cognitive condition. Since elderly are frequently excluded from trials, trial outcomes may 
not be applicable to this group of patients. It has been shown that elderly cancer patients 
are frequently treated differently from younger patients, e.g. receiving less often palliative 
radiotherapy. In chapter 7 we studied the effect on age on a pain response after palliative 
radiotherapy for painful bone metastases, in order to determine whether this treatment is 
justified in elderly patients. In total, in the DBMS, 20% of patients was 75 years and older, 
35% was between 65 and 74 years and 45% below 65 years. Elderly patients (≥ 75 years) 
were more likely to be male and to have prostate cancer. More elderly patients were not 
able to take care of themselves: 39% versus 26% of patients younger than 65 years. The 
overall pain response did not significantly differ between age cohorts: 67% of elderly 
patients had a pain response, compared to 74% of patients between 65 and 74 years and 
78% of patients below 65 years. Age was not an independent predictor for pain response. 
All QoL subscales were comparable between age cohorts both at baseline and during 
follow-up, except for activity level impairment. At baseline, elderly patients had more 
activity level impairment than younger patients, this difference remained significant 
during follow-up. In conclusion, age was not a predictor for pain response or QoL after 




elderly patients did not evaluate their overall QoL inferior compared to younger patients. 
Therefore, higher age should not be a reason to withhold palliative radiotherapy.    
    
Discussion and future perspectives
In chapter 8 the contribution of the DBMS to knowledge and treatment recommenda-
tions in radiotherapy in patients with painful bone metastases is described. Synchronizing 
methodology in trials in patients with painful bone metastases is highly recommended, to 
be able to compare the results of different trials and different treatment strategies. Using 
similar treatment outcomes and similar definitions of a pain response, including the use of 
pain medication, is important. Prognostic models, which are increasingly used in daily 
clinical practice, should be developed in accordance with methodological guidelines and 
its critical application should be covered in the education of cancer specialists and other 
physicians. Furthermore, new developments in radiotherapy for painful bone metastases 
are discussed, in particular stereotactic radiotherapy, protons and the MR linac. These 
options are more expensive and time consuming and their added value in treating 
patients with painful bone metastases remains to be proven. With regard to dose, no data 
are available showing that a higher total dose results in higher pain response rates or a 
longer duration of pain response. For stereotactic radiotherapy two trials are currently 
ongoing, randomizing between a single fraction of 8 Gy and stereotactic treatment in 
patients with spinal metastases. The outcomes of these trials will be very important to 
determine the place of stereotactic radiotherapy in the treatment of patients with painful 
bone metastases. For the use of protons and the MR linac, clinical trials should be 
undertaken proving their added value before treating patients with those techniques.
New developments outside radiotherapy include the use of bisphosphonates, which are 
frequently prescribed to reduce the frequency of skeletal-related events. In a randomized 
trial, over 56% of patients using ibandronate show a pain response, making it an alternative 
treatment when radiotherapy is not an option. Radionuclides show a pain response in 
50-60% of patients, but has not been proven to be equal or better than radiotherapy for 
localized pain. They are mainly a treatment option in patients with pain at multiple sites 
and osteoblastic bone metastases. Surgical treatment may be considered in patients with 
(impending) fractures and a relatively long survival. Due to a high complication rate and 
mortality, local surgical procedures, like vertebroplasty or kyphoplasty, seem no treatment 
option, even more since no data on pain response are known. For relatively new 
procedures, like radiofrequency ablation (RFA) and magnetic resonance high intensity 
focused ultrasound (MR HIFU), randomized trials should be awaited. Due to the complexity 
and circumstances of treatment, those treatments are not expected to become a regular 
treatment option. In conclusion, although developments in and outside radiotherapy 
have occurred over the years, a single fraction of 8 Gy palliative radiotherapy remains the 
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golden standard in the vast majority of patients with painful bone metastases. In selected 
cases, like (impending) fractures or spinal cord compression in patients in a good clinical 
condition and relatively long survival, surgery may be indicated. 
Pain flare
The appendix contains the study protocol of a recent trial in patients treated with 
radiotherapy for uncomplicated painful bone metastases. A temporary increase in pain 
after radiotherapy, the so-called pain flare, occurs in approximately 40% of patients. A pain 
flare is defined as a two-point increase of the worst pain score on an 11-point rating scale 
compared to baseline, without a decrease in analgesic intake, or a 25% increase in analgesic 
intake without a decrease in worst pain score, compared to baseline. It has a negative 
impact on QoL and is thought to be caused by periostial edema. Dexamethasone might 
diminish this edema and may therefore be effective in reducing the incidence of a pain 
flare. Two non-randomized studies already suggest that dexamethasone reduces the 
incidence of a pain flare by 20%. Recently, a randomized trial reported a decrease of pain 
flare with dexamethasone compared to placebo, 26% versus 35% respectively (p:0.05). 
This trial compared one dose schedule of dexamethasone with a placebo. Our randomized 
double-blind multicenter trial has three arms: two dosage schedules of dexamethasone 
and one arm with placebo. The primary endpoint is the occurrence of a pain flare, 
secondary endpoints are pain, QoL and side-effects of medication. The study has included 
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Introductie (hoofdstuk 1)
Bij de meeste patiënten met uitgezaaide kanker is genezing niet langer het doel van 
behandeling, maar worden andere doelen nagestreefd, zoals locale controle, symptoom-
bestrijding, levensverlenging en behoud of verbetering van kwaliteit van leven (KvL). 
Uitzaaiingen in het bot (botmetastasen) komen veel voor bij patiënten met uitgezaaide 
ziekte en kunnen leiden tot pijn, botbreuken, neurologische problemen en/of een verhoogd 
calciumgehalte in het bloed. Pijn wordt door 70% van de patiënten met botmetastasen 
aangegeven en heeft een negatief effect op hun KvL. Het is dus erg belangrijk om deze 
pijnklachten onder controle te krijgen. Pijnmedicatie is vaak de eerste stap in de behandeling, 
dit is echter niet altijd voldoende effectief of geeft veel bijwerkingen. Een andere belangrijke 
mogelijkheid voor behandeling is palliatieve bestraling ). Ongeveer 75% van de patiënten 
met pijnlijke botmetastasen wordt bestraald. 
De Nederlandse botmetastasen studie (Dutch Bone Metastasis Study, DBMS) is de grootste 
gerandomiseerde studie wereldwijd naar bestraling in patiënten met ongecompliceerde 
pijnlijke botmetastasen. In deze studie werd een eenmalige bestraling met een dosis van 
8 Gray (Gy) vergeleken met zes bestralingen van 4 Gy. De uitkomsten werden gepubliceerd 
in 1999 en toonden gelijke effectiviteit van beide schema’s, waarbij 71% van de patiënten 
reageerde met een pijnrespons (afname of verdwijnen van de pijn). Na deze publicatie 
verscheen een internationale consensus, waarin eindpunten werden beschreven in studies 
naar bestraling bij patiënten met pijnlijke botmetastasen. In deze consensus werd een 
pijnrespons gedefinieerd, waarin ook het gebruik van pijnmedicatie werd meegenomen. 
Hierop werd een nieuwe analyse verricht, waarbij de pijnrespons 71% en 73% bedroeg, bij 
respectievelijk één en zes bestralingen. Dat één bestraling net zo effectief is als meerdere 
bestralingen, werd bevestigd in meerdere overzichtsartikelen, waarbij geen verschillen in 
bijwerkingen werden waargenomen. De DBMS heeft aangetoond dat ook met betrekking 
tot kosteneffectiviteit een eenmalige bestraling de voorkeur heeft. 
Een model werd ontwikkeld om de overleving te voorspellen van patiënten met pijnlijke 
wervelmetastasen, aangezien een betrouwbare inschatting van de levensverwachting 
belangrijk is voor het vaststellen van de indicatie voor chirurgische behandeling. Voor 
patiënten met een uitzaaiing in het bovenbeen werd gevonden dat de lengte van de 
uitzaaiing  voorspellend is voor het risico op een botbreuk. Hierdoor kunnen patiënten 
worden geselecteerd waarvoor een operatie geïndiceerd is om een botbreuk te 
voorkomen. Verder is aangetoond dat een eenmalige bestraling ook de voorkeur heeft bij 
patiënten met een relatief lange overleving. 
Herbestraling kan worden overwogen bij patiënten die niet hebben gereageerd op de 
eerste bestraling of die opnieuw pijn krijgen na een eerdere respons. Een recente ge-
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randomiseerde studie onderzocht voor herbestraling een eenmalige bestraling van 8 Gy 
en 20 Gy in meerdere bestralingen. Deze studie toonde dat 45-50% van de patiënten met 
beide behandelschema’s een pijnrespons ontwikkelde. Concluderend is een eenmalige 
bestraling van 8 Gy de gouden standaard voor patiënten met pijnlijke botmetastasen, 
zowel bij de eerste behandeling als bij herbestraling.  
Ondanks dit overtuigende bewijs wordt in de dagelijkse praktijk nog steeds met diverse 
bestralingsschema’s behandeld, en zijn er patiënten bij wie van bestraling wordt afgezien. 
Het doel van dit proefschrift is om het inzicht te vergroten in palliatieve bestraling bij 
patiënten met pijnlijke botmetastasen. Verder is het doel om artsen te ondersteunen in 
het bepalen van de optimale behandelstrategie voor hun individuele patiënt. 
Voorspellen van overleving
Hoofdstuk 2 beschrijft de totstandkoming van een model om de overleving te voorspellen 
bij patiënten met pijnlijke botmetastasen. Zowel voor patiënten als hun zorgverleners is 
het belangrijk om de levensverwachting in te schatten, bijvoorbeeld omdat het invloed 
heeft op behandelbeslissingen. Daarbij is het belangrijk om de tijdsinvestering en 
bijwerkingen van een behandeling af te wegen tegen het te verwachten effect, de duur 
van het effect en de duur tot dit effect optreedt. Er bestaan meerdere modellen om de 
overleving te voorspellen, maar deze werden in de praktijk weinig gebruikt, bijvoorbeeld 
door de ingewikkeldheid ervan of het gebruik van gegevens die niet standaard 
beschikbaar zijn bij alle patiënten. Ons doel was om een eenvoudig model te ontwikkelen 
om de overleving te voorspellen. Hiervoor gebruikten wij de data van de DBMS en, voor 
externe controle, een recent cohort met patiënten, tussen 2001 en 2010 behandeld met 
bestraling vanwege wervelmetastasen. De gemiddelde leeftijd in de DBMS was 65 jaar, 
met een gemiddelde performance status (schaal die functioneren benoemt) van 70 
(d.w.z. in staat voor zichzelf te zorgen, maar niet om normale activiteiten te verrichten of 
om te werken). Patiënten hadden voornamelijk borst- (39%), prostaat- (23%) of longkanker 
(25%). De mediane en gemiddelde overleving waren respectievelijk 30 en 49 weken. 
In multivariate analyse bleken geslacht, primaire tumor, aanwezigheid van viscerale 
metastasen, performance status en scores voor algemene gezondheid en waardering van 
het leven als voorspellers voor de overleving. Dit model had een C-statistic van 0.72, wat 
beschouwd wordt als een redelijk voorspellend vermogen. Ons doel was echter om een 
eenvoudig model te maken. Derhalve werd het model teruggebracht naar twee voor- 
spellers, namelijk performance status en primaire tumor. Het model met deze twee 
voorspellers had een vergelijkbare C-statistic van 0.71. Nadere analyse toonde aan dat het 
model de overleving onderschatte. Het model voorspelde het beste voor patiënten met 
een korte overleving, te weten patiënten met een slechte performance status en een 
andere primaire tumor dan borst- of prostaatkanker. Dit is de groep waarin inschatting van 
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de overleving het meest relevant is, om te bepalen of patiënten lang genoeg zullen leven 
om toe te komen aan de voordelen van de behandeling. De externe dataset bevatte 934 
patiënten met een gemiddelde leeftijd van 65 jaar en een gemiddelde performance 
status van 70. De primaire tumor was ook hier voornamelijk borst- (29%), prostaat- (21%) 
en longkanker (25%). De mediane en gemiddelde overleving waren respectievelijk 21 en 
60 weken. Het eenvoudige model met alleen primaire tumor en performance status had 
een C-statistic van 0.72. Het uiteindelijke model met primaire tumor en performance 
status kan de overleving redelijk goed voorspellen Verder werd een overlevingstabel 
gemaakt op basis van beide voorspellers. Deze kan gebruikt worden om inzicht te geven 
in de overleving van patiënten en artsen in staat te stellen om samen met hun patiënt 
beslissingen te nemen, onder andere gebaseerd op een adequate inschatting van hun 
overleving.
Bijwerkingen
De bijwerkingen van bestraling voor pijnlijke botmetastasen zijn vaak mild en vooral 
afhankelijk van de bestraalde plaats. De helft van de patiënten meldt bijwerkingen, 
voornamelijk misselijkheid en/of braken. De bijwerkingen hangen af van het bestraalde 
gebied. Bij patiënten met pijnlijke wervelmetastasen worden twee eenvoudige technieken 
vaak gebruikt, namelijk een enkelvoudig posterior-anteriorveld (PA, waarbij van achteren 
naar voren wordt bestraald)) of opponerende anterior-posterior en posterior-anterior-
velden (APPA, waarbij zowel van voren naar achteren als van achteren naar voren wordt 
bestraald). In hoofdstuk 3 worden de bijwerkingen van beide technieken beschreven. 
In de DBMS werden 343 patiënten behandeld vanwege pijnlijke wervelmetastasen. 
Zij vulden dertien wekelijkse vragenlijsten in, welke bestonden uit vragen over pijn, medicatie, 
lichamelijke klachten en KvL. Hierna werden de vragenlijsten maandelijks ingevuld, tot 
twee jaar follow-up, overlijden of sluiten van de studie. Van de 343 patiënten werden er 
250 behandeld met een PA veld en de overige 93 patiënten (27%) met een APPA techniek. 
Doelgebied waren de lendenwervels (53%) en de borstwervels (34%) of overlappende 
niveaus (13%). De techniek die toegepast werd was veelal een vaste keuze van de 
radiotherapie afdeling,   en veel minder gebaseerd op individuele patiëntkarakteristieken. 
Bij aanvang verschilden beide groepen patiënten niet van elkaar, met uitzondering van 
systemische therapie (chemo- of hormoontherapie). Meer patiënten in de PA groep 
werden behandeld met systemische therapie dan patiënten behandeld met een APPA 
techniek (59% versus 43%). De pijnrespons was 74% in beide groepen. Over het algemeen 
waren de bijwerkingen gering. Patiënten behandeld met een APPA techniek hadden iets 
meer buikklachten, Ze hadden significant vaker diarree en er was een trend voor meer 
braken en buikpijn in vergelijking met de PA groep. In multivariate analyse voorspelden 
locatie en bestralingsschema voor het ontstaan van buikklachten. Voor huidklachten 
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waren primaire tumor en locatie voorspellend. De gebruikte techniek voorspelde niet 
voor buik- of huidklachten. Hoewel tegenwoordig ingewikkelder en meer gerichte technieken 
beschikbaar zijn, zijn de voordelen van deze technieken in deze patiëntengroep nog niet 
bewezen. Daarbij zijn deze technieken vaak duurder en kosten ze meer tijd voor zowel de 
patiënt als de bestralingsafdeling. De verwachting is daarom dat de bestudeerde 
‘eenvoudige technieken gebruikt zullen blijven worden, waarbij geen voorkeur bestaat 
voor een APPA of PA techniek.
Psychische distress 
Psychische distress heeft grote gevolgen voor patiënten en gaat gepaard met symptomen 
zoals zenuwachtigheid, piekeren, angst en depressie. Bijna de helft van de patiënten met 
ongeneeslijke kanker ervaart deze symptomen. Hoewel er meerdere interventies bestaan, 
zoals psychosociale interventies, cognitieve therapie of psycho-educatie, wordt slechts 
een minderheid van de patiënten daarvoor verwezen. Dit komt mogelijk doordat 
psychische distress niet altijd wordt herkend. In hoofdstuk 4 beschrijven we de incidentie 
en het verloop van psychische distress in patiënten in de DBMS. Psychische distress wordt 
gescoord aan de hand van vragen van de Rotterdam Symptom Checklist over de mate 
van prikkelbaarheid, piekeren, neerslachtigheid, zenuwachtigheid, wanhopig zijn over 
de toekomst, gespannen voelen en angst. De totaalscore varieert van 7 (geen psychische 
distress) tot 28 (maximale psychische distress). Voorafgaand aan behandeling was het 
gemiddelde niveau van psychische distress 13.4, met een mediaan van 12. Zevenentwintig 
procent van de patiënten had veel psychische distress (boven de afkapwaarde van 16). 
Patiënten met veel psychische distress waren meestal vrouw, hadden borstkanker, een 
slechte Karnofsky performance status en slechte KvL. Het voorspellende model liet zien 
dat leeftijd, geslacht, performance status, pijnscore en globale KvL voorspellend waren 
voor psychische distress. Psychische distress was geassocieerd met vrouwelijk geslacht, 
hogere leeftijd, slechtere performance status, lagere pijnscore en slechtere KvL. In de 
periode na behandeling bleef de gemiddelde score van psychische distress grofweg gelijk. 
Bij patiënten met veel distress voorafgaand aan de behandeling nam het gemiddelde 
niveau van distress af in de eerste weken na bestraling en stabiliseerde daarna rond de 
afkapwaarde. Bij patiënten die hun vragenlijsten na drie maanden nog retourneerden 
(waarvan aangenomen mag worden dat die in een betere klinische conditie waren, bleef 
het beloop van psychische distress vergelijkbaar, hoewel het niveau van distress wat lager 
lag. Concluderend had een kwart van de patiënten psychische distress voorafgaand aan 
bestraling. De hoeveelheid distress stabiliseerde na de behandeling rond de afkapwaarde. 
Screening kan zinvol zijn om patiënten te identificeren die baat kunnen hebben bij 
interventies, om zodoende hun KvL te behouden of te verbeteren. 
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Kwaliteit van leven 
Gezondheidsgerelateerde kwaliteit van leven (KvL) bestaat uit meerdere dimensies, 
waarbij fysiek, emotioneel, cognitief en sociaal functioneren meewegen, in relatie tot de 
gevolgen van ziekte en de behandeling ervan. Hoewel KvL een belangrijk eindpunt is in 
palliatieve zorg, wordt het slechts gerapporteerd in enkele gerandomiseerde studies naar 
bestraling bij pijnlijke botmetastasen. De studies die er wel over rapporteren, hebben een 
aantal tekortkomingen, zoals een korte follow-up of het bestuderen van globale KvL in 
plaats van in de aparte domeinen. In hoofdstuk 5 bestudeerden en modelleerden we de 
verschillende domeinen van KvL na bestraling voor pijnlijke botmetastasen. Verder 
analyseerden we voorspellers voor het beloop van KvL bij aanvang en na de behandeling. 
Alle KvL items uit de vragenlijsten werden meegenomen, waaruit drie klinisch relevante 
domeinen werden vastgesteld, namelijk het fysieke, psychosociale en functionele (hoe 
men functioneert, wat men kan doen) domein. Het niveau van KvL bleek gerelateerd aan 
de daadwerkelijke overleving. Direct na bestraling verslechterde de fysieke en functionele 
domeinen en de algemene gezondheid. De laatste twee stabiliseerden hierna en het 
fysieke domein verbeterde op den duur tijdelijk. Alleen in het psychosociale domein werd 
een verbetering gezien kort na de bestraling. Na afloop van de behandeling bleef het 
niveau van KvL in alle domeinen stabiel en toonde een verslechtering enkele weken voor 
het overlijden. Een hogere pijnscore bij aanvang en gebruik van opioïden was geassocieerd 
met een slechtere KvL op vrijwel alle domeinen, met wisselende groottes van het verschil. 
Een slechtere performance status bij aanvang en hogere leeftijd waren geassocieerd met 
een slechtere functionele KvL. Patiënten met prostaatkanker hadden een slechtere fysieke 
en functionele KvL in vergelijking met patiënten met andere primaire tumoren, terwijl 
patiënten met borstkanker een slechtere functionele KvL hadden, hoewel het verschil 
klein was. Het bestralingsschema was niet gerelateerd aan KvL, behalve in het fysieke 
domein. Patiënten die behandeld waren met zes bestralingen hadden een tijdelijke 
verslechtering van hun fysieke KvL de eerste weken na behandeling, in vergelijking met 
patiënten behandeld met een eenmalige bestraling van 8 Gy. Concluderend stabiliseerde 
KvL na bestraling voor pijnlijke botmetastasen. Dit kan een effect van behandeling zijn, 
omdat verslechtering verwacht kan worden wanneer niet behandeld zou zijn. Hoewel het 
merendeel van patiënten een pijnrespons liet zien, verbeterde de KvL niet noemenswaardig. 
Dit kan worden verklaard doordat KvL bestaat uit meerdere domeinen. Psychische en 
functionele problemen hebben ook invloed op KvL. De fysieke KvL wordt, behalve door 
pijn, ook beïnvloed door andere lichamelijke klachten ten gevolge van de ziekte of de 
behandeling ervan. Desalniettemin is behoud van KvL een belangrijke uitkomst in deze 
populatie. In hoofdstuk 6 beschrijven we KvL in relatie tot een pijnrespons. Bij patiënten 
met een pijnrespons na bestraling zou een betere KvL verwacht worden dan bij patiënten 
zonder pijnrespons. Daarnaast probeerden we factoren te bepalen die voorspellend zijn 
voor een pijnrespons, om zo patiënten te kunnen selecteren bij wie het wel of niet zinvol 
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is om palliatief te bestralen. De data van 956 patiënten uit de DBMS met borst-, prostaat- of 
longkanker werden gebruikt. De overige 156 patiënten werden buiten beschouwing 
gelaten omdat deze groep te heterogeen was. De bestudeerde domeinen van KvL waren 
psychische distress, lichamelijke symptomen, beperkingen in activiteiten, algemene 
gezondheid en algemene waardering van het leven. Van de 956 patiënten toonden 722 
patiënten (76%) een pijnrespons na bestraling, met een mediane duur tot respons van 
3 weken. Bij aanvang hadden non-responders (patiënten zonder pijnafname) significant 
meer beperkingen in activiteiten en een slechtere algemene gezondheid in vergelijking 
met patiënten die wel een pijnrespons hadden. Er waren bij aanvang geen verschillen 
t.a.v. de andere domeinen van KvL. Gedurende 12 weken na bestraling was de KvL voor 
alle domeinen slechter bij non-responders. De meeste KvL domeinen verbeterden bij 
patiënten met een pijnrespons en verslechterden bij non-responders. Alleen de beperkingen 
in activiteiten bleven stabiel bij patiënten met een respons, maar verslechterden bij non-
responders. De verschillen tussen beide groepen waren kort na bestraling beperkt, maar 
namen in de loop van de tijd toe en werden klinisch relevant. Bij aanvang waren er 
verschillen tussen patiënten met een pijnrespons en patiënten zonder. Deze laatste groep 
had vaker longkanker, uitzaaiingen in lever of longen, een slechtere lichamelijke conditie 
en kreeg minder vaak systemische therapie. Patiënten met een pijnrespons hadden een 
mediane overleving van 45 weken, terwijl deze bij patiënten zonder respons 16 weken 
bedroeg. Het voorspellend model voor een pijnrespons bevatte primaire tumor, leeftijd, 
performance status, aanwezigheid van uitzaaiingen in lever of longen en het gebruik van 
opioïden. Borst- of prostaatkanker, jonge leeftijd, goede performance status, geen 
uitzaaiingen in lever of longen en het gebruik van opioïden, waren geassocieerd met een 
hogere kans op een pijnrespons. De voorspellende waarde van het model was echter erg 
laag (C-statistic van 0.55), waardoor het niet bruikbaar bleek voor de klinische praktijk. In 
analyses per tumortype werd gevonden dat bij patiënten met borstkanker, jonge leeftijd 
en de afwezigheid van uitzaaiingen in lever of longen geassocieerd waren met een 
hogere kans op pijnrespons. Bij patiënten met prostaat- of longkanker werden geen 
aanvullende voorspellende factoren gevonden. Concluderend hadden patiënten met 
een pijnrespons na bestraling een betere KvL na behandeling dan patiënten zonder 
pijnrespons. Patiënten met een slechte performance status voorafgaand aan behandeling 
hadden minder kans om een pijnrespons te ontwikkelen. Het lukte echter niet om een 
betrouwbaar voorspellend model te maken met betrekking tot pijnrespons.
Effect van leeftijd
Het aantal oudere kankerpatiënten neemt toe door onder andere een langere levensver-
wachting, het ouder worden van de babyboomgeneratie en betere kankerbehandeling. 
Oudere kankerpatiënten zijn anders dan jongere patiënten. In het algemeen zijn ze 
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kwetsbaarder, hebben ze veel leeftijdsgebonden aandoeningen tegelijkertijd en zijn ze in 
een slechtere lichamelijke en/of cognitieve toestand. Aangezien oudere leeftijd vaak een 
uitsluitings-criterium is voor studies, is het de vraag of studieresultaten ook op deze groep 
patiënten toepasbaar zijn. Er is aangetoond dat oudere patiënten anders behandeld 
worden dan jongere patiënten, bijvoorbeeld dat ze minder vaak behandeld worden met 
palliatieve bestraling. In hoofdstuk 7 bekeken we het effect van leeftijd op pijnrespons na 
palliatieve bestraling, om te bepalen of deze behandeling gerechtvaardigd is in oudere 
patiënten. In de DBMS was 20% van de patiënten 75 jaar of ouder, 35% was tussen de 65 
en 74 jaar en 45% was jonger dan 65. Oudere patiënten (≥ 75 jaar) waren vaker man en 
hadden prostaatkanker. Oudere patiënten waren vaker afhankelijk van anderen m.b.t. de 
activiteiten van het dagelijks leven: 39% tegenover 26% van de patiënten onder de 65. Er 
werd geen verschil gevonden in pijnrespons tussen de leeftijdsgroepen: 67%, 74% en 78% 
in patiënten van respectievelijk ≥75, 65-74 en <65 jaar. Leeftijd was geen onafhankelijke 
voorspeller voor een pijnrespons. Alle KvL domeinen waren vergelijkbaar tussen de leef-
tijdsgroepen, met uitzondering van beperkingen in activiteiten. Ouderen hadden bij 
aanvang al meer beperkingen in activiteiten en dit verschil bleef aanwezig in de follow-up. 
Concluderend was leeftijd geen voorspeller voor pijnrespons of KvL na palliatieve 
bestraling voor pijnlijke botmetastasen. Ouderen vonden hun KvL niet slechter dan 
jongere patiënten. Oudere leeftijd zou dus geen reden mogen zijn om patiënten niet 
palliatief te bestralen. 
Discussie 
In hoofdstuk 8 wordt de invloed van de DBMS beschreven op kennis en aanbevelingen uit 
richtlijnen met betrekking tot palliatieve bestraling bij patiënten met pijnlijke bot-
metastasen. Voor toekomstige studies is het belangrijk om een vergelijkbare methodologie te 
gebruiken, om zodoende uitkomsten van verschillende studies en verschillende  behandel- 
methodes met elkaar te kunnen vergelijken. Het gebruik van gelijke uitkomstmaten en 
definities is erg belangrijk. Aangezien modellen om de overleving in te schatten steeds 
vaker gebruikt worden in de klinische praktijk, is het belangrijk voor artsen om op de 
hoogte te zijn van de methodologische eisen waaraan modellen zouden moeten voldoen 
en zouden ze de bruikbaarheid van een model kritisch moeten kunnen evalueren. 
Nieuwe ontwikkelingen in bestraling voor pijnlijke botmetastasen zijn bijvoorbeeld 
stereo tactische bestraling, protonen of de MRI-versneller. Deze nieuwe opties zijn meer 
tijdsintensief en duurder dan de conventionele behandeling, terwijl de meerwaarde in 
deze patiëntengroep nog niet is aangetoond. Er zijn bijvoorbeeld geen data die aantonen 
dat een hogere dosis meer effect heeft op de pijnrespons of de duur van de respons. Voor 
stereotactische bestraling bij wervelmetastasen zijn momenteel twee gerandomiseerde 
studies open, die stereotactische bestraling vergelijken met een eenmalige bestraling van 
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8 Gy. De uitkomsten daarvan zullen erg belangrijk zijn om de plaats van deze behandeling 
te bepalen bij patiënten met pijnlijke botmetastasen. Voor protonen en de MRI-versneller 
zijn nog geen studies open die de meerwaarde van deze behandeling onderzoeken.
Ook buiten het gebied van de bestraling hebben nieuwe ontwikkelingen plaatsgevonden, 
zoals het gebruik van bisfosfonaten. In een gerandomiseerde studie liet 56% van de 
patiënten hierop een pijnrespons zien. Wanneer bestraling niet mogelijk is, zijn 
bisfosfonaten een alternatief. Radionucliden geven een pijnrespons in 50-60% van de 
patiënten, maar zijn niet aangetoond beter of gelijkwaardig aan palliatieve bestraling. 
Derhalve lijkt hiervoor vooral een indicatie bij patiënten met pijnklachten op meerdere 
plaatsen als gevolg van botmetastasen. Chirurgische behandeling kan worden overwogen 
bij patiënten met (dreigende) fracturen en een relatief lange levensverwachting. Lokale 
chirurgische ingrepen, zoals kyphoplastiek of vertebroplastiek (inspuiten van cement in 
een wervel), zijn vanwege hun hoge complicatierisico en mortaliteit niet geïndiceerd, 
temeer omdat er geen data zijn over het effect op pijn. Voor relatief nieuwe en dure 
behandelopties zoals high intensity focused ultrasound (HIFU) of radiofrequente ablatie 
(RFA) ontbreken gerandomiseerde studies. Gezien de complexiteit, selectiecriteria en 
beperkte beschikbaarheid ervan, is het niet de verwachting dat deze behandelingen in de 
toekomst een plaats zullen hebben in de behandeling van patiënten met pijnlijke 
botmetastasen. Hoewel de afgelopen jaren meerdere ontwikkelingen zowel binnen als 
buiten de het gebied van de bestraling hebben plaatsgevonden, is bestraling met een 
eenmalige bestraling van 8 Gy nog steeds de gouden standaard in de behandeling van 
patiënten met pijnlijke botmetastasen. Bij bijvoorbeeld (dreigende) fracturen of myelum-
compressie, in patiënten met een goede conditie en een relatief lange levensverwach-
ting, kan er een indicatie zijn voor chirurgie.
Pijnflare
Het appendix bestaat uit het studieprotocol van de Dexa-studie. Na bestraling voor 
botmetastasen ervaart ongeveer 40% van de patiënten een tijdelijke toename van 
pijnklachten, de zogeheten pijnflare. De definitie van een pijnflare is minimaal 2 punten 
stijging van de 11-punts pijnscore, zonder afname van pijnmedicatie, of een 25% toename 
van pijnmedicatie zonder afname van de pijnscore. Een pijnflare heeft een negatieve 
invloed op KvL en wordt mogelijk veroorzaakt door oedeem rondom het botvlies. 
Dexamethason zou dit oedeem en dus de incidentie van pijnflare kunnen verminderen. 
Twee niet-gerandomiseerde studies suggereren dat dexamethason hiervoor effectief is 
en de incidentie van pijnflare halveert. Een recent gepubliceerde gerandomiseerde studie 
laat zien dat dexamethason de incidentie van pijnflare vermindert, van 35% naar 26%. 
Hierin wordt één dosering dexamethason vergeleken met een placebo. Het studieprotocol 
beschrijft een drie-armige dubbelblind gerandomiseerde multicenterstudie, waarbij twee 
189
Summary in Dutch | Nederlandse samenvatting
10
armen verschillende doses dexamethason bevatten en de derde arm placebo. Het 
primaire eindpunt is het ontstaan van een pijnflare Secundaire eindpunten zijn pijn, KvL 
en bijwerkingen van de medicatie. De benodigde 294 patiënten zijn geïncludeerd in 
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oncoloog in het Universitair Medisch Centrum Utrecht, in samenwerking met het Radio-
therapeutisch Instituut Stedendriehoek en Omstreken (opleiders prof.dr. C.H.J. Terhaard 
en drs. E.J.A. Vonk). Tijdens haar opleiding startte zij een promotietraject en coördineerde de 
landelijke Dexa-studie, beschreven in de appendix, onder begeleiding van dr. A. de Graeff 
en dr. Y.M. van der Linden. De resultaten van dit onderzoek zijn beschreven in dit proefschrift. 
In januari 2015 rondde ze haar opleiding af, sindsdien werkt ze als staflid op de afdeling 






Dit proefschrift was nooit tot stand gekomen zonder de bijdrage van anderen. Graag wil 
ik op deze plek iedereen bedanken die hierbij heeft geholpen. De belangrijkste groep 
om te bedanken, zijn de patiënten, die in deze fase van hun ziekte nog de tijd en energie 
vinden om, vaak belangeloos, mee te doen aan wetenschappelijk onderzoek. 
Prof. Marijnen, beste Corrie, bedankt voor je waardevolle input en kritische blik. De manier 
waarop je een onderzoeksprobleem weet terug te brengen naar de kern is bewonderens-
waardig.
Dr. van der Linden, beste Yvette, hoe bijzonder dat de eerste radiotherapeut waarmee ik 
kennismaakte tijdens mijn coschappen, uiteindelijk mijn copromotor werd. Dank voor je 
enthousiasme, je uitgebreide kennis over botmetastasen en je creatieve denkvermogen. 
Dr. de Graeff, beste Alexander, je enthousiasme over kwaliteit van levenonderzoek is 
inspirerend. Bedankt dat je de uitkomsten van onze analyses altijd wist te vertalen naar de 
klinische praktijk, waarbij de patiënt centraal stond. 
Alle mede-auteurs van de artikelen wil ik bedanken voor hun bijdrage. Specifiek wil ik 
dr. Monninkhof hier benoemen: beste Evelyn, bedankt voor je statistische ondersteuning 
en dat je altijd tijd wist vrij te maken om mee te denken over de analyses en uitkomsten. 
Ook de initiële onderzoekers van de Nederlandse Botmetastasenstudie ben ik veel dank 
verschuldigd. De leden van de manuscript- en oppositiecommissie wil ik bedanken voor 
hun inzet en bereidheid om zitting te nemen in de commissie. 
Alle (oud-) collega’s van de afdeling radiotherapie van het UMC Utrecht, RISO en Radboudumc 
wil ik bedanken voor de prettige samenwerking en de mogelijkheden om onderzoek 
 te doen. Prof. van Vulpen, prof. Terhaard en prof. Poortmans, beste Marco, Chris en Philip, 
bedankt voor de geboden kansen. 
Natuurlijk wil ik hier ook mijn ouders, familie en vrienden bedanken, die op hun eigen 
wijze hebben bijgedragen aan dit proefschrift. Dank voor jullie interesse, maar vooral voor 
de afleiding buiten het werk. Marie-Loes en Berteke, fijn dat jullie paranimf willen zijn. 
Onze vriendschappen gaan terug naar de middelbare school en onze studententijd, 
beide vriendengroepen zijn me dierbaar.   
Mijn kleine, alles onderzoekende Olivier: the smallest things take up the most room in your 
heart. Lieve Jelte, bedankt voor wie je bent, voor je steun, je liefde en hoe je me aanvult.

